CURRICULUM VITAE

**NAME Gerald H. Friedland, M.D. August 2017**

**Address** AIDS Program

 Infection Diseases Section

 Department of Internal Medicine

Yale University School of Medicine

135 College St. Suite 323

New Haven, CT 06510-2483

Telephone (203) 688-6959 Fax (203) 737-4051

E-Mail: Gerald.Friedland@Yale.edu

**Present positions**

 Senior Research Scientist

 Professor Emeritus of Medicine

 Professor Emeritus of Epidemiology (Microbial Diseases) and Public Health,

 Yale University School of Medicine, New Haven, CT

 Adjunct Professor

 Mailman School of Public Health

 Columbia University, NYC

**EDUCATION**

June, 1959 B.A. Columbia College, New York, NY

June, 1964 M.D. New York University School of Medicine, New York, NY

**Postdoctoral Training**

1964–1965 Internship, 1sr Medical Division, Bellevue Hospital, NYC

1965–1967 United States Public Health Service, Peace Corps Physician, Nigeria

1967–1968 Assistant Medical Resident, 1st Medical Division, Bellevue Hospital, NYC

1968–1970 Fellow in Infectious Diseases, Beth Israel Hospital-Children’s Hospital Medical Center, Harvard Medical School, Boston, MA

 Special Student, Harvard School of Public Health, Boston, MA

**ACADEMIC APPOINTMENTS**

1970 Instructor in Medicine, Harvard Medical School, Boston, MA

1972 Assistant Professor of Medicine, Harvard Medical School, Boston, MA

1977 Instructor, Department of Social and Preventive Medicine, Harvard Medical School

1975 Visiting Professor, Ben Gurion University of the Negev, Center for Health Sciences, and the Soroka Medical Center, Beer Sheva, Israel

1981 Associate Professor of Medicine, Albert Einstein College of Medicine, Bronx, NY

1983 Visiting Professor, Ben Gurion University of the Negev, Center for Health Sciences, and the Soroka Medical Center, Beer Sheva, Israel

1986 Associate Professor of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, NY

1987 Professor of Medicine, and Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, NY

1991 Professor of Medicine and Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT

1991 Clinical Professor of Nursing, Yale School of Nursing, New Haven, CT

1991 Honorary Visiting Professor of Medicine, Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa

2004 Adjunct Professor, Department of Epidemiology, Mailman School of Public Health, Columbia University, NY

**HOSPITAL APPOINTMENTS**

1970-1981 Visiting Physician, Associate in Medicine, Beth Israel Hospital, Visiting Physician in Infectious Diseases, Children’s Hospital Medical Center, Boston, MA

1974-1981 Hospital Epidemiologist, Beth Israel Hospital Boston, MA

1981-1991 Medical Service Director and Attending Physician in Internal Medicine and Infectious Diseases, Montefiore Medical Center, North Central Bronx Hospital, Bronx, NY

1987-1991 Co-Director, AIDS Center, Montefiore Medical Center, Bronx, NY

1991-2009 Director, AIDS Program, Yale School of Medicine, Yale New Haven Hospital, New Haven, CT

1992-2008 Chief, Atkins/Donaldson (AIDS) Firm, Department of Internal Medicine, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT

1991-pres Attending Physician, Donaldson Firm, Yale-New Haven Hospital, New Haven, CT

1991-pres Attending Clinician, Nathan Smith Clinic, Yale New Haven Hospital, New Haven, CT

**MEDICAL SCHOOL AND EDUCATION POSITIONS**

1972-pres Post-Graduate Lecturer at various community and teaching hospitals, national, and international meetings and courses

1974-1977 Coordinator, Community Health Preceptorship, Harvard Medical School

1975 Curriculum Design, Infectious Diseases, Microbiology, and Primary Care, Ben Gurion University of the Negev Center for Health Sciences, Beer Sheva, Israel

1976-1981 Lecturer and Course Coordinator, Clinical Infectious Diseases Course (4th year), Section Leader, Pathophysiology of Infectious Diseases Course (2nd year) Harvard Medical School,

1978-1981 Coordinator of Clinical Training, Combined Infectious Disease Program, Beth Israel Hospital, Children's Hospital Medical Center, Sidney Farber Cancer Institute, Harvard Medical School.

1981-1986 Coordinator, Clinical Clerkship and Sub internship in Medicine, Montefiore Medical Center and North Central Bronx Hospital, Albert Einstein College of Medicine, Bronx, NY

1990-1991 Co-Chairman, HIV/AIDS Education Committee, AIDS Institute, NY State Department of Health

1993-pres Course Co-Director, International AIDS Society-USA, Annual Course in Advances in HIV Therapeutics, New York City

1996-2002 Course Director, Advances in HIV Therapeutics, Yale School of Medicine, New England AIDS Educational Training Unit, New Haven, CT.

1997 Co-Director, National Conference on Adherence to HIV Therapies, Office of AIDS Research, National Minority Council on AIDS, Forum on Collaborative Research on AIDS

2001-2007 Consultant, Kwa Zulu Natal Department of Health, Nelson R. Mandela School of Medicine, Provincial Course in HIV/AIDS

2001-2016 Site Director, Tugela Ferry, South Africa, Yale-Stanford Johnson and Johnson Global Health Scholar Program

2005-pres Global Health Programs Committee, Department of Internal Medicine

2005 Co-Director, Yale Conference on HIV Medication Adherence, New Haven CT

2008-2015 Faculty coordinator, Global Health Seminar, Yale Schools of Medicine, Public Health and Nursing

2011-2016 Co-PI Doris Duke Charitable Foundation International Clinical Research Fellowships for Medical Students, Yale University

2011-pres Yale Partnership on Health and Social Justice, Yale Schools of Public Health and Law

**AWARDS/HONORS**

1. Alpha Omega Alpha

1979 Massachusetts Health Center Outstanding Physician Award, Massachusetts League
of Community Health Centers

1986 Henry L. Moses Prize for Clinical Research, Montefiore Medical Center

1991 Pacesetter Award, National Institute on Drug Abuse

1991 Outstanding Achievement Award, New York State AIDS Institute

1999 Connecticut Health Commissioner’s AIDS Leadership Award

2000 Award for Excellence, AIDS Project New Haven

2000 Joseph Globus Award, Mt. Sinai Journal of Medicine

2004 Research in Action Award, Treatment Action Group

2005 Lifetime Recognition Award, International Association of Physicians in AIDS Care

2008 Paul J. Galkin Visiting Professor, Brown School of Medicine

2009 Tim Gill Visiting Professor, University of Colorado School of Medicine

2010 Visiting Professor, Beth Israel Hospital, Harvard Medical School

2010 Visiting Professor, University of Ghana School of Medicine

2010 First Ruy Soiero Memorial Lecture, Albert Einstein College of Medicine

2010 Maxwell Finland Named Lecture, 48th Annual Meeting of IDSA Vancouver, Canada

2011 First Alan Berkman Memorial Lecture, Mailman School of Public Health, Columbia University

|  |  |  |  |
| --- | --- | --- | --- |
| 201220152016  |  |  | George Comstock Named Lecture, North American Union Against TBN’Galy N’Galy Mann Award and Lecture, Conference on Retroviruses and Opportunistic InfectionsReynard J. McDonald Named Lecture, New Jersey College and Medicine and Dentistry |

**Clinical care and Community Medicine**

1970-1981 Internist, Dimock Community Health, Roxbury, MA

1972-1974 Medical Director, Mary Eliza Mahoney Family Life Center, Roxbury, MA

1974-1977 Director of Adult Services, Dimock Community Health Center, Roxbury, MA
Chairperson, Provider Task Force, Mass. League of Community Health Centers

1975-1977 Co-Director, People’s Free Healthy Center, Roxbury, MA

1981-1991 HIV Clinician, Montefiore Medical Center, Bronx, NY

1991- pres HIV Clinician, Nathan Smith Clinic, Yale New Haven Hospital, New Haven, CT

Other Experience and Professional Memberships and Consultations

|  |  |
| --- | --- |
| 1992 - 1995 | Chairman, AIDS Clinical Trials Group, M. Tuberculosis Working Group |
| 1993 - 1998 | Governing Board, International AIDS Society |
| 1998 - 2001 | National Advisory Council, National Institute on Drug Abuse, NIH |
| 1998 - 2001 | Advisory Council, Office of AIDS Research, NIH |
| 2004 - present | Chairman, Board of Directors, Aaron Diamond Center for AIDS Research |
| 2004 - 2012 | Trustee, HIV Research Trust, International AIDS Society, London, UK |
| 2004 - 20142004 - present | HIV/TB Working Group, Stop TB Program, World Health OrganizationBoard of Directors, Philanjalo, Tugela Ferry, KwaZuluNatal, South Africa |
| 2004 - 2010 | International HIV Research Planning Group, Office of AIDS Research, NIH |
| 2007 - 2015 | DHHS Guidelines Panel, Use of Antiretroviral Agents for HIV-1 in Adults and Adolescents |
| 2008 - 2016 | Scientific Advisory Committee, Center for Global Health Policy and Advocacy, Infectious Diseases Society of America |
| 2010 - 2016 | Co-Chair, International HIV Research Planning Group, Office of AIDS Research, NIH |
| 2015 - 2016 | International Scientific Advisory Board, Africa Center; Welcome Trust; University of KwaZuluNatal |

**Professional Societies**

American College of Physicians

Infectious Disease Society of America

American Federation for Clinical Research

American Society for Microbiology

Physicians for Social Responsibility

International AIDS Society

International Association of Physicians in AIDS Care

Southern African HIV Clinicians Society

International Union against Tuberculosis and Lung Disease

**Licensure and Certification**

1972 Diplomate, American Board of Internal Medicine

1978 Diplomate, Subspecialty Board of Infectious Diseases

 Connecticut State Medical License #31909

**Review Panels**

1984 Initial Review Group, NIDA, Studies on AIDS

1985 Ad Hoc Review Committee, NIH Review of Cooperative Agreement Applications,
Studies of AIDS

1986 Site Visit Panel, AIDS Research Centers – DHHS and NIDA

1990 Consensus Panel, AZT Therapy - State of the Art, NIAID

1986-1991 Special Review Committee, NIDA, DAAR-1, Biomedical Studies on AIDS

1994-2000 Review Panels, NIAID Community Programs for Clinical Research on AIDS (CPCRA),

 HIVNET Studies, Women’s Interagency HIV Study (WIHS), Center for AIDS Research (CFAR) Program, Adolescent Trials Network

2004-2006 AIDS Research Review Committee (AIDSRRC) NIH

2007 Fogarty Global ID Review Committee Chairman, International Cooperative Programs Center for Scientific Review, NIH

**Consultant and Committee Positions**

1983 Chairman, Panel on IV Drug Abusers, Prisoners, Female Sex Partners, Children, and Haitians, NIH Research Workshop on the Epidemiology of AIDS

1985 New York City Mayor's Task Force on AIDS

1986 Consultant, Classification System for HTLV-III/LAV Infection, CDC Atlanta, GA

1987 Consultant, Advertising Council of America, AIDS Prevention Campaign

1987-1988 Task Force on Hospital Services for AIDS, Greater New York Hospital Association

1987-1988 Committee on Access to Care, AIDS Institute, NYS Department of Health

1988 Institute of Medicine, National Academy of Sciences, Confronting AIDS, 1988

1988 Physicians' Review Committee, Presidential Commission on the HIV Epidemic

1988-1989 Committee on Health Care Resources, New York City AIDS Task Force

1989-1994 Roundtable on Drug and Vaccine Development for AIDS, Institute of Medicine, National Academy of Sciences

1990 Consultant, Prevention and Management of HIV in Women and Children, CDC

1990 HIV Health and Human Services Planning Council, Mayor's Office, New York City

1991-2001 Mayor's Task Force on AIDS, New Haven, Governor's AIDS Task Force, Connecticut

1991-1998 Bristol-Myers Squibb, Inc., HIV Advisory Board

1992-1994 AIDS Clinical Trials Group, Phase II/III Studies Working Group, Opportunistic Infections Core Committee

1992-1995 AIDS Clinical Trials Group - Chairman, M. Tuberculosis Working Group

1992-1995 Governing Council, International AIDS Society

1993 Program Committee, Clinical Science, 9th- 12th IAS International Conf on AIDS

1994-1998 Board of Directors, Aaron Diamond AIDS Research Center, New York, NY

1995 AIDS Clinical Trials Group - Complications of HIV Research Agenda Committee

1995 Advisor, Behavioral Science Direction Group, NIAID

1995-1996 White House Consultant - President’s Council on AIDS

1996 Executive Committee, Connecticut Women’s Health Project, New Haven, CT

1996 Consultant - Injecting Drug Use, CDC, UNAIDS, HIV and Peacekeeping Forces

1996-2004 Advisory Board, Connecticut AIDS Drug Assistance Program

1997-2006 Executive Committee, Center for AIDS Interdisciplinary Research, Yale School of Medicine

1998-2003 Board of Directors, AIDS Interfaith Network, New Haven CT

1998-2001 National Advisory Council, National Institute on Drug Abuse, NIH

1998-2001 National Advisory Council, Office of AIDS Research, NIH

2000-2001 Scientific Committee, 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina

2000-2006 Scientific Planning Committee and Adherence Working Group, Community Program for Clinical Research on AIDS (CPCRA), NIAID,

2001-2002 International Scientific Board Member, XIV International AIDS Conference, Barcelona, Spain

2001-2002 Consultant, Secure the Future, Bristol Myers Squibb

* 1. Member, Scientific Committee, 6th International Congress on Drug Therapy in HIV Infection, Glasgow, UK

2004-pres Trustee, International AIDS Society, HIV Research Trust

2004-2012 Member, Office of AIDS Research, NIH, Planning Group for Research in International Setting

2004-pres Member, HIV/TB Working Group, Stop TB Program, World Health Organization

2004-pres Chairman, Board of Directors, Aaron Diamond AIDS Research Center, NYC

2007-pres Member, DHHS Panel on Antiretroviral Guidelines for HIV-1 in Adults and Adolescents

 Chair, subcommittees on Injection Drug Usurers, Adherence and Tuberculosis

2008 Founding Scientist and Consultant, KwaZulu Natal Research Institute for TB and HIV/AIDS (“K-RITH”), Howard Hughes Medical Institute.

2008-pres Member, Scientific Advisory Committee, Center for Global Health Policy and Advocacy, Infectious Diseases Society of America

2010-pres Member, Board of Directors, Philanjalo, Tugela Ferry, KwaZulu Natal, South Africa

2013-2016 Co-Chair, Office of AIDS Research, NIH, Planning Group for Research in International Settings

2014-2015 Scientific Advisory Board, Africa Center, Welcome Trust, University of KwaZulu Natal Mtubatuba, KwaZulu Natal, South Africa

2015-pres Scientific Advisory Committee, MRC/Newton Fund Project, Aurum Institute, Johannesburg, South Africa

**Journal and Publication Positions**

1984-pres Reviewer, New England Journal of Medicine, Lancet, Annals of Internal Medicine, Journal of the American Medical Association, Journal of Infectious Diseases, Clinical Infectious Diseases, Journal American Public Health Association, AIDS, , Journal of Acquired Immune Deficiency Syndromes, PLoS Med, International Journal of Tuberculosis and Lung Disease

1987-1995 Board of Directors, AIDSFILMS, Inc., New York, NY

1988-1992 Editorial Board, AIDS, Gower Academic Journals, London, England

1989-1994 Co-Editor, AIDS Clinical Care, Massachusetts Medical Society, Boston, MA

1992-1997 Editorial Board, AIDS in the World, The Global AIDS Policy Coalition, Harvard School of Public Health, Cambridge, MA

1994-2000 Consulting Editor, AIDS Clinical Care, Massachusetts Medical Society, Boston, MA

2014- Editorial Board, Current HIV/AIDS Reports

2015- Editorial board, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

**RESEARCH POSITIONS AND GRANT SUPPORT**

1978-1979 Investigator, Complications of Steel Needles and Teflon Catheters, Criticon Corp.

1979-1980 Principal Investigator, Perioperative Cefoxitin in the Prevention of Infectious Complications of Cesarean Section, Merck, Sharp and Dohme

1983-1986 Co-Investigator, Pathogenesis and Epidemiology of AIDS, NIAID, NCI, NIH

1983-1986 Principal Investigator, Recombinant Alpha Interferon Treatment of AIDS, Hoffman La Roche

1984-1986 Principal Investigator, Clinical and Epidemiological Studies of AIDS, NY State AIDS Institute

1984-1987 Principal Investigator, Cooperative Agreement: Study of Family Members of Heterosexual Patients with AIDS, CDC

1985 Principal Investigator, AIDS Prophylaxis and Therapy Trials, NIAID

1985-1991 Consultant, Transmission of HTLV-III from Infected Mothers to their Infants, CDC

1986-1991 Principal Investigator, Natural History of HIV Infection in Intravenous Drug Users & Transmission to Infants from Infected Mothers. The Aaron Diamond Foundation

1987-1991 Principal Investigator, Natural History of HIV Infection in Intravenous Drug Users, NIDA, NIH

1987-1991 Principal Investigator, Natural History of HIV Infection in Intravenous Drug Users and Heterosexuals, CDC

1987-1991 Co-Investigator, AIDS Clinical Trials Unit, Albert Einstein College of Medicine, NCI, NIAID

1990-1991 Co-Principal Investigator, HIV Primary Care Training Grant, New York State AIDS Institute

1990 Principal Investigator, ACTG 262 PK Interactions Between Methadone & AZT

1990-1991 Co-Principal Investigator, HIV Primary Care Fellowship Program, NY State AIDS Institute

1991-1994 Principal Investigator, Phase I Trial of D4T in Patients with AIDS, Bristol-Myers Squibb

1992-1995 Co-Principal Investigator, Natural History of HIV Infection in Intravenous Drug Users, The Aaron Diamond Foundation

1992-1997 Principal Investigator, AIDS Clinical Trials Unit, Yale School of Medicine, ACTG, NIH

1994 Protocol Co-Chair, ACTG 262, AZT Effect on Methadone Disposition

1995 Protocol Co-Chair, ACTG 290, A Randomized Double-Blind Trial of ddI vs. d4T vs. AZT and ddI vs. AZT and d4T

1995 Protocol Chair, ACTG 261, A Randomized Double-Blind Trial of Delavirdine (DLV) + AZT +ddI vs. DLV+ AZT vs. DLV+ ddI vs. AZT+ ddI

1995 Protocol Co-Chair ACTG 298, A Randomized Double-Blind Trial of AZT vs. d4T vs. AZT+d4T.

1995 Investigator, Primary Care Nursing &HIV Gynecologic Manifestations, NINR, NIH

1996 Co-Principal Investigator, Adherence to Anti-Retroviral Therapy among Incarcerated Populations, Bristol-Myers Squibb

1996-1997 Principal Investigator, Multi-Site Phase I/II Trial of FP-21399 in Patients with HIV Infection, Fuji Immuno Pharmaceuticals.

1996-1997 Principal Investigator, Phase II Randomized, Double-Blind, Placebo-Controlled Study of Viracept in Combination with Stavudine (d4T) versus Stavudine (d4T) alone, in HIV Positive Patients, Agouron Pharmaceuticals

* 1. Principal Investigator, Methadone Effect on Didanosine (ddI) and Stavudine (d4T) Disposition, Bristol-Myers Squibb.

1997-1998 Principal Investigator, Improving Adherence to Antiretroviral Therapy, Bristol-Myers Squibb

* 1. Principal Investigator, Randomized Study of Long Term Suppression of Plasma HIV RNA, Bristol Myers Squibb,
	2. Principal Investigator, Combivir and Methadone Pharmacokinetic Interaction Study, Glaxo Wellcome.

1998-pres Investigator, Center for Interdisciplinary Research of AIDS (CIRA), NIMH, NIH

1999-2004 Co-Principal Investigator, Physician-Delivered Intervention for HIV+ Individuals, NIMH, NIH

1999-2014 Investigator, HIV-Related Therapeutics in Drug Users, NIDA, NIH

1999-2000 Investigator, Peer Driven Primary Care for HIV+ Drug Users, NIDA, NIH

2000-2004 Investigator, Directly Observed Anti-Retroviral Therapy for Drug Users, NIDA, NIH

2000-2013 Principal Investigator, ProACT, New England Program for AIDS Clinical Trials, Community Program for Clinical Research on AIDS (CPCRA), NIAID, NIH

2001-2003 Principal Investigator, Pharmacokinetic Interactions Between Methadone and Atazanavir, Bristol-Myers Squibb.

2001-2003 Principal Investigator, Irene Diamond Fund, and Doris Duke Charitable Foundation Implementing Antiretroviral Therapy in Resource Constrained Settings: A Pilot Phase Study

2001-2005 Investigator, Understanding the Relationship Between Substance Use and Sexual Risk Behaviors for HIV/AIDS Among School-Going Youth in KwaZulu Natal South Africa, World AIDS Foundation

2001-2005 Investigator, Options Project, Reducing HIV Risk Behavior Among HIV+ Patients, NIMH NIH

2002-2005 Investigator, NY State AIDS Institute, Translation of Options Project into Standard of Care

2002-pres Investigator, Center for AIDS Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa, NIAID, NIH

2002- 2018 Principal Investigator, Irene Diamond Fund and President’s Fund, Yale University, Tugela Ferry Project (Sizonqoba) Integrating Antiretroviral Therapy in Rural KwaZulu Natal

2004-2009 Investigator, Changing ART Adherence Behavior NIMH, NIH

2004-2008 Principal Investigator, Doris Duke Charitable Foundation, HIV Care, Antiretroviral Therapy and Prevention through a Community Based Program in Rural South Africa

2005-2008 Co-investigator, Opioids and HIV Medications: Interactions in Drug Users, NIDA, NIH

2006-pres Investigator, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)

 NIAID, NIH

2007-2011 Principal Investigator, Doris Duke Charitable Foundation (DDCF) Operations Research on AIDS Care and Treatment in Africa (ORACTA)

2007-2012 Principal Investigator, Expansion and Integration of TB/HIV and MDR and XDR TB Care and Treatment in Rural KwaZulu Natal, South Africa, Columbia University ICAP President’s Emergency Program for AIDS Relief (PEPFAR)

2007-2011 Investigator, Integrating HIV Prevention into Clinical Care for PLWHA in South Africa

 (Fisher, PI), NIMH, University of Connecticut

2007-2017 Principal Investigator, Confronting XDR TB and HIV in Rural South Africa, Gilead Foundation

2007-2016 Co-principal Investigator, Doris Duke Charitable Foundation International Clinical Research Fellowship (ICRF)

 2007-2011 Principal Investigator, HIV Drug Resistance and ART Adherence in Life Windows Project

 NIMH, NIH, Abbott Laboratories

2007-2015 Principal Investigator R08291,)Confronting HIV and XDR TB in Tugela Ferry, President's Emergency Plan for AIDS Relief (PEPFAR

2007-2016 Co-principal Investigator International Clinical Research Fellowship (ICRF) Doris Duke Charitable Foundation

2008-pres Principal Investigator, Project Access, Newman’s Own Foundation Inc.

2008-2014 Principal Investigator, R01 DA025932-01, Drug Interactions in Substance Abusers with HIV Infection NIDA

2009-pres Principal Investigator, Africa Confronting XDR TB and HIV in Rural South Africa, Gilead Foundation

2010-2015 Co-Investigator R01DA029910, Prison Interventions and HIV Prevention Collaboration in Ukraine, (Altice, PI) NIDA. NIH

2011-2016 Co- investigator 1R01AI89349-01, Transmission of HIV-associated XDR TB in Rural South Africa (Shah PI), NIAID, NIH

2011-2012 Co-investigator, R01 AI087465, Impact of HIV, Antiretroviral Therapy, and TB Genotype on

 Survival in MDR TB, (Gandhi PI) NIAID, NIH

2012-2014 Principal Investigator, 1R21AI102756, Assessment of PIMA Point-of-Care CD4 Analyzer in Resource-Poor Rural Setting of Tugela Ferry, KwaZulu-Natal, South Africa, NIAID, NIH

2012-2016 Co-principal Investigator, Provide mentored research training for medical students in Africa International Clinical Research Fellowship (ICRF), Doris Duke Charitable Foundation

2012-2016 Co-Investigator, Improving Penetration of Isoniazid Preventive Therapy through Intensification of case finding at the community level in rural South Africa, Subcontract Philanjalo, KwaZulu Natal, South Africa, US CDC, Implementation Research , PEPFAR

2012-2014 Principal Investigator, Confronting HIV, TB and Drug Resistant TB in Rural KwaZulu Natal, Subcontract Philanjalo, KwaZulu Natal, South Africa, Aurum Institute, US CDC, PEPFAR

2012-2017 Principal Investigator, Confronting Drug Resistant TB in Rural South Africa, Irene Diamond Fund

2012-2016 Co-Investigator, Integration of HIV, TB and Drug Resistant TB Management in Rural KwaZulu Natal, South Africa, Subcontract Philanjalo, KwaZulu Natal, South Africa, Health Systems Trust, US CDC, PEPFAR

2012-2016 Friedland, Gerald (PI), Shenoi, Sheela (PI) , Improving Isoniazid Prevention Therapy (IPT) Penetration through Intensification of Case Finding, Implementation Research, US CDC. Global Health Program, (PEPFAR )

2012-2016 Principal Investigator R21 AI102756-02 Implementing Point of Care CD4 Analysis to Decentralize HIV Care in Rural Africa, NIAID

2016-2020 Co-investigator 1 R01 AI124413-01; O’ Donnell, (PI) NIAID Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa

2015-2020 Investigator , R01DA041271-01; Altice, (PI) NIDA Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings

**PUBLICATIONS**

**A. Original Communications > 300**

1. Ellis C, Long S, **Friedland GH**: The Prevalence of S. Hematobium in the Okene Area of Nigeria. *West African Medical Journal* 1968; 17:21-24.
2. Komaroff AL, Pass TM, McCue JD, Cohen AB, Hendricks MS, **Friedland GH**: Management Strategies for Symptoms of Urinary and Vaginal Infections. *Archives of Internal Medicine* 1970; 128:1069-1073.
3. Greenfield S, **Friedland GH**, Scifers S. Rhodes A. Black WL. Komaroff AL: Protocol Management of Dysuria, Frequency and Vaginal Discharge. *Annals of Internal Medicine* 1974; 81:452-457.
4. Horowitz G, Kaslow R, **Friedland GH**: Infectiousness of Laryngeal Tuberculosis. *American Review of Respiratory Disease* 1976; 114:214-244.
5. Steere A, Riffat MK, Seligmann EB, Hockstein HD, **Friedland GH**, Dasse P, Wustack KO, Axnick NJ, and Barkin LF: Pyrogen Reactions Associated with the Infusion of 25% Normal Serum Albumin (Serum). *Transfusion* 1978; 18:102-107.
6. Fincke G, and **Friedland GH**: Prevention and Management of Infection in the Catheterized Patient. *Urologic Clinics of North America* 1979; 3:313-321.
7. **Friedland GH**: Management of Common Infectious Diseases Without a Physician. *Primary Care* 1979; V6:141-155.
8. du Moulin G, Dasse P, Miller M, Morrison M, **Friedland GH**: Staphylococcal Outbreak in an Intensive Care Unit. *Heart and Lung* 1979; 8:94-99.
9. Cohen S, **Friedland GH**, Bar-Noon S, Glick S: Antibiotic Usage in Kupot Holim Clinics. *Israel Journal of Medical Sciences* 1979; 15:811-816.
10. McCue J, Komaroff A, Pass T, Cohen A, **Friedland GH**: Strategies for Diagnosing Vaginitis. *Journal of Family Practice* 1979; 9:395-402.
11. Komaroff AL and **Friedland GH**: Dysuria Pyuria Syndrome. *New England Journal of Medicine* 1980; 303:452-454.
12. Tully J, **Friedland GH**, Baldini L, Goldmann D: Complications of Intravenous Therapy with Steel Needles and Teflon Catheters - A Comparative Study. *American Journal of Medicine* 1981; 70:702-706.
13. von Reyn CF, Levy B, Arbeit RD, **Friedland GH**, Crumpacker C: Infective Endocarditis. *Annals of Internal Medicine* 1981; 94 (part I):505-518.
14. Moll B, Emeson E, Butkus-Small C, **Friedland GH**, Klein R, Spigland I: Inverted Ratio of Inducer to Suppressor T Lymphocyte Subsets in Drug Abusers with Opportunistic Infections. *Clinical Immunology and Immunopathy* 1982; 5:417-423.
15. Bor DH, Rose RM, Modlin JF, Weintraub R, **Friedland GH**: Mediastinitis Following Cardiovascular Surgery. *Reviews of Infectious Diseases* 1982; 5:885-897.
16. Harris C, Butkus-Small C, **Friedland GH**, Klein R, Moll B, Emeson E, Spigland I, and Steigbigel NH: Immunodeficiency Among Female Sexual Partners of Males with Acquired Immune Deficiency Syndrome (AIDS). *Morbidity and Mortality Weekly Report* 1982; 31:697-698.
17. Butkus-Small C, Klein R, **Friedland GH**, Moll B, Emeson E, Spigland I: Community Acquired Opportunistic Infections and Defective Cellular Immunity in Heterosexual Drug Abusers and Homosexual Men. *American Journal of Medicine* 1983; 74:433-441.
18. O'Reilly R, Kirkpatrick D, Butkus-Small C, Klein R, Keltz H, **Friedland GH**: Unexplained Immunodeficiency and Opportunistic Infections in Infants. *Morbidity and Mortality Weekly Report* 1983; 31:665.
19. Harris C, Butkus-Small C, Klein R, **Friedland GH**, Emeson E, Spigland I, Steigbigel NH: Immunodeficiency in Female Sexual Partners of Men with the Acquired Immunodeficiency Syndrome. *New England Journal of Medicine* 1983; 308:1181-1184.
20. Rosenberg PR, Uliss AE, **Friedland GH**, Harris CA, Butkus-Small C, Klein RS: Acquired Immunodeficiency Syndrome -- Ophthalmic Manifestations in Ambulatory Patients. *Ophthalmology* 1983; 90:874-878.
21. Tully J, Baldini L, Klapholtz H, **Friedland GH**: Perioperative Cefoxitin in the Prevention of Infectious Complications of Caesarian Section. *Journal of Reproductive Medicine* 1983; 28:827-832.
22. **Friedland GH**, von Reyn CF, Levy B, Arbeit RD, Dasse P, Crumpacker C: Nosocomial Endocarditis. *Infection Control* 1983; 5(6):284-288.
23. Klein RS, Mann DN, **Friedland GH**, Surks MI: Normal Adrenal Cortical Function in Patients with the Acquired Immunodeficiency Syndrome. *Annals Internal Medicine* 1983; 99:566.
24. Klein RS, Harris CA, Butkus-Small C, Moll B, Lesser M, **Friedland GH**: Oral Candidiasis in High Risk Patients as the Initial Manifestation of the Acquired Immunodeficiency Syndrome. *New England Journal of Medicine* 1984; 311:354-357.
25. **Friedland GH**: Infusion-related Phlebitis - Is the In-line Filter the Solution? *New England Journal of Medicine* 1985; 312:115-116.
26. Lewis J, Sweeney L, Baldini L, **Friedland GH**, Salzman EW: Assessment of Thromboresistance of Intravenous Cannulas by 125 I-Fibrinogen Scanning. *Journal of Biomedical Materials Research* 1985; 19:99-113.
27. Butkus-Small C, Harris CA, **Friedland GH**, Klein RS: The Treatment of Pneumocystis carinii Pneumonia in the Acquired Immunodeficiency Syndrome. *Archives of Internal Medicine* 1985; 145:837-840.
28. **Friedland GH**, Harris CA, Butkus-Small C, Shine D, Moll B, Darrow W, Klein RS: Intravenous Drug Abusers and the Acquired Immunodeficiency Syndrome (AIDS): Demographic, Drug Use and Needle Sharing Patterns. *Archives of Internal Medicine* 1985; 145:1413-1417.
29. Adachi A, Kleiner GJ, Bezahler GH, Greston WM, **Friedland GH**: Abdominal Wall Actinomycosis Associated with an IUD. *Journal Reproductive Medicine* 1985; 30(2):145-148.
30. Ho J, Shands J, **Friedland GH**, Edkin P, Fraser D: Outbreak of Type 4B Listeria Monocytogenes Infection Involving Patients from Eight Boston Hospitals. *Archives of Internal Medicine* 1986; 146:520-524.
31. **Friedland GH**, Saltzman BR, Rogers MF, Kahl PA, Lesser M, Mayers MM, Klein RS: Lack of Transmission of HTLV-III/LAV Infection to Household Contacts of Patients with AIDS and AIDS-related Complex with Oral Candidiasis. *New England Journal of Medicine* 1986; 314:344-349.
32. Saltzman BR, Motyl MR, **Friedland GH**, McKitrick JC, Klein RS: Mycobacterium Tuberculosis Bacteremia in the Acquired Immunodeficiency Syndrome. *Journal of American Medical Association* 1986; 256:390-391.
33. Kahn SA, Saltzman BR, Klein RS, Mahadevia PS, **Friedland GH**, Brandt LJ: Hepatic Disorder in Acquired Immunodeficiency Syndrome: A Clinical and Pathological Study. *American Journal of Gastroenterology* 1986; 81:1145-1148.
34. Paietta EP, Saltzman BS, Klein RS, **Friedland GH**, Stein H, Weirnik PH: Ki-1 Antigen on Mononuclear Cells from Patients with AIDS: *Annals Internal Medicine* 1986; 104:890-891.
35. **Friedland GH**: AIDS: A General Overview. *International Journal of Neurosciences* 1987; 32:677-686.
36. **Friedland GH**: Fear of AIDS. *New York State Journal of Medicine* 1987; 87:260.
37. Marantz P, Linzer M, Feiner C, Feinstein S, Kozin A, **Friedland GH**: Inability to Predict Diagnosis in Febrile Intravenous Drug Abusers. *Annals of Internal Medicine* 1987; 106:823-828.
38. Macklin R and **Friedland GH**: AIDS Research: The Ethics of Clinical Trials -- An Ethical Analysis. *Law, Medicine, and Health Care* 1987; 14:273:281.
39. Silverstein CH, McKegney FP, O'Dowd MA, Selwyn PA, Schoenbaum EE, Drucker E, Feiner C, Cox C, **Friedland GH**: A Prospective Longitudinal Study of Neuropsychologic and Psychosocial Factors in HTLV-III Seropositive Asymptomatic Patients in Methadone Maintenance. *International Journal of Neurosciences* 1987; 32:669-676.
40. Phelan JA, Saltzman BR, **Friedland GH**, Klein RS: Oral Findings in Patients with Acquired Immunodeficiency Syndrome. *Oral Surgery* 1987; 64:50-56.
41. Conant MA, **Friedland GH**, Jaffe HW: Confronting AIDS in Primary Care. *Patient Care* 1987; 21(11):18-38.
42. Makadon HJ, Bor D, **Friedland GH**, Dasse P, Komaroff AL, Aronson MD: Febrile Inpatients: House Officers' Use of Blood Cultures. *Journal of General Internal Medicine* 1987; 2:293-297.
43. Shine D, Moll B, Emeson E, Spigland I, Harris C, Butkus-Small C, **Friedland GH**: Serologic, Immunologic, and Clinical Features of Parenteral Drug Users from Contrasting Populations. *American Journal of Drug and Alcohol Abuse* 1987; 13-14:401-412.
44. **Friedland GH** and Klein RS: Transmission of the Human Immunodeficiency Virus. *New England Journal of Medicine* 1987; 317:1125-1135.
45. Klein RS, Phelan JA, Freeman K, Schable C, **Friedland GH**, Trieger N, Steigbigel N: Low Occupational Risk of Human Immunodeficiency Virus Infection for Dental Professionals. *New England Journal of Medicine* 1988; 318:86-90.
46. Bor DH, Makadon HJ, **Friedland GH**, Dasse P, Komaroff AL, Aronson MD: Fever in Hospitalized Medical Patients: Characteristics and Significance. *Journal of General Internal Medicine* 1988; 3:119-125.
47. **Friedland GH**: AIDS and Compassion. *Journal of the American Medical Association* 1988; 259:2898-2899.
48. Selwyn PA, Feingold AR, Hartel D, Schoenbaum EE, Alderman MH, Klein RS, **Friedland GH**: Increased Risk of Bacterial Pneumonia in Intravenous Drug Users Without AIDS. *AIDS* 1988; 2:267-272.
49. **Friedland GH** and the Interferon Study Group: A Randomized Placebo-Controlled Trial of Recombinant Human Interferon Alpha 2a in Patients with AIDS. *Journal of the Acquired Immunodeficiency Syndrome* 1988; 1:111-118.
50. Bulkin W, Brown L, Giannattasio E, Fraioli D, McGuire G, Tyler P, **Friedland GH**: Hospice Care of the Intravenous Drug Abuser AIDS Patient in a Skilled Nursing Facility. *Journal of the Acquired Immunodeficiency Syndrome* 1988; 2:375-380.
51. **Friedland GH** and Klein RS: Transmission of the Human Immunodeficiency Virus: an Updated Review. *International Nursing Review* 1988; 35(2):44-52.
52. Selwyn PA, Schoenbaum EE, Feingold AR, Davenny K, Robertson V, Mayers MM, Shulman J, Klein RS, Alderman MH, **Friedland GH**, Rogers MF: Pregnancy Outcomes and Perinatal Transmission of HIV in Intravenous Drug Abusers. *Journal of the American Medical Association* 1989; 261:1289-1294.
53. Selwyn PA, Schoenbaum EE, Hartel D, Klein RS, Davenny K, **Friedland GH**: A Prospective Study of the Risk of Tuberculosis Among Intravenous Drug Users with Human Immunodeficiency Virus Infection. *New England Journal of Medicine* 1989; 320:545-550.
54. **Friedland GH**: More on Bloodborne Transmission of HIV. *Current AIDS Literature* 1989; 2:471-472.
55. Zuger A and **Friedland GH**: Pneumonia in an HIV-Infected Man. *AIDS Patient Care* June 1989:4-5.
56. **Friedland GH**: Clinical Care in the AIDS Epidemic. *Daedalus* 1989; 320:545-550.
57. Schrager LK, **Friedland GH**, Maude D, Schreiber K, Adachi A, Pizzuti DJ, Koss LG, Klein RS: Cervical and Vaginal Squamous Cell Abnormalities in Women Infected with Human Immunodeficiency Virus. *Journal of the Acquired Immunodeficiency Syndrome* 1989; 2:570-575.
58. Schoenbaum EE, Selwyn PA, Hartel D, Klein RS, Davenny K, Rogers MD, Feiner C, **Friedland GH**: Risk Factors for HIV Infection in Intravenous Drug Users: The Relationship of Drug Use, Heterosexual Behaviors and Race/Ethnicity. *New England Journal of Medicine* 1989; 321:874-879.
59. **Friedland GH** and Pinching A, co-editors: Clinical Treatment *AIDS* 1989; (suppl 3):S135-215.
60. **Friedland GH**: Early Treatment for HIV - The Time Has Come. Editorial. *New England Journal of Medicine* 1990; 322:1000-1002.
61. **Friedland GH**: Risk of Transmission of HIV to Home Care and Health Workers. *Journal of the American Academy of Dermatology* 1990; 22:1174-1176.
62. Motyl MR, Saltzman BR, Levi MH, McKitrick JC, **Friedland GH**, Klein RS: The Recovery of Mycobacterium Avium Complex and Mycobacterium Tuberculosis from Blood Specimens of AIDS Patients Using Non-radiometric Bactec NR 550 Medium. *American Journal of Clinical Pathology* 1990; 94:84-86.
63. **Friedland GH** and Selwyn P: Intravenous Drug Use and HIV Infection. *AIDS Clinical Care* 1990; 2:29-32.
64. **Friedland GH**, Kahl P, Saltzman B, Rogers M, Feiner C, Mayers M, Schable C, Klein RS: Additional Evidence for Lack of Transmission of Human Immunodeficiency Virus Infection by Close Interpersonal (Casual) Contact. *AIDS* 1990; 4:639-644.
65. McKegney FP, O'Dowd MA, Feiner C, Selwyn PA, Drucker E, **Friedland GH**: A Prospective Comparison of Neuropsychologic Function in HIV Seropositive and Seronegative Methadone-Maintained Patients. *AIDS* 1990; 4:565-569.
66. Feingold AR, Vermund SH, Burk RD, Kelley KF, Schrager LK, Schreiber K, Munk G, **Friedland GH**, Klein RS: Cervical Cytologic Abnormalities and Papillomavirus in Women Infected with Human Immunodeficiency Virus. *Journal of the Acquired Immunodeficiency Syndrome* 1990; 3:896-903.
67. Schoenbaum EE, Hartel D, **Friedland GH**: Intravenous Drug Use and HIV Infection. *Current Opinion in Infectious Diseases* 1990; 3:80-93.
68. Klein RS and **Friedland GH**: Transmission of Human Immunodeficiency Virus Type 1 (HIV-1) by Exposure to Blood: Defining the Risk. *Annals of Internal Medicine* 1990; 113:729-730.
69. **Friedland GH**: Expert Panel, National Institutes of Health. State-of-the-Art Conference on Azidothymidine Therapy for Early HIV Infection *American Journal of Medicine* 1990; 89:335-44
70. Khabbaz RF, Hartel D, Lairmore M, Horsburgh CR, Schoenbaum EE, Roberts B, Hartley TM, **Friedland GH**: Human T Lymphotropic Virus Type II (HTLV-II) Infection in a Cohort of New York Intravenous Drug Users: An Old Infection? *Journal of Infectious Diseases* 1991; 163:252-256.
71. **Friedland GH**, Saltzman BR, Vileno J, Freeman K, Schrager LK, Klein RS: Survival Differences in Patients with the Acquired Immunodeficiency Syndrome. *Journal of the Acquired Immunodeficiency Syndrome* 1991; 4:144-153.
72. Schrager LK, **Friedland GH**, Feiner CJ, Kahl P: Demographic Characteristics, Drug Use and Sexual Behavior of Intravenous Drug Users with AIDS. *Public Health Reports* 1991; 106:78-84.
73. Barondess JA, Farber SJ, Rogers DE, Adler KP, Cohen JJ, Finberg L, Kase NG, Pardes H, Purpura DP, Shires GT, Corcoran JP, Foreman S, Newman RG, Rowe JW, Scherl DJ, Skinner DB, **Friedland GH**, Ho DD: The Risk of Contracting HIV Infection in the Course of Health Care. *Journal of American Medical Association* 1991; 265:1872-1873.
74. Schwartz EL, Baechbuhl A, Kahl P, Miller M, Selwyn PA, **Friedland GH**: Pharmacokinetic Interactions of Zidovudine and Methadone in Intravenous Drug Using Patients with HIV Infection. *AIDS* 1992; 5:619-626.
75. Selwyn PA, Sckell B, Alcabes P, **Friedland GH**, Klein R, Schoenbaum EE: High Risk of Active Tuberculosis in HIV-infected Drug Users with Cutaneous Anergy. *Journal of American Medical Association* 1992; 268:504-509.
76. Greenberg AE, Thomas PA, Landesman SH, Mildvan D, Seidlin M, **Friedland GH**, et al: The Spectrum of HIV-1 Related Disease Among Outpatients in New York City. *AIDS* 1992; 6:849-859.
77. Selwyn, PA, Alcabes P, Hartel D, Buono D, Schoenbaum E, Klein, RS, Davenny K, **Friedland GH**: Clinical Manifestations and Predictors of Disease Progression in Injecting Drug Users with Human Immunodeficiency Virus Infection. *New England Journal of Medicine* 1992; 327:1697-1703.
78. Gourevitch MN, Selwyn PA, Davenny K, Buono MS, Schoenbaum EE, Klein RS, **Friedland GH**: Serologic Patterns and Response to Treatment of Syphilis in a Cohort of HIV-Seropositive and HIV- Seronegative Intravenous Drug Users. *Annals Internal Medicine* 1993; 118:350-355.
79. Silberstein CH, O'Dowd MA, Schoenbaum EE, **Friedland GH**, Chartock P, Feiner F, McKegney P: Association of Baseline Neuropsychological Function and Progression of Illness Over 4 Years in HIV-Seropositive Individuals. *Psychosomatics* 1993; 34:502-505.
80. Alcabes P, Munoz A, Vlahov D, **Friedland GH**: The Incubation Period of Human Immunodeficiency Virus. *Epidemiologic Reviews* 1993; 15:303-318.
81. Silberstein CH, O’Dowd MA, Chartock P, Schoenbaum E, **Friedland GH**, Hartel D, McKegney FP: A Prospective Four-Year Follow-up of Neuropsychological Function in HIV Seropositive and Seronegative Methadone-Maintained Patients. *General Hospital Psychiatry* 1993; 15:351-359.
82. von Reyn FC, Arbeit RD, **Friedland GH**, Crumpacker CS: Criteria for the Diagnosis of Infective Endocarditis. *Clinical Infectious Diseases* 1994; 17(3):321-32.
83. Alcabes P, Selwyn PA, Davenny K, Hartel D, Buono D, Schoenbaum EE, Klein RS, **Friedland GH**: Laboratory Markers and the Risk of Developing HIV-1 Disease Among Injecting Drug Users. *AIDS* 1994; 8:107-115.
84. Alcabes P, Munoz A, Vlahov D, **Friedland, GH**: Maturity of Human Immunodeficiency Virus Infection and Incubation Period of Acquired Immunodeficiency Syndrome in Injecting Drug users. *Annals of Epidemiology* 1994; 4:17-26.
85. Zuger A and **Friedland GH**: HIV-Associated Bacterial and Mycobacterial Infections: New Developments. *Infectious Diseases in Clinical Practice* 1994; 3:161-167.
86. **Friedland GH**: Clinical Care. International AIDS Society, *Newsletter No. 3*, (Stockholm: Sweden, 1995).
87. **Friedland GH**: D4T. *AIDS Clinical Care* 1995; 7(1):2-3.
88. Hartel D, Schoenbaum, EE, Selwyn, PA, Kline J, Davenny K, Klein RS, **Friedland GH**: Heroin Use During Methadone Maintenance Treatment: Importance of Methadone Dose and Cocaine Use. *American Journal of Public Health* 1995; 85:83-88.
89. Alcabes P and **Friedland GH**: AIDS Commentary: Injection Drug Use and HIV Infection. *Clinical Infectious Diseases* 1995; 20:1467-79.
90. **Friedland GH**: A Journey Through the Epidemic. Perspectives in HIV Care: A View From the Front Lines. *Bulletin of the New York Academy of Medicine*, Summer 1995 Suppl; 72 (1):178-186.
91. **Friedland GH**, Merson M: A Changing Pandemic. *Ricerca Roche*, 1995; 20:24-25.
92. **Friedland GH:** Experience With Stavudine (D4T). *Revista Da Sociedade Brasileira De Medicina Tropical,* 1995 Supplement; 28(II):43-49.
93. **Friedland GH:** Antiretroviral Therapy in the Future. *Revista Da Sociedade Brasileira De Medicina Tropical,* 1995 Supplement; 28(II):53-66*.*
94. Griffith B, Brett-Smith H, Kim G, Mellors JW, Chacko, TM, Garner RB, Chen YC, Alcabes P, **Friedland GH:** Effect of Stavudine on Human Immunodeficiency Virus Type 1 Viral Load as Measured by Quantitative Mononuclear Cell Culture, Plasma RNA, and Immune Complex Dissociated Antigenemia. *Journal of Infectious Diseases* 1996; 173:1252-1255.
95. Wetherill P, Landry M, Alcabes P, **Friedland GH**: The Use of a Quantitative Cytomegalovirus (CMV) Antigenemia Test in Evaluation of HIV+ Patients With and Without CMV Disease. *Journal of the Acquired Immune Deficiency Syndrome* 1996; 12:33-37.
96. Hartel D, Schoenbaum EE, Selwyn P, **Friedland GH**, Klein RS, Drucker E: Patterns of Heroin, Cocaine and Speedball Injection Among Bronx (USA) Methadone Maintenance Patients: 1978-1988. *Addiction Research* 1996; 3:324-340*.*
97. Frankel R, Virata M, Hardalo C, Altice F, **Friedland GH**: Invasive Pneumonococcal Disease: Clinical Features, Serotype and Antimicrobial Resistance Patterns in HIV Positive and HIV Negative Patients. *Clinical Infectious Diseases* 1996; 23:577-88.
98. Gourevich M, Hartel D, Schoenbaum E, Selwyn P, Davenny K, **Friedland GH**, Klein R: A Prospective Study of the Association of Syphilis and HIV Infection in Injecting Drug Users. *American Journal of Public Health* 1996; 86:1112-1115.
99. Altice FL and **Friedland GH**: Epidemiology of HIV Infection and AIDS: Past, Present, and Future. *Disease Management and Health Outcomes Journal* 1997; 1(6):304-322.
100. Williams A and **Friedland GH**: Adherence, Compliance, and HAART. *AIDS Clinical Care* 1997; 9 (7):51-54, 58.
101. **Friedland GH**: Adherence: The Achilles’ Heel of Highly Active Antiretroviral Therapy. *International AIDS Society-USA* 1997; 5 (1):3-15.
102. **Friedland GH** and Williams A: El Cumplimiento: Talon de Aquiles de una Terapia Antiretroviral Altamente Activa. *Actualizaciones en SIDA* 1997; 5 (18):262-275.
103. Kaldjian LC, Jekel JF, **Friedland GH**: End of Life Decisions in HIV Positive Patients: The Role of Spiritual Beliefs. *AIDS* 1998; 12 (1):103-107.
104. Wainberg MA, **Friedland GH**: Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance. *Journal of the American Medical Association* 1998; 279:1977-1983.
105. McCance-Katz EF, Jatlow P, Rainey PM, **Friedland GH**: Methadone Effects on Zidovudine Disposition. *Journal of the Acquired Immunodeficiency Syndrome* 1998; 18:435-443.
106. Altice FL, **Friedland GH**: The era of Adherence in Antiretroviral Therapy. *Annals of Internal Medicine* 1998; 129:503-505.
107. Gourevitch MN and **Friedland, GH**: Methadone and Antiretroviral Medications, Parts I and II, *AIDS Clinical Care* 1999; 4 and 5:30-31, 37, 43, 45-46.
108. Lin PF, Gonzalez CJ, Griffith B, **Friedland GH**, Calvez V, Ferchal F, Schinazi RF, Shepp DH, Ashraf AB, Wainberg M, Soriano V, Mellors JW, and Colonno RJ: Staduvine Resistance: An Update on Susceptibility Following Prolonged Therapy. *Antiviral Therapy* 1999; 4:21-28.
109. Altice FL, **Friedland GH**, Cooney EL: Nevirapine Induced Opiate Withdrawal Among Injection Drug Users With HIV Infection Receiving Methadone. *AIDS* 1999; 13: 957-962.
110. **Friedland GH**, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Nevin T, Hirsch M, Connick E, Fischl M, ACTG 261 Team: The Efficacy and Safety of Delavirdine Mesylate in Combination with Zidovudine and Didanosine Compared to Two Drug Combinations of These Drugs (ACTG 261). *Journal of the Acquired Immunodeficiency Syndrome* 1999; 21:281-292.
111. **Friedland GH** and Williams AB: The Future: Attaining Higher Goals in HIV Treatment: The Central Importance of Adherence. *AIDS 1999*; 13(Suppl 1):S61-S72.
112. Ethier KA, Rodriguez MR, Fox-Tierney RA, Martin C, **Friedland GH**,Ickovics JR: Recruitment in AIDS Clinical Trials: Investigation of Sociodemographic and Psychosocial Factors Affecting Participation in Clinical Research. *AIDS and Behavior* 1999; 3(3):219-230.
113. Buitrago M and **Friedland GH**: Tuberculosis and HIV Infection. *Current Infectious Disease Reports* 1999; 1:105-109.
114. Soloway B and **Friedland GH:** Antiretroviral Failure: A Biopsychosocial Approach. *AIDS Clinical Care* 2000; 12(3):23-25, 30.
115. Havlir DV, Tierney C, **Friedland GH**, Pollard RB, Smeaton L, Sommadossi, JP, et al: In Vivo Antagonism with Zidovudine Plus Stavudine Combination Therapy. *Journal of Infectious Diseases* 2000; 182:321-5.
116. **Friedland GH**: Breaking the Silence. Editorial. *AIDS Clinical Care* 2000; 12(8):1, 69-70.
117. Rainey PM, **Friedland GH**, McCance EF, Andrews L, Mitchell SM, Jatlow P, et al: Interaction of Methadone with Didanosine (ddI) and Stavudine (d4T). *Journal of the Acquired Immunodeficiency Syndrome* 2000; 24:241-248.
118. **Friedland GH:** Issues in HIV Therapy in “Triple Diagnosed” Patients: HIV Infections, Substance Use and Mental Illness*. Topics in HIV Medicine* 2000; 8:14-18.
119. Gourevitch MN and **Friedland GH**: Interactions Between Methadone and Medications Used to Treat HIV Infection: A Review. *Mt Sinai Journal of Medicine* 2000; 67(5): 429-436.
120. Schooley R, Spino C, Kuritzkes D, Walker B, Valentine F, Hirsch M, Cooney E, **Friedland G**, et al: Two Double Blinded Randomized Comparative Trials of Four HIV-1 Envelope Vaccines in HIV-1 Infected Individuals Across a Spectrum of Disease Severity (ACTG 209 and 214). *Journal of Infectious Diseases* 2000; 182:1357-1364.
121. Russi M, Buitrago M, Goulet J, Calello D, van Rhijn D, Nash E, **Friedland GH**, Hierholzer W: Antiretroviral Prophylaxis of Health Care Workers at Two Urban Medical Centers. *Journal of Occupational Environmental Medicine* 2000; 42:1092-1100.
122. Tchetgen E, Kaplan EH, **Friedland GH**: The Public Health Consequences of Screening Patients for Adherence to HAART. *Journal of the Acquired Immunodeficiency Syndrome* 2000; 26:118-129.
123. **Friedland G** and Andrews LA: Adherence to Antiretroviral Therapy. *AIDS Reviews* 2001; 3(3):111-120.
124. Altice F, Mostashari F, **Friedland GH**: Trust and the Acceptance of and Adherence to Antiretroviral Therapy. *Journal of Acquired Immune Deficiency Syndromes* 2001; 28:47-58.
125. McCance-Katz EF, Rainey PM, **Friedland GH**, Kosten TR, Jatlow P: Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition. *American Journal on Addictions* 2001; 10:296-307.
126. Rainey PM, **Friedland GH**, Snidow JW, McCance-Katz EF, Mitchel SM, Andrews L, et al: The Pharmacokinetics of Methadone Following Co-Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate-Dependent Subjects (NZTA4003). *American Journal of Addictions* 2002; 11:66-74.
127. Mannheimer S, **Friedland GH**, Matts J, Child C, Chesney M: The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for HIV Infected Persons in Clinical Trials. *Clinical Infectious Diseases* 2002; 34(8):1115-21.
128. Broadhead RS, Heckathorn DD, Altice FL, van Hulst Y, Carbone M, **Friedland GH**, et al: Increasing Drug Users’ Adherence to HIV Treatment: Results of a Peer-Driven Intervention Feasibility Study. *Social Science and Medicine* 2002; 55:235-246.
129. **Friedland GH**: Adherence to Antiretroviral Therapy. *Journal of HIV Clinicians Society of South Africa* March, 2002; 25-32.
130. Pollard R, Tierney C, Havlir D, Fox L, Smeaton L, Richman D, **Friedland GH**: A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine vs Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naïve (ACTG 298). *AIDS Research and Human Retroviruses* 2002; 18(10):699-704.
131. Schreibman T and **Friedland GH**: HIV/AIDS: HIV Prevention in the Clinical Care Setting. *Clinical Infectious Diseases* 2003; 36:1171-1176.
132. Pawinski R, Bobat R, **Friedland G**, Jeena P, Lalloo U: Antiretroviral treatment and Research in Resource –Poor Countries. *The Lancet* 2003; 361(9355):434-435.
133. McCance-Katz EF, Rainey P, **Friedland G**, Jatlow P: The Protease Inhibitor Kaletra (Lopinavir-Ritonavir) May Produce Opiate Withdrawal in Methadone-Maintained Patients. *Clinical Infectious Diseases* 2003; 37:476-482.
134. Haas D, Zala C, Schrader S, Piliero P, Jaeger H, Nunes D, Thiry A, Schnittman S, Sension M Protocol AI424-009 Study Group (**Friedland G**, Member): Therapy with Atazanavir vs. Saquinavir in Patients Failing Highly Active Antiretroviral Therapy: A Randomized Comparative Pilot Trial. *AIDS* 2003; 17:1339-1349.
135. Altice FL, Springer S, Buitrago M, Hunt DP, **Friedland GH**: Pilot Study to Enhance HIV Care Using Needle Exchange-Based Health Services for Out-of-Treatment Injecting Drug Users. *Journal of Urban Health*: *Bulletin of the New York Academy of Medicine* 2003; 80(3):416-427.
136. Schreibman T and **Friedland G**: Use of Total Lymphocyte Count for Monitoring Response to Antiretroviral Therapy. *Clinical infectious Diseases* 2004; 38:257-262.
137. **Friedland GH**: A Journey Through the Epidemic. Perspectives in HIV Care: A View From the Front Lines. *Bulletin of the New York Academy of Medicine*, Summer 1995 Suppl; 72 (1):178-186.
138. Abdool Karim S, Abdool Karim Q, **Friedland G**, Lalloo U and El-Sadr Won behalf of the START Project: Implementing Antiretroviral Therapy in Resource Constrained Settings: Opportunities and Challenges in Integrating HIV and Tuberculosis Care. *AIDS* 2004; 18:975-979.
139. **Friedland G**, Abdool Karim S, Abdool KarimQ, Lalloo U, Jack C, Gandhi N, El-Sadr W: The Utility of Tuberculosis Directly Observed Therapy (DOT) Programs as Sites for Access and Provision of Antiretroviral Therapy in Resource Limited Settings. *Clinical Infectious Diseases,* 2004; 38 (Suppl 5):S421-S428.
140. Uebel K, **Friedland G**, Pawinski R, Holst H: HAART for hospital health care workers an innovative programme. *South African Medical Journal* 2004; 94(6):423-427.
141. McCance-Katz EF, Rainey PM, Smith P, Morse G, **Friedland G**, Gourevitch M, Jatlow P: Drug Interactions Between Opioids and Antiretroviral Medications: Interaction Between Methadone, LAAM, and Nelfinavir. *The American Journal of Addictions* 2004; 13:163-180.
142. Altice FL, Mezger J, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, **Friedland G**: Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. *Clinical Infectious Diseases* 2004; 38(Suppl5):S376-387.
143. Jack C, Lalloo U, Abdool Karim Q, Abdool l Karim S, El-Sadr W, Cassol S, **Friedland G**: A Pilot Study of Once Daily Antiretroviral Therapy Integrated with Tuberculosis Directly Observed Therapy (TBDOT) In A Resource Limited Setting. *Journal of Acquired Immune Deficiency Syndromes* 2004; 36:929-934.
144. Fisher JD, Cornman DH, Osborne C, Amico KR, Fisher WA, **Friedland G**: Clinician-Initiated HIV-Risk Reduction Intervention for HIV+ Persons: Formative Research, Acceptability, and Fidelity of the Options Project.  *Journal of Acquired Immune Deficiency Syndromes* 2004; 37(Suppl 2):S78-S87.
145. Kozal, MJ, Amico R, Chiarella J, Schreibman T, Cornman D, Fisher WA, Fisher JD, **Friedland G**: Antiretroviral Resistance and High-Risk Transmission Behavior Among HIV-Positive Patients in Clinical Care. *AIDS* 2004; 18:2185-2189.
146. Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu A, **Friedland G**: Quality of Life in HIV-Infected Individuals Receiving Antiretroviral Therapy is Related to Adherence. *AIDS CARE* January 2005; 17(1):10-22.
147. Cassol E, Page T, Mosam A, **Friedland G**, Jack C, Lalloo U, Kopetka J, Patterson B, Esterhuizen T, Coovadia H: Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with Either *Mycobacterium* Tuberculosis or Human Herpesvirus-8*. Journal of Infectious Diseases* 2005; 191:324-332.
148. Smith PF, DiCenzo R, Forrest A, Shelton M, **Friedland G**, Para M, Pollard R, Fischl M, DiFrancesco R, Morse GD: Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected Individuals HIV. *Clinical Pharmacokinetics* 2005; 44(1):99-109.
149. Mosam A, Cassol E, Page T, Bodasing U, Cassol S, Dawood H, **Friedland GH**, Scadden DT, Aboobaker J, Jordaan JP, Lalloo UG, Esterhuizen TM, Coovadia HM: Generic Antiretroviral Efficacy in AIDS-Associated Kaposi’s Sarcoma in Sub-Saharan Africa. *AIDS* 2005; 19(4):441-443.
150. Kozal MJ, Amico RK, Chiarella J, Cornman D, Fisher W, Fisher J, **Friedland G**: HIV Drug Resistance and HIV Transmission Risk Behaviors Among Active Injection Drug Users. *Journal of Acquired Immune Deficiency Syndromes* 2005; 40(1):106-109.
151. Kapadia F, Vlahov D, Donahoe RM, **Friedland G:** The Role of Substance Abuse in HIV Disease Progression: Reconciling Differences from Laboratory and Epidemiologic Investigations. *Clinical Infectious Diseases* 2005; 41(7):1027-1034.
152. **Friedland GH**, Andrews L, Schreibman T, Argawala S, Daley L, Child M, Shi J, Wang Y, O’Mara E: Lack of an Effect of Atazanavir on Steady-State Pharmacokinetics of Methadone in Patients Chronically Treated for Opiate Addiction, *AIDS* 2005; 14 (15):1635-1641.
153. Fisher JD, Fisher WA, Cornman DH, Amico RK, Bryan A, **Friedland GH**: Clinician-Delivered Intervention During Routine Clinical Care Reduces Unprotected Sexual Behavior Among HIV-Infected Patients. *Journal of Acquired Immune Deficiency Syndromes* 2006; 41(1):44-52.
154. McCance-Katz EF, Rainey PM, Smith P, Morse GD, **Friedland G**, et al: Drug Interactions between Opioids and Antiretroviral Medications: Interactions between Methadone, LAAM, and Delavirdine. *American Journal of Addictions* 2006; 15:23-34-2006.
155. Bruce RD, Altice FL, Gourevitch MG, **Friedland GH**: A Review of Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications: Implications and Management for Clinical Practice. *Journal of Acquired Immune Deficiency Syndromes* 2006; 41(5):563-572.
156. Kozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, Fisher J **Friedland GH**: Population Based and Longitudinal Study of Sexual Behavior and Multidrug Resistant HIV Among Patients in Clinical Care, *eJournal of the International AIDS Society,* 2006; 8(2):72-79 PMC 1785162.
157. Gandhi N, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, **Friedland GH**: Extensively Drug-Resistant Tuberculosis (XDR TB) as a Cause of Death among TB/HIV Co-infected Patients in a Rural Area in South Africa. *Lancet* 2006; 368:1575–80.
158. **Friedland GH**, Khoo S, Jack C, Lalloo U: Administration of Efavirenz (600 mg/day) with Rifampin Results in Highly Variable Levels Which do not Predict Clinical Outcomes in Patients Treated for Tuberculosis and HIV. *Journal of Antimicrobial Chemotherapy* 2006; 58:1299–1302.
159. **Friedland GH**: HIV Medication Adherence: The Intersection of Biomedical, Behavioral and Social Science Research and Clinical Practice. *Journal of Acquired Immune Deficiency Syndromes* 2006; 43: (Suppl 1):S3-S9.
160. Mannheimer S, Morse E, Matts J, Andrews L, Child C, Schmetter B, **Friedland G** for the Terry Beirn Community Programs for Clinical Research on AIDS: Sustained Benefit From a Long-Term Antiretroviral Adherence Intervention: Results of a Large Randomized Clinical Trial. *Journal of Acquired Immune Deficiency Syndromes* 2006; 43(Suppl 1):S41-S47.
161. Wong I, Lawrence NV, Struthers H, McIntyre J, **Friedland G**: The Development and Assessment of an Innovative, Culturally-Sensitive Educational Video to Improve Adherence to Highly-Active Antiretroviral Therapy (HAART) in Soweto, South Africa. *Journal of Acquired Immune Deficiency Syndromes* 2006; 43(Suppl 1):S41-S47.
162. Kiene S, Christie S, Cornman D, Fisher W, Shuper P, Pillay S, **Friedland G**, Fisher J: Sexual Risk Behaviour Among HIV-Positive Individuals in Clinical Care in Urban KwaZulu-Natal, South Africa. *AIDS*, 2006; 20(13):1781-1784.
163. Fiellin DA, **Friedland G**, Gourevitch MN: Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments. *Clinical Infectious Diseases* 2006; 43(Suppl 1):S169-172.
164. McCance-Katz EF, Moody DE, Morse GD, **Friedland G**, Pade P, Baker J, et al: Interactions Between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. *Clinical Infectious Diseases* 2006; 43(Suppl 1):S224-234.
165. McCance-Katz EF, Moody DE, Smith PF, Morse GD, **Friedland G**, Pade P, et al: Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir. *Clinical Infectious Diseases* December 15, 2006; 43(Suppl 1):S235-246.
166. Padayatchi N and **Friedland G**: Managing Multiple and Extensively Drug-Resistant Tuberculosis and HIV. *Expert Opinion Pharmacotherapy* 2007; 8(8):1035-1037.
167. **Friedland G**: Tuberculosis, Drug Resistance and HIV/AIDS: Triple Threat. *Current Infectious Diseases Reports* 2007; 9:252-261*.*
168. **Friedland G,** Harries A, Coetzee D: Implementation Issues in HIV-TB Collaboration and Integration. *Journal of Infectious Diseases*, 2007; 196 (Suppl 1): S114-S123.
169. Altice FL, Smith-Rohrberg D, Bruce, RD, Springer S, **Friedland G**: Superiority of Directly Administered Antiretroviral Therapy Compared to Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. *Clinical infectious Diseases,* 2007; 45(6):770-8 PMC 2693907.
170. Andrews J, Shah NS, Gandhi N, Moll A, **Friedland G**: Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Implications for the HIV Epidemic and Antiretroviral Therapy Roll-Out in South Africa. *Journal of Infectious Diseases*, 2007; 196(Suppl 3): S482-S490.
171. Tsiouris S, Gandhi N, El-Sadr W, **Friedland G:** Tuberculosis and HIV – Needed: A New Paradigm for the Control and Management of Linked Epidemics. eJIAS: eJournal of the International AIDS Society. Medscape General Medicine. 2007; 9(3):62 PMC 2100118.
172. McCance-Katz EF, Moody DE, Morse G, Quing Ma Q, DiFrancesco R, **Friedland G**, Pade P, Rainey P: Interactions between Buprenorphine and Atazanavir or Atazanavir/Ritonavir, *Drug and Alcohol Dependence.* 2007; 91:269-278 PMID 17643869 NIHMS 33190.
173. Basu S, Andrews J, Poolman E, Gandhi N, Shah S, Moll A, Moodley P, Galvani A, **Friedland G:** Prevention of Nosocomial Transmission of Extensively Drug-resistant Tuberculosis in Rural South African District Hospitals: An Epidemiological Modelling Study. *The Lancet* 2007; 370:1500-1507.
174. Bruce RD, Altice FL, **Friedland G:** A Review of Pharmacokinetic Drug Interactions Between Drugs of Abuse and Antiretroviral Medications: Implications and Management for Clinical Practice. *Expert Review of Clinical Pharmacology* 2008; 1(1):115-127. ([www.future-drugs.com](http://www.future-drugs.com)).
175. Springer AD, **Friedland GH**, Doros G, Pesanti E, Altice FL: Antiretroviral Treatment Regimen outcomes Among HIV-Infected prisoners. *HIV Clinical Trials,* 2007; 8(4): 205-212 PMC 2409059.
176. Mannheimer S, Matts J, Gardner E, Telzak E, Child C, Wu A, Chesney M, **Friedland G** for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA)**:** Mild-to-Moderate Symptoms Worsen Quality of Life in HIV-infected Individual.  *Clinical Infectious Diseases* 2008; 46(6):941-945.
177. Gardner EM, Sharma S, Peng G, Huppler-Hullsiek K, Burman WJ, MacArthur RD, Chesney M, Telzak E, **Friedland G,** Mannheimer SB: Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. *AIDS* 2008; 22(1):75-82 PMC 2405889.
178. Burman W, Grund B, Roediger M, **Friedland G**, Darbyshire J, Weu A, for the SMART Study Group and INSIGHT: The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life. *Journal of Acquired Immune Deficiency Syndromes* 2008; 47(2):185-193.
179. Mannheimer S, Thackeray L, Huppler-Hullsiek K, Chesney M, Gardner E, Wu A, Telzak E, Lawrence J, Baxter J, **Friedland G:** A Randomized Comparison of Two Instruments for Measuring Self-Reported Antiretroviral Adherence. *AIDS Care* 2008; 20(2):161-169.
180. Mosam A , Hurkchand HP , Cassol E , Page T, Casso S, Bodasing U, Aboobaker J, Dawood H , **Friedland GH**,  Coovadia HM: Characteristics of HIV-1-Associated Kaposi 's sarcoma Among Women and Men in South Africa. *International Journal of STD & AIDS* 2008; 19(6):400-405.
181. **Friedland G:** Protecting Health Care Workers; the Critical Role of Airborne Infection Control, Editorial. *The International Journal of Tuberculosis and Lung Disease* 2008; 12(6):585.
182. Padayachi N, **Friedland G:** Decentralised Management of Drug-Resistant Tuberculosis (MDR and XDR TB) In South Africa: An Alternate Model of Care. *The International Journal of Tuberculosis and Lung Disease* 2008; 12(8):978-980.
183. Norton WE, Amico KR, Fisher WA, Copenhaver MM, Kozal MJ, Cornman DH, **Friedland G**, Fisher JD: Attitudes toward needle-sharing and HIV transmission risk behavior among HIV+ injection drug users in clinical care. AIDS Care. 2008; Apr,20(4):462-9.
184. Cornman D, Keine S, Christie S, Fisher W, Shuper P, Pillay S, **Friedland G,** Thomas C, Lodge L, Fisher J: Clinic-based Intervention Reduces Unprotected Sexual Behavior Among HIV-Infected Patients in KwaZulu-Natal, South Africa: Results of a Pilot Study. *Journal of Acquired Immune Deficiency Syndromes* 2008; 48(5) 15 Aug: 553-560 PMC 2813056.
185. Burman W, Grund B, Neuhaus J, Douglas Jr J, **Friedland G**, Telzak E, Colebunders R, Paton N, Fisher M, and Rietmeijer C for the SMART Study Group and INSIGHT: Episodic Antiretroviral Therapy Increases HIV Transmission Risk Compared With Continuous Therapy: Results of a Randomized Controlled Trial. *Journal of Acquired Immune Deficiency* Syndromes 2008; 49:142–150.
186. Andrews J, Gandhi N, Moodley M, Shah S, Bohlken L Moll A Pillay M, **Friedland G**, Sturm W:Exogenous Re-infection with Multidrug- and Extensively Drug-Resistant Tuberculosis Among Patients Receiving Treatment for Tuberculosis in Rural KwaZulu Natal, South Africa. *Journal of Infectious Diseases* 2008; 198(1 December):1582-9.
187. Gandhi N, Moll A, Lalloo U, Pawinski R, Zeller K, Moodley P, Meyer E, **Friedland G**: Successful Integration of Tuberculosis and HIV Treatment in Rural South Africa: the *Sizonq’oba* Study. *Journal of Acquired Immunodeficiency Syndrome* 2009;50:37-43 Jan 1.
188. Shenoi S, Heysell S, Moll T, **Friedland G:** Multidrug Resistant and Extensively Drug Resistant TB: Consequences for the Global HIV Community. *Current Opinion in Infectious Diseases* 2009; 22:11-17 PMCID 30132260.
189. **Friedland, G**: Tuberculosis Immune Reconstitution Inflammatory Syndrome: Drug Resistance and the Critical Need for Better Diagnostics. *Clinical Infectious Diseases* 2009; 48:5:677-679.
190. Orenstein EW, Basu S, Shah NS, Andrews JR, **Friedland, GH**, Moll AP, Gandhi NR and Galvani AP: Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. *Lancet Infectious Diseases* 2009; 9:153-161.
191. Shenoi S, **Friedland G**: Extensively Drug-Resistant (XDR) Tuberculosis: A New Face to an Old Pathogen. *Annual Reviews in Medicine*, 2009, 60:307–20 PMCID 3013225.
192. Basu S, **Friedland G**, Andrews J, Shah S, Gandhi N, Moll A, Moodley P, Sturm W, Medlock, Galvani A: The Emergence and Transmission Dynamics of XDR Tuberculosis in Rural KwaZuluNatal, South Africa. *Proceedings of the National Academy of Science PNAS,* 2009; 106(18):7672-7677s.) PMID 19365076 PMCID 2678614.
193. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, **Friedland GH:** HIV Co-infection in Multidrug- and Extensively Drug-Resistant Tuberculosis Results in High Early Mortality. *American Journal of Respiratory and Critical Care Medicine*.2010; 181:80-86.
194. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T; Nair G, Bamber S, Singh A, Khan M; Pienaar J,El-Sadr W, **Friedland G,** Abdool Karim Q: Timing of Initiation of Antiretroviral Drugs During Tuberculosis Therapy. *New England Journal of Medicin*e. February 25, 2010; 362(8):697-706.
195. Simon M, Altice F, Moll A, Shange M, **Friedland G:** Preparing for highly-active antiretroviral therapy rollout in rural South Africa: an assessment using the information, motivation, and behavioral skills model. *AIDS Care.* March 05, 2010. Article: DOI: 10.1080/09540120903220253 URL:
196. Gardner EM, Hullsiek KH, Telzak EE, Sharma S, Peng G, Burman WJ, Chesney M, **Friedland G**, MacArthur R, Mannheimer SB: Antiretroviral Medication Adherence and Class-Specific Resistance in a Large Prospective Clinical Trial. *AIDS*, 2010, 24:395-403 PMC 2886717.
197. Churchyard GJ, **Friedland G,** Fielding K, Nardell E: [Opportunities afforded by new drugs for tuberculosis.](http://www.biomedexperts.com/Experts/Abstract.aspx?pid=20510274&login=gchurchyard@auruminstitute.org&lid=20100608) *The Lancet* *Infectious Diseases,* 2010; 10 (6):368-9.
198. Heysell SK, Moll AP, Gandhi NR, Eksteen FJ, Babaria P, Coovadia Y, Roux L, Lalloo U, **Friedland G** and Shah NS. Extensively Drug-resistant Mycobacterium Tuberculosis from Aspirates, Rural South Africa. *Emerging Infectious Diseases* [www.cdc.gov/eid, 2010](http://www.cdc.gov/eid%2C%202010); 16(3):557 .
199. Shenoi, S, Escombe AR, **Friedland G:** Transmission of Drug-Susceptible and Drug-Resistant Tuberculosis and the Critical Importance of Airborne Infection Control in the Era of HIV Infection and Highly Active Antiretroviral Therapy Rollouts *Clinical Infectious Diseases*, 2010; 50(Suppl 3):S231-237, PMC3029014.
200. Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin D, Fang WB, Ma Q, and **Friedland GH:** Pharmacokinetic Interactions Between Buprenorphine/ Naloxone and Once-Daily Lopinavir/Ritonavir *Journal of Acquired Immune Deficiency Syndrome*, August 15, 2010; 54(5):511–514 PMID 20672450.
201. Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, Li X, Ladutko L, Campbell S, **Friedland G**, Mitton‐Fry M, and Miller PF: Pharmacokinetics and whole blood bactericidal activity against *Mycobacterium tuberculosis* of single doses of PNU‐100480 in healthy volunteers, *Journal of Infectious Diseases* 2010:202 (1 Sept).
202. Altice F, Kamarulzaman A, Soriano V, Schechter M, **Friedland G,** Medical, Psychiatric and Substance Use Co-Morbidities Among HIV-Infected Drug Users: Optimizing Treatment and Clinical Outcomes. *Lancet*, 2010; Jul 31; 376(9738):367-87.
203. **Friedland G**, Infectious Disease Co-Morbidities Adversely Affecting Substance Users with HIV: Hepatitis C and Tuberculosis, *Journal of Acquired Immunodeficiency Syndromes,* 2010; 55(Suppl 1):S37-S42.

1. Thomas T, Shenoi S, Heysell S, Eksteen F, Sunkari V, Gandhi N, **Friedland G,** Shah S: Extensively Drug-Resistant Tuberculosis in Children with HIV from Rural South Africa, *International Journal of Tuberculosis and Lung* 2010; 14(10):1244-1251, PMC 3030274 NIHMS 261603.
2. Heysell S, Thomas T, Gandhi N, Moll AP, Eksteen F, Coovadia Y, Roux L, Babaria P, Lalloo U, **Friedland G** and Shah S: Blood cultures for the diagnosis of multidrug-resistant and extensively drug-resistant tuberculosis among HIV-infected patients from rural South Africa: a cross-sectional study. *BMC Infectious Diseases* 2010 December; 10:344 PMCID PMC3016377.
3. Andrews J, Shah S, Weissman D,  Moll A, **Friedland G**, Gandhi N: Predictors of Multidrug- and Extensively Drug-Resistant Tuberculosis in a High HIV Prevalence Community *PLoS ONE* Dec 29, 2010 101371/journal.pone.0015735 [www.ploseone.org](http://www.ploseone.org).
4. Abdool Karim, Q, Abdool Karim SS, Baxter C, **Friedland G,** Gengiah T, Gray A, Grobler A, Naidoo K, Padayatchi N, El-Sadr W: The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis *South African Medical Journal* December 2010; 100(12):808-809.
5. Shah N, Richardson J, Moodley P, Moodley S, Babaria P,Ramtahal M, Heysell S, Li X, Moll AP, **Friedland G**, Sturm A, Gandhi N: Increasing Drug Resistance in Extensively Drug-Resistant Tuberculosis, South Africa. *Emerging Infectious Diseases* 2011; 17(3):510-513.
6. Shah SS, Moodley P, Babaria P, Moodley S, Ramtahal M, Richardson J, Heysell S, Li X, Moll A, **Friedland G**, Sturm AW, and Gandhi GR. Rapid Diagnosis of Tuberculosis and Multidrug Resistance by the Microscopic-Observation Drug-Susceptibility Assay *American Journal of . Respiratory Care and Critical Care Medicine* May 2011; 183:1427-33.
7. Brust J, Lygizos M, Chaiyachati K, Scott M, van der Merwe T, Moll A, Li X, Loveday M, Bamber S, Lalloo U, **Friedland G**, Shah S and Gandhi N: Culture Conversion among HIV Co-infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa. *PLoS ONE*, Research Article, published 06 Jan 2011 10.1371/journalpone.0015841.
8. Heysell SK, Shenoi SV, Catterick K, Thomas TA, **Friedland G** Pr**e**valence of methicillin-resistant *Staphylococcus aureus nasa*l carriage among hospitalized patients with tuberculosis in rural KwaZulu-Natal. *South African Medical Journal 2011*; 101:332-334. 10.1371/journal.pone.0015841 [www.ploseone.org](http://www.ploseone.org).
9. Fisher JD, Amico KR, Fisher WA, Cornman DH, Shuper PA, Trayling C, Redding C, Barta W, Lemieux AF, Altice FL, Dieckhaus K, **Friedland G**, for the LifeWindows Team. (2011). Computer-based intervention in HIV clinical care setting improves antiretroviral adherence: The LifeWindows Project. *AIDS and Behavior*, 2011; 15(8):1635-1646.
10. Moodley P, Shah NS, Tayob N, Connolly C, Zetola N, Gandhi NR, **Friedland GF**, Sturm AW Spread of Extensively Drug-resistant Tuberculosis in KwaZulu-Natal Province, South Africa., *PLoS ONE* , 2011, 6(5): e17513. doi:10.1371/journal.pone.0017513.
11. Vella V, Racalbuto V, Guerra R, Marra C, A, Mhlanga Z, Maluleke M, Mhlope H, Margot B, **Friedland G**, Shah S, Gandhi N, Household Contact Investigation of Multidrug and Extensively Drug-resistant Tuberculosis in a High HIV-Prevalence Setting, *International Journal of Tuberculosis and Lung Diseases,* 2011; 15(9):1170-5.
12. McCance-Katz EF, Moody DE, Prathikanti S, **Friedland G**, Rainey PM, Rifampin, but not Rifabutin, May Produce Opiate Withdrawal in Buprenorphine-Maintained Patients,  *Drug and Alcohol Dependence,* 2011 Nov 1; 118(2-3):326-34. Epub 2011, May 19.
13. Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Gengiah Naidoo A, Jithoo N, Nair, El-Sadr, W, **Friedland G,** Abdool Karim Q, Integration of Antiretroviral Therapy with Tuberculosis Treatment, *New England Journal of Medicine* 2011; 365:1492-1501.
14. Gandhi NR, Andrews JR, Brust JCM, Montreuil R, Weissman D, Heo M, Moll AP,

**Friedland GH**, Shah NS, Risk Factors for Mortality Among MDR- and XDR-TB Patients in a High HIV Prevalence Setting. *Internation Journal of Tuberculosis and Lung Diseas*e 16(1):90–97 © 2012 The Union http://dx.doi.org/10.5588/ijtld.11.0153.

1. Kanjee Z, Catterick K, Moll AP, Amico KR, **Friedland GH**, Tuberculosis Infection Control in Rural South Africa: Survey of Knowledge, Attitude and Practice in Hospital Staff, *Journal of Hospital Infection,* 2011, 79:333-338.
2. Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, Master I, van der Merwe TL, **Friedland GH,** (2012) Survival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa. *PLoS ONE:* Research Article, published 06 Mar 2012 10.1371/journal.pone.0031786 PMC3295798.
3. Kanjee, Z, Amico KR, Moll A, Mbolekwa K, Fangyong L, **Friedland G**, Tuberculosis Infection Control in a High Drug-Resistance Setting in Rural South Africa: Information, Motivation, Behavioral Skills, *Journal of Infection and Public Health*, 2012; 5:67-81.
4. Mosam A, Esterhuizen T, Uldrick T, Aboobaker J, Shaik **F, Friedland G**, Coovadia H, A randomized controlled trial of HAART versus HAART and chemotherapy in therapy-naïve patients with HIV-associated Kaposi sarcoma in South Africa. *Journal of Acquired Immune Deficiency Syndrome* 2012; 0:1-8.
5. Naidoo K, Yende-Zuma N, Padayatachi N, Naidoo Ka, Jithoo N, Nair G, Bamber S, Gengiah S, El-Sadr WM, **Friedland G** and Karim SA, The Immune Reconstitution Inflammatory Syndrome After Antiretroviral Therapy Initiation in Patients With Tuberculosis: Findings From the SAPiT Trial *Annals of Internal Medicine* 4 September 2012; 157(5): 313-324.
6. Brust JCM, Shah NS, Scott M, Chaiyachati K, Lygizos M, van der Merwe TL, Bamber S, Radebe Z, Loveday M, Moll AP, Margot B; Lalloo UG, **Friedland G**, Gandhi NR, Integrated, Home-based Treatment for MDR-TB and HIV in Rural South Africa: An Alternate Model of Care *International Journal of Tuberculosis and Lung Disease* 1 August 2012; 16(8): 998-1004(7).
7. Gandhi NR, Weissman D, Moodley P, Ramathal M, Elson I, Kreiswirth BN, Mathema B, Shashkina E, Rothenberg R, Moll AP, **Friedland G**, Sturm AW, and Shah NS. Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in a Rural Hospital in South Africa. *Journal of Infectious Disease* 19, November 2012, 10.1093/infdis/jis631.

1. Bruce RD, Moody DE, Fang WB, Chodkowski D, Andrews L, Parsons T, **Friedland GH.** Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subject Receiving Chronic Buprenorphine/Naloxone. *American Journal of Drug and Alcohol Abuse*; 2013; 39(2): 80-85.
2. Shenoi, SV, Brooks RP, Catterick K, Moll AP, **Friedland GH**. ‘Cough officer’ nurses in a general medical clinic successfully detect drug-susceptible and -resistant tuberculosis. 2013. *Public Health Action* 2013; 3(1):46-50.
3. Chaiyachati K, Loveday M, Lorenz S, Neal N, Larkan L, Cinti S, **Friedland G**, and Haberer J. A Pilot Study of an mHealth Application for Healthcare Workers: Poor Uptake Despite High Reported Acceptability at a Rural South African Community-Based MDR-TB Treatment Program; May 2013; *PLOS ONE;*  8(5); e64662: 1-8
4. Bruce RD, Moody DE, Altice FL, Gourevitch MN, **Friedland GH**. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. *Expert Reviews in Clinical Pharmacology*; May 2013; Vol. 6; No. 3: 249-269.
5. Bruce RD, Winkle R, Custodio J, Yin X, Rhee M, Andrews J, Kearney BP, Ramanathan S, **Friedland, GH**. The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. *Journal of Acquired Immunodeficiency Syndromes,* 2013; 63(4): 480-484.
6. Lygizos M, Shenoi SV, Brooks RP, Bhushan A, Brust JCM, Zelterman D, Deng Y, Northup V, Moll AP, **Friedland GH**. Natural Ventilation and TB transmission risk in traditional homes in rural KwaZulu-Natal, South Africa. *BMC Infectious Diseases*, 2013, 13:300 doi:10.1186/1471-2334-13-300.
7. Kompala T, Shenoi S, **Friedland G**, Transmission of Tuberculosis in Resource-Limited Settings, *Current HIV/AIDS Reports*, 2013 DOI 10.1007/s11904-013-0164-x.
8. **Friedland G**, Pumersh P, Abdool-Gafoor, B, Yunus M, Ramdial P, Gandhi R, Case 29-2013: A 32-Old HIV-Positive African Man with Dyspnea and Skin Lesions, *New England Journal of Medicine* Sept 2013 369; 12:152-161.
9. Brust JCM, Berman AR, Zalta B, Haramati LB, Ning Y, Heo M, van der Merwe T, Bamber S, Moll A, **Friedland G**, et al., (2013). Chest Radiograph Findings and Time to Culture Conversion in Patients with Multidrug-Resistant Tuberculosis and HIV in Tugela Ferry, South Africa. *PLoS ONE* September 2013; 8(9): e73975.
10. Bruce R, Winkle P, Custodio J , Wei L, Rhee M, Kearney B, Ramanathan S, and **Friedland G**, An investigation of the interactions between methadone and elvitegravir/cobicistat in subjects receiving chronic methadone maintenance, *Antimicrobial Agents and Chemotherapy* 2013, 57(12):6154. 01229-13.
11. Brust JCM , Shah NS, Van Der Merwe TL, Bamber S, Ning Y, Heo M, Moll AP, Loveday M, Lalloo UG, **Friedland GH**, Gandhi NR. Adverse events in an integrated home-based treatment program for MDR-TB and HIV in Kwazulu-Natal, South Africa. *Journal of Acquired Immune Deficiency Syndromes* 2013; 62(4):436-440.
12. Padayatchi N, Abdool Karim S, Naidoo K, Grobler A, **Friedland G**, Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial, *International Journal of Tuberculosis and Lung Disease*, 2014, 18(2):1–8. <http://dx.doi.org/10.5588/ijtld.13.0627>.
13. Thomas T, Heysell S, Moodley P, Montreuil R, Ha X, **Friedland G**, Bamber S, Moll A, Gandhi N, Brant W, Sturm AW, Shah S, Intensified specimen collection to improve tuberculosis diagnosis in children from rural South Africa, an observational study. *BMC Infectious Diseases*, 2014; 14(11). http://www.biomedcentral.com/1471-2334/14/11.
14. Gandhi NR, Brust JCM, Moodley P, Weissman D, Heo M, Ning Y, Moll AP, **Friedland G**, Sturm AW and Shah NS. Minimal Diversity of Drug-Resistant Mycobacterium tuberculosis Strains, South Africa *Emerging Infectious Diseases* March 2014; 20(3): 426-433. [www.cdc.gov/eid](http://www.cdc.gov/eid) <http://dx.doi.org/10.3201/eid2003.131083>.
15. Peluso M, Hung A, Lukasiewicz A, Chang H, Ramallo J, Bartlett M, **Friedland G**, Ellis P , Successful Management of Latent Tuberculosis Infection in an Underserved Community by a Student-run Free Clinic, *Journal of Health Care for the Poor and Underserved,* May 2014;25(2): 837-862 DOI: 10.1353/hpu. 2014.0109.
16. Fisher JD, Cornman DH, Shuper PA, Christie S, Pillay S, Macdonald S, Ngcobo N, Amico KR, Lalloo U, **Friedland G**, Fisher WA; SA Options Team. [HIV prevention counseling intervention delivered during routine clinical care reduces HIV risk behavior in HIV-infected South Africans receiving antiretroviral therapy: the Izindlela Zokuphila/Options for Health randomized trial.](https://urldefense.proofpoint.com/v2/url?u=http-3A__www.ncbi.nlm.nih.gov_pubmed_25230288&d=AwMFaQ&c=-dg2m7zWuuDZ0MUcV7Sdqw&r=ZQp31UBa97w0HljBtWPQKEYvNS_Tg0uDXMW2RCSuHEM&m=1KlOELQ2ABDM4TZvR7UVkzAlIsXOHhONqdAl_RGEInQ&s=EIAik__yCenYt97H3TykYILQzdHPODH6redxATAmZS0&e=) *Journal of Acquired Immunodeficiency Syndromes.* 2014 Dec 15;67(5):499-507. doi: 10.1097/QAI.0000000000000348 PMID: 25230288
17. Rodger A, Lampe F, Grulich A, Fisher M, **Friedland G**, Phanuphak N, Bogner J, Pereira L, Rietmeijer C, Burman W, Phillips A; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.[Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.](https://urldefense.proofpoint.com/v2/url?u=http-3A__www.ncbi.nlm.nih.gov_pubmed_25711325&d=AwMFaQ&c=-dg2m7zWuuDZ0MUcV7Sdqw&r=ZQp31UBa97w0HljBtWPQKEYvNS_Tg0uDXMW2RCSuHEM&m=aUmZFMla6-0kTuVD0wyjOrl6YCRNW8crixApcRA3FuM&s=gVzKEW9Qn7301cKaycSjtOfm8iJT6Fkm1FyRk39vinI&e=) *HIV Medicine*. 2015 Apr;16 Suppl S1:64-76. doi: 10.1111/hiv.12235 PMID: 25711325
18. Jacobson K, Tate M, Eksteen F, Moll AP, Padayatchi N, **Friedland G**, Shenoi S; Challenges in the care of the XDR-TB patient who has failed treatment *Lancet Respiratory Medicine* 2015 Apr 3; 4: 269-270.
19. Gilbert JA, Long EF, Brooks RP, **Friedland GH,** Moll AP,Townsend JP, Galvani AP, Shenoi SV**;** Integrating Community-Based Interventions to Reverse the Convergent TB/HIV Epidemics in Rural South Africa, *PLoS ONE* 2015 May 4;10(5):e0126267. doi: 10.1371/journal.pone.0126267. eCollection 2015.PMID: 25938501
20. Jacobson KB, Moll AP, **Friedland GH**,Shenoi SV;Successful Tuberculosis Treatment Outcomes among HIV/TB Coinfected Patients Down-Referred from a District Hospital to Primary Health Clinics in Rural South Africa. *PloS One* 2015 May 19; 10(5): e0127024. doi:10.1371/journal.pone.0127024. PMID: 25993636
21. Cowell A, Shenoi SV, Kyriakides TC, **Friedland G**, Barakat LA; Trends in hospital deaths among human immunodeficiency virus-infected patients during the antiretroviral therapy era, 1995 to 2011 *Journal of Hospital Medicine* 2015 Jun 30. doi: 10.1002/jhm.2409. [Epub ahead of print] PMID: 26130520 [PubMed - as supplied by publisher]
22. Upadhya D, Moll AP, Brooks RP, **Friedland G**, Shenoi SV; What motivates use of community-based human immunodeficiency virus testing in rural South Africa? *International Journal of STD and AIDS* 2015 Jul 1. pii: 0956462415592789. [Epub ahead of print] PMID: 26134323 [PubMed - as supplied by publisher]
23. O'Donnell MR, Daftary A, Frick M, Hirsch-Moverman Y, Amico KR, Senthilingam M, Wolf A, Metcalfe JZ, Isaakidis P, Davis JL, Zelnick JR, Brust JC, Naidu NGarretson M, Bangsberg DR, Padayatchi N, **Friedland G.** Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV.Int J Tuberc Lung Dis. 2016 Apr;20(4):430-4. doi: 10.5588/ijtld.15.0360. PubMed
24. **Friedland G**. Marking Time in the Global HIV/AIDS Pandemic. JAMA. 2016 Jul 12;316(2):145-6. doi: 10.1001/jama.2016.9006. PubMed PMID: 27404179249.
25. Ogbuagu O, **Friedland G**, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):721-31. doi: 10.1080/17425255.2016.1183644. Review. PubMed PMID:27140427
26. Kompala T, Moll AP, Mtungwa N, Brooks RP, **Friedland GH**, Shenoi SV. Impact of nurse-delivered community-based CD4 services on facilitating pre-ART care in rural South Africa. BMC Health Serv Res. 2016 Aug 11;16(a):374. doi:10.1186/s12913-016-1627-8. PubMed PMID: 27515233; PubMed Central PMCID: PMC4982129
27. Gilbert JA, Shenoi SV, Moll AP, **Friedland GH**, Paltiel AD, Galvani AP. Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLoS One. 2016 Dec 1;11(12):e0165614. doi: 10.1371/journal.pone.0165614. PubMed PMID: 27906986; PubMed Central PMCID: PMC5131994252.
28. Padayatchi N, Naidu N, **Friedland G**, Naidoo K, Conradie F, Naidoo K, O'Donnell MR. Turning the Tide Against Tuberculosis. Int J Infect Dis. 2017 Feb 3. pii:S1201-9712(17)30015-2. doi: 10.1016/j.ijid.2017.01.012. [Epub ahead of print] PubMed PMID: 28167256
29. Villanueva M,and **Friedland G**, [Responding to an Ever Changing Epidemic: The Evolution of HIV Care in New Haven](#_bookmark12), Connecticut Medicine, April 2017, 81, no 4, 237-241
30. Shenoi SV, Moll AP, Brooks RP, Kyriakides TK, Andrews L, Kompala T, Upadhya D, Altice F, Eksteen F, Friedland GH. Integrated TB/HIV Community-Based Case Finding in Rural South Africa: Implications for TB Control Efforts. Open Forum Infectious Diseases · May 2017DOI: 10.1093/ofid/ofx092

* **Books, Chapters, letters and web site presentations >100**
1. **Friedland G**: Parasitic Infections. In Graef J and Cone TE, Jr., eds., Manual of Pediatric Therapeutics (Little, Brown & Company 1974, 1980).
2. Stottmeier K, and **Friedland G**: Atypical Mycobacteria from Non-pulmonary Sources. In Von Graevenitz A and Sall T, eds. Pathogenic Micro-organisms from Atypical Sources (New York: Marcel Dekker, 1974)
3. **Friedland G**, McCue J, Perlman F, Greenfield S, and Komaroff AL: Symptoms of Urinary Tract Infection and Vaginitis. In Komaroff AL and Winikoff RN, eds., Common Acute Illness: A Problem-oriented Textbook (Little, Brown & Co 1977), 41-80.
4. **Friedland G** and Rubin D: Infectious Diseases. In May ed., Emergency Medicine (New York: Wiley Medical Publications, 1984).
5. Steigbigel NH and **Friedland G**: Acquired Immunodeficiency Syndrome. In Kass and Platt, eds., Current Therapy in Infectious Disease (Philadelphia, B. C. Decker Inc., The C. V. Mosby Company 1985).
6. **Friedland G**: Fever and Lymphadenopathy. In Kass and Platt, ed., Current Therapy in Infectious Disease (Philadelphia: B. C. Decker Inc., The C. V. Mosby Company 1983-1984; Second Edition, 1986).
7. **Friedland G** and Klein RS: Real and Perceived Risk of AIDS in the Family and Household, AIDS: Information on AIDS for the Practicing Physician (Chicago: American Medical Association 1987).
8. **Friedland G**: Editor, Clinical Treatment. AIDS 1988; (Suppl 1): S133-205.
9. **Friedland G**, Kaslow R, and Francis D, eds: AIDS and IV Drug Abuse: Epidemiology of AIDS (New York: Oxford University Press 1989).
10. Samuels J and **Friedland G**: Diagnosis of HIV Infection. In Conn RB, ed. Current Diagnosis (W.B. Saunders Co., 1991).
11. **Friedland G**: Natural History of HIV Infection in Intravenous Drug Users and Homosexual Men in Longitudinal Studies of HIV Infection in Intravenous Drug Users: Methodologic Issues in Natural History Research. U.S. Department of Health and Human Services, National Institute on Drug Abuse Research Monograph Series 109, 1991; 3:29-50.
12. Samuels J and **Friedland G**: Emergency Management of the Patient with Human Immunodeficiency Virus Infection. In May H. ed., Emergency Medicine, (Little Brown & Company, 1992); 1030-1043.
13. **Friedland G** and Klein R: Tuberculosis and other Bacterial Infections. In DeVita V, Hellman S, Rosenberg S, eds: AIDS: Etiology, Diagnosis, Treatment and Prevention. (Philadelphia: JB Lippincott Co., 1992).
14. Hecht F and **Friedland G**: Asymptomatic HIV Infection: Assessment and Prophylaxis, HIV: Advances in Research and (CT: Cliggott Communications, 1992).
15. Brett-Smith H and **Friedland G**: Transmission and Treatment. In Dalton H, Burris S, Miller J Yale Law School, eds., AIDS Law Today, 2nd edition; (New York, NY: Wiley Law Publications, 1992).
16. **Friedland G** and Selwyn PS: Infections in Injection Drug Users. In Isselbacher, Braunwald, Wilson, Martin, Fauci and Kasper eds., Harrisons' Textbook of Medicine (McGraw Hill Inc. Thirteenth Edition, 1994).
17. **Friedland G**: Shifts in At Risk Communities: Issues for Clinical Research. AIDS Clinical Research and Care: Meeting the Challenges of an Epidemic in Flux. Public Responsibility in Medicine and Research (PRIM&R) and Tufts University School of Medicine, 1995.
18. **Friedland G** and Rigsby MO: Fever and Lymphadenopathy. In Schlossber D, ed: Current Therapy of Infectious Disease. (Philadelphia: Mosby-Year Book, Inc., 1995).
19. **Friedland G**: Natural History of HIV Infection. In Kmiecik-Baran, Ceynowa Andrzej, eds., HIV/AIDS Social and Medical Aspects. (Poland: Universytet Gdanski, Gdansk, 1995).
20. **Friedland G** and Rigsby MO: Tuberculosis and HIV Infection. In DeVita V, Hellman S, Rosenberg, eds., AIDS: Biology, Diagnosis, Treatment and Prevention, Fourth Edition, (Lippincott-Raven Publishers, 1996).
21. Williams AB and **Friedland G**: Substance Abuse Issues in Women With HIV. In Cotton DJ, & Watts DH, eds., Medical Management of AIDS in Women, (New York: John J. Wiley & Sons, Inc., 1996).
22. **Friedland G** and Selwyn PS: Infections in Injection Drug Users. In Isselbacher, Wilson, Martin, Kasper, Hauser, Fauci, Braunwald, and Longo, eds., Harrisons' Textbook of Medicine Fourteenth Edition (McGraw Hill Inc., 1996).
23. **Friedland G:** Dunkle LW, Cross AP: Stavudine (d4T, Zerit®). In Mill SJ, Volberding PA, and Corey L, eds., Proceedings of the Fourth Triennal Symposium Antiviral Chemotherapy: New Directions for Clinical Application and Research (New York: Plenum, 1996).
24. Rigsby MO and **Friedland G**: Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS). In: Zaret BL and Jatlow P, eds., Your Guide to Test and Procedures. (William Morrow and Co., 1997).
25. Del Rio C, Cahn P, and **Friedland G**: Antiretroviral Therapy in Latin America. In International AIDS Society, (Stockholm, Sweden, Spring, 1998).
26. **Friedland G**: HIV Disease in Substance Abusers: Treatment Issues. In Sande MA and Volberdg P, eds., The Medical Management of AIDS, Sixth Ed., (Philadelphia, WB Saunders Company, 1999).
27. Brosgart C, Brown L Jr, **Friedland G,** Sherer R: HIV and Injection Drug Use in America, Identification, Access and Treatment. (Chicago, IL MATEP Adherence Initiative, 1999).
28. Ringel M. **Friedland G**, Hirschhorn L, Powderly WG, Silverman MF, consultants: HIV Disease in the New Century in Patient Care (Montvale, NJ, Medical Economics Company, October 1999).
29. Andrews L and **Friedland G**: Progress in HIV Therapeutics and the Challenges of Adherence to Antiretroviral Therapy. In Infectious Disease Clinics of North America, (Philadelphia, W.B. Saunders Co., 2000).
30. Buitrago M and **Friedland G**: Fever and Lymphadenopathy. In Schlossberg, David ed, Current Therapy of Infections Disease, 2nd edition, (Philadelphia, PA, Mosby, Inc, 2001) 87-92.
31. **Friedland G**, Pawinski R, Govendor M, Govendor T: HIV in the Community and Workplace. In Reichmann D, ed., Human Virus Guide, (London, International Medical Press, 2003).
32. **Friedland G**: Medicine as a Calling. In Spiro H and Donaldson R, eds., Yale Guide to Medicine and the Health Professions (New Haven CT, Yale University Press, 2003) 176-180.
33. **Friedland G**: Progression of HIV Disease in Injection Drug Users: Clinical Considerations, Clarifying The Controversy About Whether Drug Abuse Influences AIDS Progression, NIDA Satellite Sessions in Association with the XIV International AIDS Conference (Barcelona, Spain July, 2002).
34. **Friedland G**: Injection Drug Users, Special Populations. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. National Institutes of Health, US Department of Health and Human Services Washington, DC 2004.
35. Williams A and **Friedland G**, eds: Adherence to Antiretroviral Medications, Supplement to *Journal of Acquired Immune Deficiency Syndromes*, 2006, December 1; 43 Supplement 1.
36. **Friedland G**, Churchyard G, Nardell, E, eds: Tuberculosis and HIV Co-infection: Current State of Knowledge and Research Priorities, Supplement to *Journal of Infectious Diseases*, 2007, August 15; 196 Supplement 1.
37. Bruce RD, Altice FL, **Friedland G:** HIV Disease Among Substance Misusers: Treatment Issues. In Volberding P, ed., Global AIDS/HIV Medicine*.* San Diego, CA, Elsevier Inc. 2007.
38. Moll T, Gandhi, N, Shah S**, Friedland G**: Extensively Drug-resistant Tuberculosis (XDR-TB), Chapter 53a, Tuberculosis – A Comprehensive Clinical Reference, Zumla A and Schaaf S eds , Elsivier Ltd. 2009.
39. Shenoi S**,** Moll AP, **Friedland G:** Approaches to the Prevention and Management of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. From the Ground Up. Elizabeth Glaser AIDS Foundation. 2010.
40. **Friedland, G** and Vlahov, D Guest Editors, Integration of Buprenorphine for Substance-Abuse Treatment by HIV Care Providers, *Journal of Acquired Immune Deficiency Syndromes* 2011, Supplement, Volume 56:S1-2 (1-104).
41. Cassell GH, Berwick DM, Bloom BR, Bond EC, Chaisson RE, Farmer P, Fauci A, Filerman G, **Friedland GF**, Gallin EK, Groft SC, McGovern V, Sung N, Widdus R: The Emerging Threat of Drug-Resistant Tuberculosis in Southern Africa, Global and Local Challenges and Solutions by the Institute of Medicine and the Academy of Science of South Africa, 2011.
42. Shenoi S and **Friedland G**: 28. Lymphadenopathy / lymphadenitis. In Schlossberg, David ed, *Current Therapy of Infections Disease,* 24th  edition, (Academic Publishing Cambridge University Press Cambridge UK , 2015)
43. Heysell S and **Friedland G** Epidemiology of extensively drug-resistant tuberculosis *UptoDate* 2011,2013,1015
44. Heysell S and **Friedland G** Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis *UptoDate* 2011,2013, 2014, 2016

**Website Presentations**

# Article II. Mini-symposium at the NIDA Symposium Drug Interactions, 3rd International PK (Pharmacology) Meeting, April 13, 2002, Washington, DC. Drug interactions presentations on the Virology-Education website. <http://www.virology-education.com/index2.html><http://www.hivpharmacology.com>.

1. International AIDS Society-USA, Presentation: Cases on the Web, “HIV Therapy in ''Triple Diagnosed'' Patients: HIV Infection, Drug Use, and Mental Illness” Update: November 15, 2002
2. <http://www.iasusa.org/cow>.
3. National Institutes of Health, US Department of Health and Human Services Washington, DC 2004. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents; Injection Drug Users October 29, 2004; 31-33. *AIDS info* Web site. [http://aidsinfo.nih.gov](http://aidsinfo.nih.gov/guidelines).
4. Treatment & Management of HIV Infection in the United States for VAHIV Posted on Veterans Healthcare Administration Public Health Strategic Health Care Group, Website Case Report, May 1, 2005 http://vhaaidsinfo.cio.med.va.gov/; <http://www.USHIVconference.org>.
5. Schreibman T, Gandhi NR, **Friedland G:** Tuberculosis in the Setting of HIV Infection. in International Association of Physicians in AIDS Care (IAPAC) Global AIDS Learning and Evaluation Network (GALEN) Module on HIV and Coinfections.
6. <http://www.iapac.org/home>; http://www.thebody.com/iapac/oct02/galen.html.
7. Bruce RD, **Friedland G:** “Substance Abuse and Global AIDS” HIVeDucation.
8. [www.hiveducation.net](http://www.hiveducation.net).
9. **LiveMed Journal HIV/AIDS, Live Virtual Session on Sept 14, 2006. Titled; A Population-Based and Longitudinal Study of Sexual Behavior and Multidrug-Resistant HIV Among Patients in Clinical Care.** [www.LiveMedJournal.com](http://www.livemedjournal.com/).
10. **Friedland G:** “Opportunistic Infections: Tuberculosis and HIV Coinfection” Medscape LLC. April, 2008 In Production.
11. ADD Schlossberg and Up to Date Chapters

**C. Letters & Reviews**

1. Taylor P and **Friedland G**: Uncertainties in the Treatment of Chlamydial Infections in Infants. *New England Journal of Medicine* 1977; 296:1123.
2. Klein RS, Mann DN, **Friedland G**, Surks MI: Normal Adrenal Cortical Function in Patients with the Acquired Immunodeficiency Syndrome. *Annals Internal Medicine* 1983; 99:566.
3. Klein RS and **Friedland G**: AIDS Precautions for Other High-risk Groups. *Infection Control* 1984; 5:466.
4. Klein RS, Harris CA, **Friedland G**: Oral Candidiasis and AIDS. *New England Journal of Medicine* 1984; 311:1379.
5. Paietta EP, Saltzman BS, Klein RS, **Friedland G**, Stein H, Weirnik PH: Ki-1 Antigen on Mononuclear Cells from Patients with AIDS: *Annals Internal Medicine* 1986; 104:890-891.
6. **Friedland G**: Review, AIDS: An Atlas of Cases for Diagnosis and The ABC of AIDS. *Annals of Internal Medicine* 1988; 109:518-519.
7. **Friedland G**: Review, Skin Signs in AIDS and Color Atlas of AIDS. *Annals of Internal Medicine* 1989; 111(2):190.
8. **Friedland G**: Review, AIDS and Infections of Homosexual Men and Opportunistic Infections in Patients with the Acquired Immunodeficiency Syndrome. *Annals of Internal Medicine* 1989; 111(11):956.
9. **Friedland G**: Transmission of HIV-1 From One Child To Another: *New England Journal of Medicine* 1994; 330:1314.
10. von Reyn FC, Arbeit RD, **Friedland G**, Crumpacker CS: Criteria for the Diagnosis of Infective Endocarditis. *Clinical Infectious Diseases* 1994; 17(3):321-322.
11. **Friedland G**. Syringe and Needle Regulation, Blood-Borne Disease Transmission, and Concern for Public Safety. *Journal of American Medical Association* 1997; 277(15):1202-1203.
12. Pawinski R, Bobat R, **Friedland G**, Jeena P, Lalloo U: Antiretroviral treatment and research in resource –poor countries. *The Lancet* (Correspondence) 2003:361(9355) 434-435.
13. **Friedland, G.** "Review of AIDS Therapy, 3rd Edition," *Clinical Infectious Diseases* (Book Review) *2008; Nov 1*

**INVITED PRESENTATIONS >150**

1. Studies on the transmission of HTLV-III/LAV infection. New York State AIDS Institute Symposium. New York Academy of Sciences, 1986.
2. Epidemiology of AIDS. Conference on AIDS and Addiction, New York State Legislature, Albany, NY, February 1986
3. AIDS, clinical aspects. National Conference on AIDS and Addiction: Setting a Preventive Course for the Future, New York State Division of Substance Abuse Services, March 1986.
4. AIDS, a general overview. Conference on Neurologic and Psychiatric Aspects of AIDS, Albert Einstein College of Medicine, Bronx, NY, March 1986
5. Transmission of lack thereof, of HIV. AIDS Symposium, 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 1986.
6. Testimony before the City Council of the City of New York on behalf of Bill No. 721 introduced by Councilwoman Carol Maloney -- Provision of Sterile Needles for Drug Abusers, December 1986.
7. Overview of the AIDS epidemic and transmission trends. Conference on the Acquired Immunodeficiency Syndrome (AIDS), University of Miami School of Medicine, Miami, FL, January 1987.
8. Testimony before the New York State Assembly Standing Committee on Health, public hearing on AIDS -- Prevention of Transmission, New York City, NY, February 1987.
9. Transmission of HIV, Symposium Honoring Dr. Jerome Horwitz, Wayne State University School of Medicine, Detroit, MI, February 1987.
10. Medical background of the AIDS debate, Symposium on AIDS and the Humanities, New School for Social Research, New York City, NY, February 1987.
11. Women and AIDS, Hastings Center Conference on Women and Children with AIDS, March 1987.
12. Compassion in the care of AIDS patients. American Medical Association Conference on AIDS and Public Policy, Chicago, IL, April 1987.
13. Lack of transmission of HIV by "casual contact", Society for Epidemiologic Research, 20th Annual Meeting, Amherst, MA, June 1987.
14. Clinical care of AIDS patients. Presidential Candidate Seminar on AIDS, American Foundation for AIDS Research (AMFAR), Washington, DC, November 1987
15. Transmission of HIV infection. 45th Anniversary of the Public Health Research Institute, Rockefeller University, New York, November 1987
16. Screening for HIV infection. Symposium on AIDS and medical ethics. Jacobovits Center for Medical Ethics, Ben Gurion University School of Medicine, Beer Sheva, Israel, November 1987.
17. Testimony before the Presidential Commission of the Human Immunodeficiency Virus Epidemic. Washington, DC, January 1988.
18. Face of AIDS, Symposium. The Person with AIDS: 4th International Conference on AIDS, Stockholm, Sweden, June 1988.
19. AIDS and graduate medical education. Committee on Graduate Medical Education, New York State Department of Health, May 1989
20. Natural history of HIV infection. New York State AIDS Institute, July 1989.
21. Care of persons with HIV infection. Belgium National Conference on AIDS, Brussels, Belgium, December 1989.
22. Treatment of the asymptomatic patient with HIV infection. Johns Hopkins Centennial Conference on AIDS, April 1990.
23. Clinical presentation and survival characteristics of women with AIDS. National Conference on Women and HIV Infection, NIAID, Washington, DC, December 1990.
24. AIDS and Drug Abuse. Strengthening the Linkages Conference, U.S. Dept. of Health and Human Services. Washington DC, February 1992.
25. Differences in HIV Manifestations in Differing Populations. 8th International Conference on AIDS. Amsterdam, Netherlands, July 1992.
26. Natural History of HIV Infection. International Conference on AIDS, Gdansk, Poland, March 1993.
27. Injection Drug Use Complications and HIV. 9th International Conference on AIDS, Berlin, Germany, July 1993.
28. Tuberculosis and HIV. International AIDS Society Symposium. New York, NY, March 1994.
29. Antiretroviral Therapy. Medical Academy of Gdansk, Gdansk, Poland, July 1994.
30. Drug Abuse and AIDS, NIDA, 20th Anniversary Symposium, NIH, Bethesda, MD, September 1994.
31. Stavudine (D4T). 3rd Annual Conference on Antiviral Therapy, San Francisco, CA, December 1994.
32. Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors. International AIDS Society, AIDS Symposium, New York, NY, March 1995.
33. Community Forum, Perspectives in HIV Care: A View from the Frontlines, New York Academy of Medicine, New York, NY, March 1995.
34. Experience with Stavudine and Future Anti-retroviral Therapy. International Symposium on New Approaches to the Treatment of Patients with HIV, Sao Paulo, Brazil, August 1995.
35. Substance Abuse: White House Conference on HIV and AIDS, Washington DC, December 1995.
36. Injecting Drug Use: Medical Issues, Syringe Laws and Regulations to Address the Dual Epidemics of HIV Infection and Substance Abuse, Centers for Disease Control, Atlanta, GA, May 1996.
37. Why is Adherence Important? First National Conference on Adherence to HIV Therapies. Office of AIDS Research, Forum for Interdisciplinary Research on AIDS, Minority Council on AIDS, Washington DC, November 1997
38. Adherence to HAART: Interventions to Improve Adherence, IAS-USA Conference on HIV Pathogenesis, Antiretrovirals and other Related Issues in Diseases Management, New York, NY, March 1998
39. Symposium on Antiretroviral Therapy in Latin America, International AIDS Society, UNAIDS, Latin American Conference on STDs and AIDS, Lima, Peru, March 1998
40. Adherence: Clinical and Biological Considerations, Symposium on Adherence, 12th World AIDS Conference, Geneva Switzerland July 1998
41. Adherence to Antiretroviral Therapy, IX Congreso Panamericano de Infectologia, I Congreso Panamericano de SIDA, Guatemala City, Guatemala, May 1999.
42. Symposium on Access to Antiretroviral Therapy in Latin America, Guatemala City, Guatemala, May 1999.
43. Adherence to Antiretroviral Therapy, State of the Art Conference on HIV Therapeutics, Rome, Italy, September 1999.
44. Therapeutic Strategies of "Triple-Diagnosed" Patients: HIV, Substance Use, and Mental Illness, An Advanced CME Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management, New York, NY, March 2000.
45. The Pharmacokinetics of Methadone Following Co-Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate-Dependent subjects (NZTA4003), Los Angeles, CA, March 2000.
46. Adherence to Medication: Adherence to Highly Active Antiretroviral Therapy. 13th International Conference on AIDS. July, 2000, Durban, South Africa.
47. Adherence to Antiretroviral Therapy, Provision of HIV Therapy to Vulnerable Populations, National AIDS Conference, Buenos Aires, Argentina, September, 2000.
48. Adherence to Antiretroviral Therapy, 5th International Congress on Therapy in HIV Infection, Glasgow, Scotland, October 2000.
49. Adherence, 10th Panamerican Congress of Infectious Diseases, IAS-SHARE Course, Guadalajara, Mexico, May 2001.
50. ART Therapy in Special Populations Drugs Addicts, 10th Panamerican Congress of Infectious Diseases, IAS-SHARE Course, Guadalajara, Mexico, May 2001
51. HIV Therapy in Injecting Drug Users, Louisiana State University Ted Wisniewski Lectureship, New Orleans, Louisiana, May 2001.
52. Antiretroviral Therapy: Opportunities and Challenges, Department of Medicine, Nelson Mandela School of Medicine, Durban South Africa: September 2001.
53. Series of Lectures: Antiretroviral Therapy, Adherence to Therapy, Opportunistic Infections- Treatment and Prophylaxis, Transmission of HIV, Lessons from the Developed World-KwaZulu-Natal Department of Health and Nelson Mandela School of Medicine, KwaZulu-Natal, South Africa October 2001-January 2002.
54. Antiretroviral Therapy, An International Perspective-Treatment Action Campaign Meeting, Johannesburg, South Africa, December 2001.
55. Adherence to Antiretroviral Therapy, HIV Clinicians Society, South Africa, December 2001.
56. The HIV-Infected Substance Abuse Patient as a Research Subject, Interactions Between Drugs of Abuse and Therapeutics Used in the Treatment of Infections, Drug Addiction and Mental Disorder, 3rd International Conference on Pharmacology of Antiretroviral Therapeutics, Washington, DC, USA, April 2002.
57. Progression of HIV Disease in Injection Drug Users: NIDA Satellite Sessions in Association with the XIV International AIDS Conference, Barcelona, Spain. July, 2002
58. Policy Issues for Adherence and Antiretroviral Therapy, Conference on Adherence to Antiretroviral Therapy: Elements of Success, Dallas, December, 2002
59. DOT in Developing Countries, A Working Group On The Use Of Directly Observed Therapy And Other Community Based Efforts To Get HAART To Those Who Aren’t Getting It. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, February, 2003
60. Inserting Antiretroviral Therapy into Existing TB DOT Programs, Symposium on Directly Observed Therapy, 10th Conference on Retroviral and Antiretroviral Therapy, Boston, February, 2003.
61. Integrating HIV Prevention and Care: Studies at the Interface of Behavior and Biology, Pennsylvania Center for AIDS Research, Seminar Series 2002-2003, March 2003
62. AIDS in the Bronx and South Africa; One Epidemic - Two Decades. Montefiore Medical Center May 2003.
63. Treatment in resource poor settings, The 2nd IAS Conference on HIV Pathogenesis & Treatment, Paris, France, July, 2003.
64. Antiretroviral Treatment for HIV Infected Drug User in “Resource Rich” Settings, Treatment for Drug Users Around the World, International Harm Reduction Network, XV International Conference on AIDS, Bangkok, Thailand, July, 2004.
65. Adherence–the Achilles Heel of ARV, Invitation to Deliver the Vinodh Gathiram Memorial Lecture. University of KwaZulu Natal, Nelson R. Mandela School of Medicine, Durban, South Africa, September 2004.
66. Studies at the Intersection of Biology and Behavior, Invited External Keynote Lecturer, Annual Faculty Research Day, University of KwaZulu Natal, Nelson R. Mandela School of Medicine, Durban, South Africa, September 2004.
67. HIV and TB Co-infection and Disease, Annual CFAR Meeting, Boston, Nov. 2004
68. Integration of TB and HIV Care and Treatment in Resource-limited Settings, WHO 4th Meeting of TB/HIV Working Group, Geneva, 2005
69. Issues in the Integration of TB and HIV Treatment, 31st meeting of the Tuberculosis Surveillance and Research Unit (IUATLD), in Paris, France, March 2005.
70. Operations Issues in Integration of TB and HIV-Harvard CFAR Conference, Boston MA, June, 2005
71. Integration of TB and HIV Care and Treatment, Rwanda National Infectious Diseases Meeting, Kigali, Rwanda, August, 2005.
72. Injection and Non-Injection Drug Use, National US Conference on Treatment and Management of HIV Infection in the US for VAHIV, Atlanta GA, September 2005.
73. HIV Prevention in Clinical Care Setting, NY Academy of Medicine, NY, September 2005.
74. HIV TB Integration, UNDP/World Bank/UNICEF/WHO Special Programme for Tropical Disease Research and Training (TDR) Scientific Working Group (SWG), WHO Geneva, Switzerland October 2005.
75. Adherence: The intersection of Behavior and Biology, Enhancing Adherence: A State of the Science Meeting on Intervention Research to Improve Anti-Retroviral Adherence, Keynote Speaker, New Haven, CT, November 2005.
76. Integrating TB and HIV Treatment, 9th Annual Research Symposium of the NIH Centers for AIDS Research: Penn Center for AIDS Research, Philadelphia, PA, November 2005.
77. XDR TB, as a cause of death in HIV co-infected patients in rural South Africa, NIAID, NIH. February 2006
78. HIV/AIDS The first 25 Years IAS-USA Course in Advanced HIV Therapeutics, New York, March 2006
79. First Twenty Five Years of AIDS, 4th Annual Infectious Diseases Update Symposium, Maimonides Medical Center, Brooklyn NY, May 2006.
80. The First Quarter Century of AIDS, HIV Course, Montefiore Medical Center/Albert Einstein College of Medicine, May 2006.
81. AIDS: The First Quarter Century The New York Course, New York, June 2006
82. Integration of TB, HIV Care and TB Drug Resistance, WHO UNAIDS, IAS, CDC, WHO, Treatment Action Group and Forum for Collaborative HIV Research, Toronto Canada, August 2006.
83. MDR TB and HIV, XVI International AIDS Conference Toronto, Canada August 2006
84. XDR TB, National Center for TB, New Jersey College of Medicine, Newark, October 2006.
85. XDR TB and HIV, Albert Einstein College of Medicine Bronx, NY October 2006
86. XDR TB in Rural South Africa, Seminars in Clinical Research, The Rockefeller University, November 2006.
87. Tuberculosis Infection Control in the Era of HIV-AIDS and MDR-TB, 37th Union World Conference on Lung Health, Palais des Congrès in Paris October 2006.
88. XDR TB as a Cause of Death in HIV/TB Co Infected Patients in Rural South Africa, The Rockefeller University Hospital, Seminars in Clinical Research, November 2006.
89. 25 Years of the HIV/AIDS Epidemic, Columbia University, Mailman School of Public Health, New York, December 2006.
90. The First Quarter Century of the HIV/AIDS Epidemic, Chalfen Lecture on Public Health at the Cambridge Health Alliance Cambridge Hospital, Cambridge MA January 2007.
91. Natural History of HIV Disease, HIV/AIDS Course, Nelson R Mandela School of Medicine, Durban, South Africa January 2007.
92. Drug resistant TB and HIV**,** Nelson R Mandela School of Medicine, Fogarty International Program, Durban South Africa February 2007.
93. XDR TB, Research Issues. WHO Stop TB Meeting, Los Angeles, CA. February 2007.
94. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in rural South Africa**,** Columbia University Department of Epidemiology, Mailman School of Public Health, New York, February 2007.
95. XDR TB in South Africa**,** NIAID, NIH Bethesda, MD, February 2007.
96. Update on XDR TB and HIV in KwaZulu Natal, Global TB/HIV Working Group of the Stop TB Partnership14th Conference on Retroviruses and Opportunistic Infections (CROI) Los Angeles, CA February 2007.
97. Reducing HIV Risk Behavior among HIV Seropositives in Clinical Care: The Options Project, Harlem Hospital New York, NY, March 2007.
98. Extensively Drug Resistant TB (XDR-TB) in Rural South Africa - Tip of the Iceberg? Keynote Speaker Keystone Meeting on TB, Vancouver British Columbia, March 2007.
99. Extensively Drug Resistant TB (XDR-TB) in Rural South Africa - Tip of the Iceberg? British Columbia Center for Excellence St. Paul’s Hospital, Vancouver, British Columbia, March 2007.
100. HIV Treatment Adherence: The Intersection of Biomedical, Behavioral, and Social Science Research with Clinical Practice, 2nd IAPAC International Conference on HIV Treatment Adherence, Jersey City, NJ Keynote Address, March 2007.
101. XDR TB, The World Health Organization, UNAIDS, International AIDS Society, Treatment Action Group and Forum for Collaborative HIV Research Global TB/HIV Working Group of the Stop TB Partnership, AIDS Research Advisory Council, Division of AIDS, NIAID, Bethesda, MD May 2007.
102. Extensively Resistant Tuberculosis (XDR-TB): Public Health and Policy Implications, ASM General Meeting XDR TB symposium Toronto, CA Toronto, May 2007.
103. Treatment and Prevention of M/XDR TB11/15/2008, MDR/XDR TB Symposium Co-sponsored by UCSF-GIVI-Center for AIDS Research and SFGH HIV Grand-Rounds. M/XDR TB with particular focus on the epidemic in rural South Africa; San Francisco General Hospital, San Francisco, CA, October 2007.
104. The Tale of Two Infections: HIV and TB, 45th Annual Meeting IDSA. Session: HIV and the Global Pandemic, San Diego, CA, October 2007.
105. Combating TB Drug Resistance and HIV, 38th Union World Conference on Lung Health: Confronting the challenges of HIV and MDR in TB prevention and care; Special session on Infection Control Working Group TF CaRes Collaborators, Cape Town, South Africa, November 2007.
106. Confronting the Catastrophe of M/XDR TB, 15th CROI Conference on Retroviruses and Opportunistic Infections. Symposium Targeting TB: New Opportunities and Challenges. Boston, MA, February 2008.
107. HIV and XDR TB in rural South Africa, Columbia University HIV Center for Clinical & Behavioral Studies New York State Psychiatric Institute Columbia University, Grand Rounds, New York, NY, March 2008.
108. State-of-the-Art Overview of Tuberculosis: Multidrug-resistant and Extensively Drug-resistant Tuberculosis and HIV”, IAS-USA NY New York, NY, March 2008.
109. Combating MDR & XDR TB & HIV in Rural South Africa, DDCF ORACTA Mtg, HIV/AIDS & TB: Strategies and Directions from South Africa, New York, NY, March 2008.

111. Confronting XDR TB in rural South Africa, Annual Spring Symposium, Greater Washington Infectious Disease Society at NIH. Bethesda Maryland, March 2008.

112. Combating MDR and XDR TB and HIV in Rural SA, Doris Duke Charitable Foundation ORACTA, HIV/AIDS and TB: Strategies and Directions New Jersey, March 2008.

1. Exciting New Therapies for HIV/AIDS, Bridgeport Hospital ID Conference - Bridgeport, CT, March 2008.
2. Confronting M/XDR TB in Rural South Africa, VA Works in Progress Seminar. XDR TB in South Africa New Haven, CT, June 2008.
3. XDR TB, In the Air and On the Ground. Miriam Hospital Immunology Center Rhode Island, September 2008.
4. XDR TB, In the Air and On the Ground. The 12th Annual Paul J. Galkin lecture, Visiting Professor Brown University School of Medicine Grand Rounds, Rhode Island Hospital, September 2008.
5. Overview of Drug Resistant TB - Global Perspective 48th ICAAC & 46th IDSA Washington, DC, October 2008.
6. Challenges and New Approaches in Mycobacterial Infections, 48th ICAAC & 46th IDSA Washington, DC, October 2008.
7. HIV/MDR-XDR-TB: Implications, Institute of Medicine (IOM) Drug Resistant TB Meeting “Addressing the Threat of Drug Resistant TB: A Realistic Assessment of the Challenges”, November 2008.
8. HIV-TB co-infection and TB drug resistance: an emerging threat to both HIV and TB programs, 9th International Congress on Drug Therapy in HIV Infection: Glasgow UK, November 2008.
9. HIV, TB and Drug abuse Treatment, 5th European Conference on Clinical and Social Research on AIDS and Drugs, Vilnius, Lithuania April 2009.
10. Plenary address, Advances in Operations Research: TB and HIV, 5th International AIDS Society Conference on Pathogenesis and Treatment, Cape Town South Africa July 2009.
11. Studies in Infection Control to Combat XDRTB in Rural KwaZulu Natal, 40th Union World Conf on Lung Health Cancun, Mexico December 2009.
12. Confronting Multiple an Extensively Drug Resistant (M and XDR) TB in South Africa University of Colorado School of Medicine, Denver, Colorado 2009.
13. HIV, TB and TB drug resistance, University of Ghana School of Medicine, Korle-bu Hospital, Accra, Ghana 2009.
14. Confronting MDR and XDR in Rural KwaZulu-Natal, South Africa Beth Israel Hospital, Boston 2010.
15. HIV, TB and TB drug resistance, from the Bronx to South Africa and back, Ruy Soiero Memorial Lecture, Albert Einstein College of Medicine, Bronx NY, July 2010.
16. Drug development for TB prevention strategies; what to do? Consensus and clarity NIAID, Forum TRIUMPH, TB Research Washington DC, July 2010.
17. The Epidemiology and Management of XDR TB, 50th ICAAC, Boston September 2010.
18. The Convergent Epidemics of TB, HIV and Drug Resistant TB, Etiology, Challenges and the Way Forward. Maxwell Finland Named Lecture, 48th Annual Meeting of IDSA Vancouver, Canada, October 2010.
19. HIV Controversies: Treating the HIV-infected TB Patient in the Same Clinic, 41st Union World Conference on TB, HIV and Lung Health ‘From research and innovation to solutions’ Berlin, Germany, November 2010
20. Leadership in Biomedicine Research Seminar, “A Journey Through Three Epidemics: HIV, TB and XDR TB” Yale University, New Haven CT, February 2010.
21. First Annual Alan Berkman Memorial Lecture, A Journey Through Three Epidemics: HIV, TB and XDR TB, Mailman School of Public Health, Columbia University, April 2011.
22. Confronting Drug Resistant TB in South Africa, Launch of Institute of Medicine report of MDR TB in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu Natal, July 2011.
23. Survival among XDR TB Patients is Associated with Modifiable Clinical Characteristics, KwaZulu Natal. Research in TB and HIV Laboratory (K-RITH) Groundbreaking Ceremony and Symposium, Durban, July 2011.
24. The George Comstock Lecture; Community based strategies to address the TB, HIV and M/XDR TB epidemics in South Africa. 16th Annual Conference of the Union North American Region (NAR) San Antonio, TX, February 2012.
25. Occupational Safety and Health Care for Caregivers Tugela Ferry, KZN, 3rd South African TB Conference, Durban, June 2012.
26. A Journey through Three Epidemics, HIV, TB and XDR TB, University of Chicago, February 2013
27. Confronting HIV, TB and extensively and multidrug resistant tuberculosis (XDR/MDR TB) in South Africa, University of Chicago, February 2013
28. The George Thornton Lecture, A Journey through Three Epidemics, HIV, TB and XDR TB,

Waterbury Hospital, Waterbury CT, May 2013

1. The rise and fall of extensively drug resistant tuberculosis in Tugela Ferry, how we did it. Plenary Lecture, 4th South African Tuberculosis Conference, Durban, South Africa, June 2014
2. Global Tuberculosis, Tuberculosis at a Crossroads: Staying on Track Towards Elimination, Connecticut Department of Public Health, November 6, 2014, Hartford, CT
3. N’Galy Mann Award and Lecture, Confronting HIV and TB in the Bronx and rural South Africa Conference on Retroviruses and Opportunistic Infections, Boston February 2016.
4. , Lessons learned confronting TB and HIV from the Bronx, NY to Tugela Ferry, KwaZuluNatal, South Africa, Reynard J. McDonald Named Lecture, New Jersey College and Medicine and Dentistry, Newark NJ, March 2016.
5. , Harold Wise Award and Lecture, TB and HIV from the Bronx, NY to Tugela Ferry and Back, Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx April 2016.
6. Philip Bondy Lecture, Yale School of Medicine, Medical Grand Rounds HIV and TB, From the Bronx to New Haven to Tugela Ferry, South Africa. New Haven December 2016.

**ABSTRACTS at national and international meetings, >275**

1. Greenfield S, Scifers S, Komaroff A, **Friedland G**: Management of certain GU complaints by a physician extender and a specified protocol. American Public Health Association -- Annual Meeting: November 1973, San Francisco, CA.
2. Komaroff A, Pass T, McCue J, Cohen A, Hendricks M, and **Friedland G**: Management strategies for symptoms of urinary and vaginal infections. American Federation for Clinical Research: May 1977, Washington, DC.
3. du Moulin GC, **Friedland G**, Indorato K, Stottmeier K: Contamination of mycobacterial specimens with a waterborne strain of Mycobacterium intracellulare. American Society for Microbiology: May 1978, New Orleans, LA.
4. Abelman W, von Reyn CF, Levy B, Arbeit R, **Friedland G**, Crumpacker C: Bacterial endocarditis in the seventies. World Congress of Cardiology: September 1978, Tokyo, Japan.
5. **Friedland G**, Dasse P, Boyle C, du Moulin G, Stottmeier K: Pseudoepidemic traced to contamination of clinical specimens by waterborne atypical mycobacteria. Association for Practioners in Infection Control. 6th Annual Conference: April 1979, Houston, TX.
6. Tully JL, **Friedland G**, Goldmann DA: Complications of intravenous therapy with steel needles and small-bore teflon catheters. 19th Interscience Conference on Antimicrobial Agents and Chemotherapy: October 1979, Boston, MA.
7. von Reyn CF, Levy B, Arbeit R, **Friedland G**, Dasse P, and Crumpacker C: Nosocomial infective endocarditis. Association for Practitioners in Infection Control, 7th Annual Conference: June 1980, San Francisco, CA.
8. Tully JL, **Friedland G**, Baldini LB, Goldmann DA: Complications of intravenous therapy with steel needles and teflon catheters -- a comparative study. 2nd International Conference on Nosocomial Infections, Center for Disease Control: August 1980, Atlanta, GA.
9. Bor D, Rose R, Modlin J, Weintraub R, **Friedland G**: Mediastinitis following cardiac surgery. 20th Interscience Conference on Antimicrobial Agents and Chemotherapy: September 1980, New Orleans, LA.
10. Ho J, Shands K, **Friedland G**, Edkin P, Fraser D: Outbreak of type 4B Listeria monocytogenes infection involving patients from eight Boston hospitals. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy: September 1981, Chicago, IL.
11. Makadon H, Bor D, **Friedland G**, Komaroff A, Aronson M: Febrile inpatients: Initial evaluation and empiric antibiotic use. American Federation for Clinical Research 30: May 1981, Washington, DC.
12. Bor D, Makadon H, **Friedland G**, Komaroff A, Aronson M: Febrile inpatients: Epidemiology and clinical determinants of bacterial infection. American Federation for Clinical Research 30: May 1981, Washington, DC.
13. Butkus-Small C, Klein R, **Friedland G**, Moll B, Emeson E, Spigland I: Community acquired opportunistic infections and defective cellular immunity in heterosexual drug abusers and homosexual men. 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy: October 1982, Miami Beach, FL.
14. Grenell SL, Butkus-Small C, Harris CA, **Friedland G**, Leeds NE, Zimmerman RD, Klein RS: Central nervous infections in Acquired Immune Deficiency Syndrome. 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy: October 1983, Las Vegas, NV.
15. Klein RS, Harris CA, Butkus-Small C, Moll B, **Friedland G**: Oral candidiasis as the initial manifestations of the Acquired Immune Deficiency Syndrome. 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy: October 1983, Las Vegas, NV.
16. Butkus-Small C, Harris CA, Klein RS, **Friedland G**: Trimethoprim sulfa-methoxazole treatment of Pneumocystis carinii pneumonia in patients with Acquired Immune Deficiency Syndrome. 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy: October1982, Las Vegas, NV.
17. Harris CA, Butkus-Small C, Klein RS, Shine D, Moll B, Reiss R, Darrow W, **Friedland G**: Needle sharing as a route of transmission of the Acquired Immune Deficiency Syndrome. 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy: October 1982, Las Vegas, NV.
18. Harris CA, Cabradilla C, Klein R, **Friedland G**, Kalyranaraman V, Getchell J, Catalano M, Steigbigel N: Antibodies to a core protein of lymphadenopathy-associated virus and immunodeficiency in heterosexual partners of AIDS patients. 24th Interscience Conference on Antimicrobial Agents and Chemotherapy: October 1984, Washington, DC.
19. Harris CA, Cabradilla C, Robert-Guroff M, Klein RS, **Friedland G**, Kalyanaraman VS, Catalano MT, Hewlett JM, Gallo RC, Steigbigel NH: Immunodeficiency and HTLV-III/LAV serology in heterosexual partners of AIDS patients. International Conference on Acquired Immunodeficiency Syndrome (AIDS): April 1985, Atlanta, GA.
20. Kahn S, Saltzman BR , Brandt LJ, Klein RS, Mahadevia P, Frager J, **Friedland G**: Granulomatous hepatitis in AIDS patients. International Conference on Acquired Immunodeficiency Syndrome (AIDS): April 1985, Atlanta, GA.
21. Shine D, Moll B, Emeson E, Spigland I, Weiss S, Bodner A, **Friedland G**: Serologic, immunologic and clinical features of IV drug abusers without AIDS. International Conference on Acquired Immunodeficiency Syndrome (AIDS): April 1985, Atlanta, GA.
22. Callan M, Klein RS, Hewlett J, Vileno J, Kahl P, **Friedland G**: Heterosexual AIDS patients and their families: Identification of psychosocial needs and provision of support services. International Conference on Acquired Immunodeficiency Syndrome (AIDS). April 1985, Atlanta, GA.
23. Rogers M, **Friedland G**, Saltzman BR, Klein RS, Kahl P: Lack of transmission of HTLV-III infection to household members of patients with AIDS. The CDC EIS Conference. May 1985, Atlanta, GA.
24. Saltzman BR, **Friedland G**, Harris CA, Vileno J, Kahl P, Hewlett J, Klein RS: Special features of AIDS in an urban heterosexual population. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy. October 1985, Minneapolis, MN.
25. Saltzman BR, **Friedland G**, Rogers MF, Kahl P, Getchell JP, Lesser M, Mayers M, Klein RS: Lack of household transmission of HTLV-III infection. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy. October 1985, Minneapolis, MN.
26. Harris CA, Cabradilla CD, Robert-Guroff M, Klein RS, **Friedland G**, Getchell JP, Saltzman BR, Kalyanaraman VS, Catalano MC, Hewlett JM, Gallo RD, Steigbigel NH: HTLV-III/LAV infection and AIDS in heterosexual partners of AIDS patients. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy. October 1985, Minneapolis, MN.
27. Paietta E, Saltzman BRR, Klein RS, **Friedland G**, Wiernik PH: A "Hodgkin's-specific" antigen (Ki-1) expressed on mononuclear cells from patients with AIDS. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy. October 1985, Minneapolis, MN.
28. Motyl MR, McKitrick JC, Saltzman BR, Klein RS, **Friedland G**: Recovery of Mycobacterium avium-intracellulare (MAI) and Mycobacterium tuberculosis from blood cultures of AIDS patients using the Bactec NR 660. The American Society of Microbiology Annual Meeting. March 1986, Washington, DC.
29. Silverstein C, McKegney FP, O'Dowd MA, Selwyn PA, Drucker E, **Friedland G**: Neuropsychologic dysfunction in HTLV-III/LAV seropositives. The American Psychiatric Association Annual Meeting. May 1986, Washington, DC.
30. Marantz PR, Linzer M, Feiner CJ, Feinstein SA, **Friedland G**: Should all febrile intravenous drug abusers be hospitalized? Clinical Research, 1986; 34(2):828A.
31. Schoenbaum EE, Selwyn PA, Klein RS, Rogers MF, Freeman K, **Friedland G**: Prevalence of and risk factors associated with HTLV-III/LAV antibodies among intravenous drug abusers in a methadone program in New York City. 2nd International Conference on the Acquired Immunodeficiency Syndrome. June 1986, Paris, France.
32. Selwyn PA, Schoenbaum EE, Mayers MM, Rogers MF, Klein RS, **Friedland G**: HTLV-III/LAV infection and pregnancy outcomes in intravenous drug abusers. 2nd International Conference on the Acquired Immunodeficiency Syndrome. June 1986, Paris, France.
33. Klein RS, Phelan J, **Friedland G**, Schable C, Trieger N, Steigbigel NH: Prevalence of antibodies to HTLV-III/LAV among dental professionals. 2nd International Conference on Acquired Immunodeficiency Syndrome. June 1986, Paris, France.
34. Saltzman BR, **Friedland G**, Rogers MF, Kahl P, Feiner CJ, Lesser M, Klein RS: Lack of household transmission of HTLV-III/LAV infection. 2nd International Conference on Acquired Immunodeficiency Syndrome. June 1986, Paris, France.
35. Saltzman BR, Harris CA, Klein RS, **Friedland G**, Kahl PA, Steigbigel NH: HTLV-III/LAV infection and immunodeficiency in heterosexual partners of AIDS patients. 2nd International Conference on Acquired Immunodeficiency Syndrome. June 1986, Paris, France.
36. Saltzman BR, **Friedland G**, Kahl PA, Vileno JL, Klein RS: Epidemiologic and clinical features of heterosexual men and women with AIDS. 2nd International Conference on the Acquired Immunodeficiency Syndrome. June 1986, Paris, France.
37. Callan M, Gordon L, **Friedland G**, Kahl PA, Vileno JL, Klein RS: Women with AIDS -- Psychosocial issues and needs. 2nd International Conference on Acquired Immunodeficiency Syndrome. June 1986, Paris, France.
38. Motyl MR, McKitrick JC, Saltzman BR, Klein RS, **Friedland G**. Recovery of Mycobacterium avium-intracellulare (MAI) and Mycobacterium tuberculosis from blood cultures of AIDS patients. 2nd International Conference on Acquired Immunodeficiency Syndrome. June 1986, Paris, France.
39. Selwyn PA, Schoenbaum EE, Klein RS, Rogers MF, Freeman K, **Friedland G**: Risk factors for HTLV-III/LAV exposure in intravenous drug abusers in New York City. 114th Annual Meeting, American Public Health Association. September 1986, Las Vegas, NV.
40. Selwyn PA, Schoenbaum EE, Mayers MM, Rogers MF, Klein RS, Mouson JS, Colley S, Iezza A, Satyadeo M, **Friedland G**: Prenatal care, HTLV-III/LAV exposure, and pregnancy among high risk female intravenous drug abusers. 114th Annual Meeting, American Public Health Association. September 1986, Las Vegas, NV.
41. Schoenbaum EE, Selwyn PA, Mayers MM, Rogers MF, Klein RS, Ciccarelli R, DeCroce R, Robertson V, Shulman J, Klein RS, **Friedland G**: HTLV-III/LAV Infection and pregnancy outcomes in intravenous drug abusers. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 1986, New Orleans, LA.
42. Saltzman BR, **Friedland G**, Klein RS, Maude DM, Steigbigel NH: Female-to-male sexual transmission of HTLV-III/LAV. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 1986, New Orleans, LA.
43. Klein RS, Phelan J, **Friedland G**, Schable C, Treiger M, Steigbigel NH: Prevalence of antibodies to HTLV-III/LAV among dental professionals. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 1986, New Orleans, LA.
44. **Friedland G**, Landesman SH, Crumpacker CS, Hirsch MS, Handsfield HH, Pizzuti DH, et al: A clinical trial of recombinant alpha interferon in patients with AIDS. 3rd International Conference on AIDS. June 1987, Washington, DC.
45. **Friedland G**, Saltzman BR, Rogers M, Kahl P, Feiner CJ, Mayers M, et al: Additional evidence for lack of transmission of HIV infection to household contacts of AIDS patients. 3rd International Conference on AIDS. June 1987, Washington, DC.
46. **Friedland G**, Kahl P, Feiner CJ, Rogers M, Mayers M, Klein RS, et al: The effect of AIDS diagnosis upon close personal interactions among family members of AIDS patients. 3rd International Conference on AIDS. June 1987, Washington, DC.
47. Schoenbaum EE, Selwyn PA, Hartel D, Klein RS, Davenny K, **Friedland G**, et al: HIV seroconversion in intravenous drug abusers: Rate and risk factors. 3rd International Conference on AIDS. June 1987, Washington, DC.
48. Selwyn PA, Schoenbaum EE, Hartel D, Peterman T, Klein RS, **Friedland G**, et al: Natural history of HIV infection in intravenous drug abusers. 3rd International Conference on AIDS. June 1987, Washington, DC.
49. Selwyn PA, Feingold AR, Hartel D, Schoenbaum EE, **Friedland G**, Alderman MH, et al: Bacterial pneumonia and HIV infection in parenteral drug users with AIDS. 3rd International Conference on AIDS. June 1987, Washington, DC.
50. Klein RS, Phelan J, **Friedland G**, Freeman K, Schable C, Steigbigel N, et al: Low occupational risk of HIV infection for dental professionals. 3rd International Conference on AIDS. June 1987, Washington, DC.
51. Schrager L, Klein RS, Freeman K, Motyl M, Ricci L, **Friedland G**: Analysis of bacteremias in patients with AIDS. 3rd International Conference on AIDS. June 1987, Washington, DC.
52. Schrager L, **Friedland G**, Klein RS, Maude D, Schreiber K, Koss LG, et al: Increased risk of cervical and/or vaginal squamous atypia in women infected with HIV. 3rd International Conference on AIDS. June 1987, Washington, DC.
53. Bulkin W, McNally L, McGuire G, Brown L, **Friedland G**: Hospice care of intravenous drug abuser AIDS patients in a skilled nursing facility. 3rd International Conference on AIDS. June 1987, Washington, DC.
54. Selwyn PA, Schoenbaum EE, Hartel D, Klein RS, Pollard C, Tozzi S, Gates J, Kennedy K, Kipke MD, Davenny K, Holmberg S, **Friedland G**: Natural history of HIV infection in intravenous drug users (IVDUs). American Public Health Association Annual Meeting. October 1987, New Orleans, LA.
55. Selwyn PA, Schoenbaum EE, Feingold AR, Davenny K, Robertson V, Mayers MM, Shulman J, Klein RS, **Friedland G**, Alderman MH, Rogers MF: Pregnancy outcomes and perinatal transmission of HIV in intravenous drug abusers. American Public Health Association Annual Meeting. October 1987, New Orleans, LA.
56. Schoenbaum EE, Selwyn PA, Hartel D, Klein RS, **Friedland G**: HIV infection in intravenous drug users in New York City: The relation of drug use and heterosexual behaviors and race/ethnicity. 4th International Conference on AIDS. June 1988, Stockholm, Sweden.
57. Selwyn PA, Schoenbaum EE, Klein RS, Hartel D, Davenny K, **Friedland G**: AIDS and HIV-related mortality in intravenous drug users. 4th International Conference on AIDS. June 1988, Stockholm, Sweden.
58. Hartel D, Selwyn PA, Schoenbaum EE, Klein RS, **Friedland G**: Methadone maintenance treatment and reduced risk of AIDS. 4th International Conference on AIDS. June 1988, Stockholm, Sweden.
59. Selwyn PA, Lewis VA, Schoenbaum EE, Hartel D, Klein RS, Davenny K, **Friedland G**: HIV infection and tuberculosis in intravenous drug users (IVDU) in a methadone program (MMTP). 4th International Conference on AIDS. June 1988, Stockholm, Sweden.
60. O'Dowd MA, McKegney FP, Selwyn PA, Drucker E, Feiner CJ, **Friedland G**: Comparison of neuropsychologic function in HIV seropositive and seronegative intravenous drug abusers in a methadone maintenance program. 4th International Conference on AIDS. June 1988, Stockholm, Sweden.
61. Saltzman BR, **Friedland G**, Klein RS, Vileno J, Freeman K, Gutelle P, Schrager L: Comparison of AIDS clinical manifestations between men and women in a primarily heterosexual population. 4th International Conference on AIDS. June 1988, Stockholm, Sweden.
62. Saltzman BR, **Friedland G**, Klein RS, Vileno J, Freeman K, Schrager LK: Factors that predict survival of AIDS patients, experience at a single New York City medical center. 4th International Conference on AIDS. June 1988, Stockholm, Sweden.
63. Schrager LK, **Friedland G**, Kahl P, Feiner CJ, Klein RS: Demographics, drug use and sexual behavior of intravenous drug users (IVDUs) with AIDS. 5th International Conference on AIDS. June 1989, Montreal, Canada.
64. Bulkin W, O'Dowd MA, Callan M, **Friedland G**, Gordon L, Klein RS, et al: Multidisciplinary AIDS team role in morale and stress reduction among health care workers (HCWs). 5th International Conference on AIDS. June 1989, Montreal, Canada.
65. Schoenbaum EE, Hartel D, Selwyn PA, Davenny K, **Friedland G**, Klein RS: Lack of association of T-cell subsets with continuing intravenous drug use and high risk heterosexual sex, independent of HIV infection and disease. 5th International Conference on AIDS. June 1989, Montreal, Canada.

A66. .Schoenbaum EE, Hartel D, Selwyn PA, Klein RS, **Friedland G**, et al: Low HIV seroconversion and change in high risk behavior in intravenous drug users (IVDUs) from 1985-1988 in the Bronx, New York City. 5th International Conference on AIDS. June 1989, Montreal, Canada.

A67. Selwyn PA, Hartel D, Schoenbaum EE, Klein RS, **Friedland G**: Clinical progression of HIV-related disease in intravenous drug users (IVDUs) in a prospective cohort study, 1985-1989. 5th International Conference on AIDS. June 1989, Montreal, Canada.

A68. Selwyn PA, Hartel D, Schoenbaum EE, Klein RS, Buono D, **Friedland G**: Use of clinical criteria to predict HIV antibody status among intravenous drug users (IVDUs) in a prospective cohort study. 5th International Conference on AIDS. June 1989, Montreal, Canada.

A69. Hartel D, Schoenbaum EE, Selwyn PA, Drucker E, Wasserman W, **Friedland G**: Temporal patterns of cocaine use and AIDS in intravenous drug users in methadone maintenance. 5th International Conference on AIDS: June 1989, Montreal, Canada.

A70. Horsburgh R, Hartel D, **Friedland G**, Davenny K, Selwyn PA: HTLVI infection correlates with increased age in IVDUs. 5th International Conference on AIDS. June 1989, Montreal, Canada.

A71. Schwartz EL, Brechbuhl AB, Kahl P, Miller MH, Selwyn PA, **Friedland G**: Altered pharmacokinetics of Zidovudine in former IV drug-using patients receiving methadone. 6th International Conference on AIDS. June 1990, San Francisco, CA.

A72. **Friedland G**, Budner N, Selwyn PA, Hartel D, Schoenbaum EE, Shaw JF, et al: Zidovudine therapy (AZT Rx) delays progression to AIDS in intravenous drug users (IVDUs) with oral thrush (OT). 6th International Conference on AIDS. June 1990, San Francisco, CA.

A73. Schoenbaum EE, Hartel D, **Friedland G**: Crack use predicts incident HIV seroconversion. 6th International Conference on AIDS. June 1990, San Francisco, CA.

A74. Davenny K, Buono D, Schoenbaum EE, **Friedland G**: Baseline health status of intravenous drug users with and without HIV infection. 6th International Conference on AIDS. June 1990, San Francisco, CA.

A75. Selwyn PA, Hartel D, Schoenbaum EE, Davenny K, Budner N, Klein RS, **Friedland G**: Rates and predictors of progression to HIV disease and AIDS in a cohort of intravenous drug users (IVDUs), 1985-1990. 6th International Conference on AIDS. June 1990, San Francisco, CA.

A76. Gurewich M, Selwyn P, Davenny K, Buono D, Gachupin-Garcia A, **Friedland G**: Syphilis among intravenous drug users in a pro- spective cohort study in a New York City methadone treatment program. 7th International Conference on AIDS. June 1991, Florence, Italy.

A77. McKegney FP, Silberstein C, O'Dowd MA, Cochrane K, Hartel D, Schoenbaum EE, **Friedland G**: Subtle neuropsychological impairment is related to progression to illness in initially asymptomatic HIV-1 positive intravenous drug users. 7th International Conference

A78. Silberstein C, O'Dowd MA, **Friedland G**, Schoenbaum EE, Cochrane K, Hartel D, McKegney FP: A four-year decline in neuropsycho- logical function in symptomatic HIV seropositives compared to asymptomatic seropositives and seronegative former intravenous drug users. 7th International Conference on AIDS. June 1991, Florence, Italy.

A79. Alcabes P, **Friedland G**, Vlahov D, Munoz A: An incident HIV seroconvertors and a method to impute date of conversion in prevalent seropositives. 7th International Conference on AIDS. June 1991, Florence, Italy.

A80. Brett-Smith H, Griffith B, Mellors J, Joiner K, Mark R and **Friedland G**: Effects of D4T on HIV viremia. 8th International Conference on AIDS. July 1992, Amsterdam, Netherlands.

A81. Rigsby M, Patterson TF, **Friedland G**: Factors associated with survival in patients with AIDS and disseminated mycobacterium avium complex infection. 8th International Conference on AIDS. July 1992, Amsterdam, Netherlands.

A82. Holmes J, Zampano C, **Friedland G**: Analysis of avoidable and unnecessary acute care hospitalizations for HIV disease in a northeastern U.S. industrial city. 8th International Conference on AIDS. July 1992, Amsterdam, Netherlands.

A83. Selwyn PA, Alcabes P, Hartel D, Buono D, Schoenbaum EE, Klein RS, Davenny K, **Friedland G**: Clinical manifestations and predictors of disease progression in a cohort of HIV-infected drug injectors. 8th International Conference on AIDS. July 1992, Amsterdam, Netherlands.

A84. Sckell, B, Selwyn PA, Alcabes P, Schoenbaum E, Klein R, **Friedland G**: High risk of active tuberculosis in HIV-positive anergic drug injectors; effectiveness of isoniazid prophylaxis in tuberculin reactors. 8th International Conference on AIDS. July 1992, Amsterdam, Netherlands.

A85. Hartel D, Schoenbaum EE, Selwyn PS, Fleming I, Gachupin-Garcia A, **Friedland G**: Gender differences in cocaine use and HIV-related mortality among injection drug users (IDUS). 8th International Conference on AIDS. July 1992, Amsterdam, Netherlands.

A86. Alcabes P, Munoz A, Vlahov D, **Friedland G**: Estimation of time from seroconversion to AIS in HIV-infected intravenous drug users in the U.S. 8th International Conference on AIDS. July 1992, Amsterdam, Netherlands.

A87. Kim GP, Brett-Smith H, **Friedland G**, Chang CP, Griffith BP, Prusoff W, Cheng YC: Anti-HIV effect, toxicity, and pharmacokinetics of 2'3'-didehydro-3'-deoxythymidine (D4T) at low/moderate doses. The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. October 11-14, 1992, Anaheim, CA.

A89. Meisler A, Ickovics J, Walesky M, Fiellin M, Skowronski C, **Friedland G**: Adherence to clinical trials among women, minorities, and injection drug users. 9th International Conference on AIDS. June 1993, Berlin, Germany.

A90. Booss J, Guarnaccia J, Selwyn PA, **Friedland G**: HIV Neurology in the primary care setting. 9th International Conference on AIDS. June 1993, Berlin, Germany.

A91. Altice FL, Fleck EM, Selwyn PA, Kaplan EH, Barry M, Gomez J, Zampano C, **Friedland G**: Provision of health care and HIV counseling and testing for clients of the New Haven needle exchange program (NEP). 9th International Conference on AIDS. June 1993, Berlin, Germany.

A92. Griffith, B, Chacko T, Garner R, Brett-Smith H, Kim G and **Friedland G**. Correlation between immune complex dissociated human immunodeficiency virus antigenemia and quantitative viremia in a phase I/II clinical trial of Stavudine. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. October 1993, New Orleans, LA.

A93. Wetherill P, Landry M, Ferguson D, Alcabes P, **Friedland G**: Use of a quantitative CMV antigen test (Ag) in patients with and without CMV disease (dz). The First National Conference on Human Retroviruses and Related Infections. December 1993, Washington, DC.

A94. Brett-Smith H, Griffith B, Kim G, Walesky M, **Friedland G**: Degree and duration of D4T antiviral effect n human subjects. The First National Conference on Human Retroviruses and Related Infections. December 1993, Washington, DC.

A95. Holmes J, Alcabes P, Zampano C, Selwyn P, **Friedland G**: Reducing Length of Stay (LOS) for HIV + Patients at an urban medical center, 10th International Conference On AIDS International Conference on STD. August 1994, Yokohama, Japan.

A96. Hardalo C, Khoshnood K, Alcabes P, **Friedland G**: High incidence and recurrence rates of bacterial endocarditis in HIV+ drug injectors. 10th International Conference on AIDS International Conference on STD. August 1994, Yokohama, Japan.

A97. Altice FL, Selwyn PA, Sigh R, Zampano C, **Friedland G**: Linking mobil health services to the New Haven needle exchange program (NEP). 10th International Conference on AIDS International Conference on STD. August 1994, Yokohama, Japan.

A98. Wetherill P, Hatcher T, **Friedland G**, Landry M. Correlation of CMV antigenemia with clinical response to CMV therapy in patients with AIDS. Infectious Disease Society of America 32nd Annual Meeting. October 1994, Orlando, FL.

A99. Frankel R, Hardalo, **Friedland G**: Invasive pneumococcal disease-serotypes, antimicrobial resistance and reccurence rates in HIV + and HIV- patients. Infectious Disease Society of America 32nd Annual Meeting. October 1994, Orlando, FL.

A100. McCance E, Jatlow P, Rainey P, Trapnell C, **Friedland G**: Methadone effect on AZT disposition. 3rd National Conference on Human Retroviruses and Related Conditions. January 1996, Washington, DC.

A101. Kaljian L, Jekel J, **Friedland G**: Spiritual beliefs among HIV+ patients: relevance to clinical care. 11th International Conference on AIDS. July 1996, Vancouver, BC.

A102. Demeter LM, Scott W, Nokta M, Bosch RJ, Fisher E, **Friedland G**, Fischl MA, Pollard RB, Freimuth WW, Griffith B: HIV-1 Delavirdine (DLV) susceptibilities during therapy with DLV+AZT, DLV+DDI, or DLV+AZT+DDI (ACTG 261). Antiretroviral Resistance Meeting. June 1997, St. Petersburg, FL.

A103. Altice FL, Mostashari F, Thompson AS, **Friedland G**: Perceptions, Acceptance and adherence to antiretrovirals among prisoners. 4th Conference on Retroviruses and Opportunistic Infections. January 1997, Washington, DC.

A104. **Friedland G**, Fischl MA, Pollard RB, et al: ACTG261, A phase II double-blind study of Delavirdine Mesylate (DLV) in combination with Zidovudine (ZDV) and/or Didanosine (ddI) versus ZDV and ddI combination therapy. 23rd ACTG Meeting. July 1997, Washington, DC.

A105. **Friedland G**, Fischl MA, Pollard RB, et al: Delavirdine Mesylate (DLV) in two- and three-drug combinations with Zidovudine (ZDV) and Didanosine (ddI), (ACTG261). Infectious Diseases Society of America, 35th Annual Meeting. September 1997, San Francisco, CA.

A106. Havlir DV, **Friedland G**, Pollard R, et al: Combination Zidovudine (ZDV) therapy versus other nucleosides: Report of two randomized trials (ACTG 290 and 298). 5th Conference on Retroviruses and Opportunistic Infections. February 1998, Chicago, IL.

A107. Sommadossi JP, Zhou XJ, Moore J, et al: Impairment of Stavudine (d4T) phosphorylation in patients receiving a combination of Zidovudine (SDV) and d4T (ACTG 290). 5th Conference on Retroviruses and Opportunistic Infections. February 1998, Chicago, IL.

A108. Griffith B, Morse G, Demeter L, et al: Relationship between Delavirdine (DLV) plasma levels, HIV RNA responses and DLV resistance during combination therapy with Zidovudine (ZDV), and Didanosine (ddI). 12th World AIDS Conference. June 1998, Geneva, Switzerland.

A109. Rawlings JE, Holmes J, Belton, et al: Changes in HIV/AIDS patterns of care and estimated costs at an urban medical center during the era of HAART. 12th World AIDS Conference. June 1998, Geneva, Switzerland.

A110. **Friedland G**, Williams A: MATEP adherence initiative: Achieving adherence to HIV therapies. 12th World AIDS Conference. June 1998, Geneva, Switzerland.

A111. Russi, M, Buitrago, M, Perlotto J, et al: Antiretroviral prophylaxis of occupationally exposed health care workers at two large urban medical centers. 12th World AIDS Conference. June 1998, Geneva, Switzerland.

A112. Altice FL, Cooney E, **Friedland G**: Nevirapine induced Methadone withdrawal: Implications for antiretroviral treatment of opiate dependent HIV infected patients. 6th Conference on Retroviruses and Opportunistic Infections. February 1999, Chicago, IL.

A113. Rainey PM, **Friedland G**, Snidow J, McCance-Katz E, Andrews L, Mitchell SM, Lane B, and Jatlow P. Effects of Zidovudine Plus Lamivudine on Methadone Disposition. 2000 Annual Meeting of the American Society for Clinical Pharmacology and

 Therapeutics, March 14-18, 2000, Los Angeles, CA. *American Journal of* *Clin Pharmacol Therap* 2000; 67:165.

A114. Andrews LA, **Friedland G**, Mannheimer S, Morse E, Miller C, Brizz B, et., al: A method for assessing patient readiness to begin and adhere to highly active antiretroviral therapy (HAART). 13th International Conference on AIDS. July, 2000, Durban South Africa.

A115. **Friedland G**, Kaplan E: Screening for adherence: A decision-analytic model. 13th International Conference on AIDS. July, 2000, Durban South Africa.

A116. Mannheimer S, **Friedland G**, Matts J, Chen L, Child C, Macarthur R, Kostman J, Chesney M, Brizz B, Self-reported antiretroviral adherence levels correlate with HIV viral load and decline over time. 13th International Conference on AIDS. July, 2000, Durban South Africa.

A117. Rawlings, J, Holmes J, Belton B, **Friedland G**, HAART-related decline in cost and hospital utilization have reached a plateau, 13th International Conference on AIDS. July, 2000, Durban, South Africa.

A118. Fisher W, Fisher J, **Friedland G**, HIV care clinician’s reactions to adopting an active HIV prevention counseling role with their HIV+ patients 13th International Conference on AIDS. July, 2000, Durban, South Africa.

A119. Boynton R, **Friedland G**, Fisher JD, Differences in HIV transmission risk perception & behavior among HIV seropositive patients in clinical care, Challenges for prevention in the clinical encounter. 13th International Conference on AIDS. July, 2000, Durban, South Africa.

A120. Mannheimer S, **Friedland G**, Matts J, Child C, Chesney M, Adherence to medication: adherence to Highly Active Antiretroviral Therapy. 13th International Conference on AIDS. July, 2000, Durban, South Africa.

A121. Mannheimer S, **Friedland G**, Matts J, Child C, Chesney M, Antiretroviral Adherence Correlates with Quality of Life, 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 2001.

A122 Amico KR, Cornman DH, Fisher JD, Fisher WA, **Friedland G**, Risk Behaviors, Adherence, Stages of Change, and Well-Being in HIV Positive Patients in Clinical Care. 5th International Conference on AIDS Impact: Biopsychosocial Aspects of HIV Infection, Brighton, United Kingdom, July 2001.

A123. **Friedland G**, Mannheimer S, Matts J, Child C, Telzak E, Chesney M, Duration of Antiretroviral Adherence Predicts Biologic Outcomes in Clinical Trials, 1st International AIDS Society Conference on HIV Pathogenesis and Therapy, Buenos Aires, Argentina, July 2001.

A124. **Friedland G**, Fisher J, Fisher W, Amico KR, Cornman D, Frequency, Patterns, and Correlates of HIV Transmission Risk Behaviors Among HIV Seropositive Patients in Clinical Care. 1st International AIDS Society Conference on HIV Pathogenesis and Therapy, Buenos Aires, Argentina, July 2001.

A125. **Friedland G**, Fisher JD, Fisher WA, Amico R, Cornman DH, Frequency, Patterns, and Correlates of HIV Transmission Risk Behaviors Among HIV Seropositive Patients in Clinical Care. Center for Disease Control 2001 National HIV Prevention Conference, Atlanta, Georgia, August 2001.

A126. Amico KR, Cornman DH, Fisher JD, Fisher WA, **Friedland G**, The Options Project: Computer-Delivered Assessment of Risk Behavior in HIV Positive Patients in Clinical Care. Center for Disease Control 2001 National HIV Prevention Conference, Atlanta, Georgia, August 2001.

A127. Fisher JD, Fisher WA, **Friedland G**, Cornman DH & Amico KR: Physician-Delivered Interventions: The Options Project. Paper presented at the HIV Prevention in Treatment settings: U.S. and International Priorities Conference, August, 2001, Washington, DC.

A128. Kozal MJ, **Friedland G**, Kyriakides T, Chiarella J, Concato J, Schreibman T, Klinzman D, Stapelton J, Prevalence of HIV and GBV-C Co-infection and the Likelihood of HIV Genotypic Resistance Development 9th Conference on Retrovirus and Opportunistic Infections. Seattle, Washington, February 2002

A129. **Friedland G**, Rainey P, Jatlow P, Andrews L, Damle B, McCance-Katz E, Pharmacokinetics (pK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) vs chewable tablet formulation in patients (pts) on chronic methadone therapy 14th International AIDS Conference, July 7-12, 2002, Barcelona Spain.

A130. Kozal M, Amico R, Chiarella J, Fisher J, Cornman D, Fisher W, **Friedland G**, Prevalence of antiretroviral resistance (ART) resistance mutations (RM) in patients (pts) in clinical care reporting high risk HIV transmission behavior 14th International AIDS Conference, July 7-12, 2002, Barcelona Spain.

A131. Cornman DH, Amico KR, Fisher JD, Fisher WA, **Friedland G**, The Options Project: A Healthcare Provider-Initiated Risk Reduction Intervention for HIV-Infected Individuals in Clinical Care Settings 14th International AIDS Conference, July 7-12, 2002, Barcelona Spain.

A132. Rawlings J, Holmes J, **Friedland G**, Belton B, Altice F, Manzo G, Ingraham S, Crombie P, Reducing hospitalization re-admissions among HIV patients with psychosocial, mental health and substance use co-morbidities 14th International AIDS Conference, July 7-12, 2002, Barcelona Spain.

A133. Rawlings J, Holmes J, Cooney E, Belton B, Manzo G, **Friedland G**, Altice F, HAART Related Decline in Cost and Hospital Utilization Have Reached a Plateau 14th International AIDS Conference, July 7-12, 2002, Barcelona Spain

A134. Jack C, **Friedland G**, Lalloo U, El Sadr W, Murmann M, Karim Q, Karim S, The START Study: A Pilot project to integrate antiretroviral therapy into Tuberculosis Directly Observed Therapy/Short Course (TBDOTS) Program in a resource constrained setting. 14th International AIDS Conference, July 7-12, 2002, Barcelona Spain.

A135. Lalloo UG, Pawinski RA, Bobat R, Moodley D, Jinabhai CC, Amod F, Conway S, **Friedland G**, A comprehensive HIV/AIDS training course to meet the needs of public sector health care workers in the province of KwaZulu Natal (KZN), South Africa. Presented at the XIV International AIDS Conference, July 7-12, 2002, Barcelona Spain.

A136. Osborn CY, Cornman D, Fisher JD, Amico R, Fisher WA & **Friedland G**, Barriers to Prevention among HIV+ Patients: Implications for Provider-Delivered Interventions. Poster presented at the 4th Annual Meeting of the Society for the Psychological Study of Social Social Issues, Toronto, Canada, June, 2002

A137. Uebel KE, Holst H, Patton V, **Friedland G**, Implementation of an HIV treatment and management programme for health care workers at a South African Hospital. Presented at the XIV International AIDS Conference, July 7-12, 2002, Barcelona Spain.

A138 Houser R, Broadhead R, Altice FL, van Hulst Y, **Friedland G**, et al., Playing a *Health* Game to Improve HIV+ Drug Users’ Adherence to Health Care: Part I. Presented at the 4th National Harm Reduction Conference, Seattle, WA, August 2002.

A139. Van Hulst Y, Broadhead R, Altice FL, Houser R, **Friedland G**, et al, The Preliminary Results of a Health Game to Improve Drug Users’ Adherence to Health Care: Part II.”. Presented at the 4th National Harm Reduction Conference, Seattle, WA, August 2002.

A140. Van Hulst Y, Broadhead R, Altice FL, Heckathorn D, **Friedland G**, et al, Can a PDI “Health Game” Improve HPDUs” Adherence to Health Care? International Harm Reduction Conference, Thailand, April, 2003.

A141. Mosam A, Coovadia HM, Page T, Cassol E, Bodasing U, **Friedland G** et al, HIV Associated Kaposi’s Sarcoma an entry point for antiretroviral therapy in South Africa. International Conference on Chemotherapy, Durban South Africa, May, 2003.

A142. Kozal M, Amico R, Chiarella J, Schreibman T, Cornman D, Fisher W, Fisher J, **Friedland G**, Patients with antiretroviral resistance HIV infections engaging and high risk transmission behavior among HIV+ patients in clinical care. Abstract 116, XII International HIV Drug Resistance Workshop, Cabo del Sol, Los Cabos, Mexico, June, 2003.

A143. Altice FL, Mezger J, Hodges J, Bruce RD, **Friedland G**, Special Considerations for DOT Programs for HIV+ Drug Users Abstract 660, Ref 3264: The 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris France, July, 2003.

A144. Altice FL, Mezger J, Hodges J, Bruce D, Springer S, **Friedland G**, Directly Observed Therapy (DOT) for HIV+ Drug Users (IDUs). Abstract 40, ref 3250: The 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris France, July, 2003.

A145. Karim QB, Karim S, Lalloo U, El-Sadr Wand **Friedland G**, Integrating TB and AIDS Care-a Feasible Option for Resource Constrained Settings? South African AIDS Conference, Durban South Africa, 2003.

A146. Jack C, Lalloo U, **Friedland G,** Karim S, Karim Q, El-Sadr W, Starting Antiretroviral Treatment in Adult Patients Co-infected with Tuberculosis in Resource Constrained Settings – The START Pilot Study. South African AIDS Conference, Durban South Africa, 2003.

A147. Mosam A, Aboobaker J, Jordaan JP, Scadden D, Dawood H, Lalloo U, Odasing, Coovadia HM, **Friedland G** et al, Human Immunodeficiency Virus Associated Kaposi’s Sarcoma: Demographic, Clinical Immunological and Virological Characteristics of 103 South African Patients. South African AIDS Conference, Durban South Africa, 2003.

A148. Mosam A, Obaker JA, Jordaan JP, Scadden D, Dawood H, Lalloo U, Odasing U, Coovadia HM, **Friedland G**, Management of HIV Kaposi’s Sarcoma: A Prospective, Randomised, Open-Labelled Trial Comparing the Response to HAART with the combination of HAART
and Chemotherapy (CXT). South African AIDS Conference, Durban South Africa, 2003.

A149. Moll T, **Friedland G**, Comprehensive HIV Programs in a Rural Setting. South African AIDS Conference, Durban South Africa, 2003.

A150. **Friedland G**, Altice F, Preliminary Results of a Randomized Controlled Trial (RCT) of Modified Enhanced Directly Observed Antiretroviral Therapy (MDAAART+) vs. Standard of Care Therapy (SAT): A Model for Administration of ARV in Resource Constrained Settings. South African AIDS Conference, Durban South Africa, 2003.

A151. Bodasing U, Coovadia HM, Mosam A, **Friedland G**, Adherence to Highly Active Antiretroviral Therapy (HAART) for Management of Kaposi’s Sarcoma. South African AIDS Conference, Durban South Africa, 2003.

A152. Altice F, Mezger J, Bruce RD, Springer S, Hodges J, **Friedland G**. Preliminary Results of a Randomized Control Trial (RCT) of Modified Enhanced Directly Administered Antiretroviral Therapy (mDAART) vs. Standard of Care Therapy (SAT): A Model for Administration of ART in Marginalized Populations. (ABS#652) 41st Annual Meeting of Infectious Diseases Society of America (IDSA), San Diego, CA, October 2003.

A153. Kozal M, Amico R, Chiarella J, Schreibman T, Cornman D, Fisher W, Fisher J, and **Friedland G**, Continuing High-risk Sexual Behavior and Increasing Antiretroviral Resistance among HIV+ Patients in Care Helps Explain the Rising Prevalence of Resistance among New HIV Infections. 11th Conference on Retrovirus and Opportunistic Infections. San Francisco, CA, February 2004.

A154. Mannheimer S, Matts J, Child C, Chesney M, Telzak E, Wu A, **Friedland G**, and the Terry Beirns Community Programs for Clinical Research on AIDS (CPCRA), CPCRA Statistical and Data Monitoring Ctr., Minneapolis, MN, USA. [Low-grade Symptoms Worsen Quality of Life for HIV-infected Individuals in Antiretroviral Therapy Clinical Trials](http://www.retroconference.org/2004/cd/Abstract/754.htm). 11th Conference on Retrovirus and Opportunistic Infections. San Francisco, CA, February 2004

A155. Kozal MK, Amico R, Chiarella J, Fisher J, Cornman D, Fisher W, **Friedland G**. HIV Drug Resistance Among HIV+ Injection Drug Users: Risk Behavior and Patients’ Beliefs on the Transmissibility of HIV (Abstract #89). XIII International HIV Drug Resistance Workshop, Tenerife Sur, Canary Islands, Spain, June 8-10, 2004.

A156. **Friedland G**, Andrews L, Argawala S, Schreibman T, Daley L, Child M, Wang Y, O’Mara E,Lack of an effect of Atazanavir on Steady-State Pharmacokinetics of Methadone in Chronically Treated Subjects, International Symposium HIV and Emerging Infectious Disease, Toulon France, June 2004

A157. Gandhi NR, Moll A, Pawinski R, Jack C, Lalloo U, **Friedland G**, Initiating and providing antiretroviral therapy for TB/HIV coinfected patients in a rural tuberculosis directly observed therapy program in South Africa: The Sizonqoba study. XV International AIDS Conference Bangkok, Thailand, July 2004 (Abstract #MoOrB1014)

A158. Jack CG, Naidoo V, Lalloo U, Ziyani C, **Friedland G**, Follow-up of patients continuing antiretroviral therapy by self-administration after initial concomitant TB/HIV directly observed therapy. (#MoPeB3355) XV International AIDS Conference Bangkok, Thailand, July 2004

A159. Taylor M, Dlamini SB, Nyawo N, Jinabhai CC, Morar N, Esterhuizen T, **Friedland G**, Use of substances and risk of HIV infection – a cross sectional study amongst urban and rural high school students in KwaZulu-Natal (KZN), South Africa (SA) (Abstract #TuOrA1219) XV International AIDS Conference Bangkok, Thailand, July 2004

A160. Cassol E, Page T, Mosam A, Dwyer E, **Friedland G**, Antiretroviral treatment of African patients infected with HIV-1 subtype C: Suppression of viral replication in CD4+CD45RO+ and CD14+ CD16+ reservoirs is predictive of immunological recovery and clinical outcome (TuPeA4353). XV International AIDS Conference Bangkok, Thailand, July 2004

A161. Gandhi NR, Moll A, Pawinski R, Jack C, Lalloo U, **Friedland G**, Developing strategies to implement HAART in high TB prevalence communities in resource constrained settings in rural South Africa (TuPpE2055 12:40) XV International AIDS Conference Bangkok, Thailand, July 2004

A162. Altice FL, Mezger J, Bruce RD, Springer SA, **Friedland G**, Implications for implementing directly administered antiretroviral therapy (DAART) for HIV+ injection drug users (IDUs) (WePeB5839). XV International AIDS Conference Bangkok, Thailand, July 2004

A163. Kiene SM, Fisher JD, Cornman D, **Friedland G**, Moll A, Challenges of and possibilities for HIV prevention in the clinical care setting in KwaZulu-Natal, South Africa (9ThOrC1409) XV International AIDS Conference Bangkok, Thailand, July 2004

A164. Cassol E, Page T, Mosam A, Cassol S, Jack C, Lalloo U, **Friedland G**, Coovadia HM Therapeutic response of HIV-1 subtype C in African patients co-infected with mycobacterium tuberculosis or HHV-8 (ThOrA1402) XV International AIDS Conference Bangkok, Thailand, July 2004

A165. Fisher J D, Fisher WA, Cornman DH, Amico KR, **Friedland G**, Effects of a clinician-initiated HIV prevention intervention among HIV+ patients(ThPeC7471) XV International AIDS Conference Bangkok, Thailand, July 2004

A166. Burman W, Neuhaus J, Rietmeijer C, Douglas J, McCartin C, **Friedland, G**, HIV transmission risk among pt enrolled in large clinical trial evaluating treatment interruption(ThPeD7625) XV International AIDS Conference Bangkok, Thailand, July 2004

A167. Altice FL, Mezger J, Bruce RD, Springer SA, Hodges J, **Friedland G** Randomized, controlled trial of directly administered antiretroviral therapy. (DAART) versus self-administered therapy (SAT) among HIV+ drug users (ThPpB2093). XV International AIDS Conference Bangkok, Thailand, July 2004

A168. Page TN, Cassol E, Mosam A, **Friedland G**, Coovadia HM, Cassol S HHV-8 viral load as an indicator of patient response to therapy (ThPeA6948) XV International AIDS Conference Bangkok, Thailand, July 2004

A169. Mannheimer S, Mase E, Matts J, Andrews L, Schmetter B, **Friedland G** CPCRA 062 Study Team, Sustained benefit from a long-term antiretroviral (AR) adherence intervention: Results of a large randomized clinical trial (Abstract #LbOrB15 XV) International AIDS Conference Bangkok, Thailand, July 2004

A170. **Friedland G**, Jack C, Lalloo U, Neel N ,Moll T, Pawinski R, El-Sadr W, Karim Q, Karim S Studies on the Integration of Once-Daily Antiretroviral Therapy (ART) Into Existing TB Directly Observed Therapy (TB DOT) Programs in Urban and Rural Settings in South Africa, WHO 4th Working Group on TB and HIV, Addis Ababa, Ethiopia, 2004

A171. Jack C, Khoo S, Lalloo U, Naidoo V, **Friedland G:** Efavirenz levels and clinical outcomes in patients with TB and HIV treated concomitantly with ART and rifampin containing TB regimen. 12th Conference on Retroviruses and Opportunistic Infections, Boston, 2005.

A172. McCance-Katz E, Pade P, **Friedland G**, Morse G, Moody D, Rainey P, Efavirenz is not associated with opiate withdrawal in buprenorphine-maintained individuals. 12th Conference on Retroviruses and Opportunistic Infections, Boston, 2005

A173. Cornman DH, Christie S, Fisher JD, Glaros R, Alvaro C, **Friedland G**. Model for Translation and Dissemination of a Provider-Delivered Risk Reduction Intervention for HIV-Positive Patients in Clinical Care. (MoPe10.7p22) 3rd IAS Conference on HIV Pathogenesis and Treatment Rio de Janeiro, Brazil July 2005.

A174. Mosam A, Cassol E, Page T, Bodasing U, Cassol S, Dawood H, **Friedland G**, Scadden D, Aboobaker J, Lalloo U, Jordaan J, Esterhuizen T, Coovadia H. Fixed Dose Combination Generic HAART In Sub-Saharan Africa A Prospective Study Over 52 Weeks. (MoPe11.7CO1) 3rd IAS Conference on HIV Pathogenesis and Treatment Rio de Janeiro, Brazil July 2005.

A175. Gandhi NR, Moll A, Pawinski R, Jack C, Lalloo U, **Friedland G**. Initiating and Providing Antiretroviral Therapy for HIV/TB Coinfected Patients in a Rural Tuberculosis Directly Observed Therapy Program in South Africa: The Sizonqoba Study. (TuPe7.1C24) 3rd IAS Conference on HIV Pathogenesis and Treatment Rio de Janeiro, Brazil July 2005.

A176. Mosam A, Coovadia H, Cassol S, Page T, Cassol E, Bodasing U, **Friedland G**, Jordaan J, Scadden D, Dawood H, Aboobaker J, Lalloo U, Chetty R, Hurkchand H. AIDS Associated Kaposi´s Sarcoma In South Africa: A Cross Sectional Study Of 152 Patients From Kwazulu Natal. (TuPe7.7CO1) 3rd IAS Conference on HIV Pathogenesis and Treatment Rio de Janeiro, Brazil July 2005.

A177. Fisher JD, Fisher WA, Cornman DH, Amico KR, Bryan AD, **Friedland G:** Effects of a provider-initiated HIV prevention intervention among HIV+ patients. (WePe10.4P13) 3rd IAS Conference on HIV Pathogenesis and Treatment Rio de Janeiro, Brazil July 2005.

A178. Moll A, Gandhi NR, Pawinski R, Lalloo U, Zeller K, Sturm W, **Friedland G**, Early favorable tuberculosis and HIV therapeutic outcomes in integrated TB-HIV program in rural KwaZulu Natal, South Africa, (PS-1835-20) International Union Against Tuberculosis and lung Disease 36th Union World Conference on Lung Health, Paris France, October, 2005.

A179. Gandhi NR, Moll A, Pawinski R, Jack C, Lalloo U, **Friedland G**. Initiating and providing antiretroviral therapy for TB/HIV coinfected patients in a rural tuberculosis directly observed therapy program in South Africa: The Sizonqoba study. (MoOrB1014 ORAL) 13th Conference on Retroviruses & Opportunistic Infections (CROI), Denver, Colorado February, 2006.

A180. Jack CG, Naidoo V, Lalloo U, Ziyani C, **Friedland G**. Follow-up of patients continuing antiretroviral therapy by self-administration after initial concomitant TB/HIV directly observed therapy. (MoPeB3355) 13th Conference on Retroviruses & Opportunistic Infections (CROI), Denver, Colorado February, 2006.

A181. Taylor M, Dlamini SB, Nyawo N, Jinabhai CC, Morar N, Esterhuizen T, **Friedland G**. Use of substances and risk of HIV infection – a cross sectional study amongst urban and rural high school students in KwaZulu-Natal, South Africa. (TuOrA1219 ORAL) 13th Conference on Retroviruses & Opportunistic Infections (CROI), Denver, Colorado February, 2006.

A182. Cassol1 E, Page T, Mosam A, Dwyer E, **Friedland G**. Antiretroviral treatment of African patients infected with HIV-1 subtype C: Suppression of viral replication in CD4+CD45RO+ and CD14+ CD16+ reservoirs is predictive of immunological recovery and clinical outcome. (TuPeA4353) 13th Conference on Retroviruses & Opportunistic Infections (CROI), Denver, Colorado February, 2006.

A183. Gandhi NR, Moll A, Pawinski R, Jack C, Lalloo U, **Friedland G**. Developing strategies to implement HAART in high TB prevalence communities in resource constrained settings in rural South Africa. (TuPpE2055) 13th Conference on Retroviruses & Opportunistic Infections (CROI), Denver, Colorado February, 2006.

A184. Altice FL, Mezger J, Bruce RD, Springer SA, **Friedland G**. Implications for implementing directly administered antiretroviral therapy (DAART) for HIV+ injection drug users. (WePeB5839) 13th Conference on Retroviruses & Opportunistic Infections (CROI), Denver, Colorado February, 2006.

A185. Kiene S M, Fisher JD, Cornman D, **Friedland G**, Moll A. Challenges of and possibilities for HIV prevention in the clinical care setting in KwaZulu-Natal, South Africa. (ThOrC1409 ORAL) 13th Conference on Retroviruses & Opportunistic Infections (CROI), Denver, Colorado February, 2006.

A186. Cassol E, Page T, Mosam A, Cassol S, Jack C, Lalloo U, **Friedland G**, Coovadia HM. Therapeutic response of HIV-1 subtype C in African patients co-infected with mycobacterium tuberculosis or HHV-8. (ThOrA1402 ORAL) 13th Conference on Retroviruses & Opportunistic Infections (CROI), Denver, Colorado February, 2006.

A187. Fisher JD, Fisher WA, Cornman DH, Amico KR, **Friedland G**. Effects of a clinician-initiated HIV prevention intervention among HIV+ patients. (ThPeC7471) 13th Conference on Retroviruses & Opportunistic Infections (CROI), Denver, Colorado February, 2006.

A188. Page TN, Cassol E, Mosam A, **Friedland G**, Coovadia HM, Cassol S. HHV-8 viral load as an indicator of patient response to therapy. (ThPeA6948) 13th Conference on Retroviruses & Opportunistic Infections (CROI), Denver, Colorado February, 2006.

A189. Moll A, Gandhi NR, Pawinski R, Andrews J, Zeller K, Lalloo U, Sturm W, **Friedland G**. Identification of a Multidrug Resistant Tuberculosis Cluster as a Cause of Death Among HIV Coinfected Patients in Rural South Africa. Conference on Retroviruses and Opportunistic Infections. Denver, Colorado. 2006

A190. **Friedland, G**. A Randomized Comparison of Two Instruments for Assessing Self-Reported Antiretroviral Adherence. NIMH/IAPAC International Conference on HIV Treatment Adherence, New Jersey, March, 2006.

A191. Gandhi NR, Moll A, Pawinski R, Zeller K, Lalloo JC, **Friedland G**. Favorable outcomes of the integration of TB & HIV treatment in rural South Africa: the Sizonq'oba study. (MOPE0181) XVI International AIDS Conference Toronto, Canada, August, 2006.

A192. Simon M, Moll T, Shange M, Altice F, Pawinski R, Zeller K, **Friedland G**. HAART-Felt Prospects: Information, motivation, and behavioral skills among at-risk youth regarding introduction of highly active antiretroviral therapy in rural South Africa. (MOPE0861). XVI International AIDS Conference Toronto, Canada, August, 2006.

A193. Moll A, Pawinski R, Gandhi NR, M Mabogoane ,F Eksteen,T vd Merwe, **Friedland G**. Transition from palliation to HAART in HIV-1 infected patients in a rural home and hospice care program in KwaZulu-Natal, South Africa. Towards turning the disease tide around. (TUPE0231) XVI International AIDS Conference Toronto, Canada, August, 2006.

A194. Andrews JR, Gurubacharya DL, Adhikari MP, Koirala SK, **Friedland G**. A Pilot, Community-based antiretroviral therapy program in Urban Nepal (TUPE0269) XVI International AIDS Conference Toronto, Canada, August, 2006.

A195. Cornman DH, Kiene SM, Christie S, Fisher JD, Shuper P, Fisher WA, Pillay S, **Friedland G**. Predictors of sexual risk behavior among people living with HIV/AIDS in KwaZulu-Natal, South Africa (TUPE0452). XVI International AIDS Conference Toronto, Canada, August, 2006.

A196. Zeller KA, Moll A, Pawinski R, Gandhi NR, Lalloo UG, **Friedland G**. Feasibility and Acceptability of interactive picture-based audio/computer-assisted technology for collection of sensitive sexual transmission risk information in resource-poor, low-literacy settings (WEPE0314) XVI International AIDS Conference Toronto, Canada, August, 2006.

 Use of an innovative picture-based, audio-assisted, interactive computer technology to collect sexual transmission risk information in the context of providing antiretroviral therapy to HIV patients in a low literacy setting.

A197. Zeller KA, Moll A, Pawinski R, Gandhi NR, Lalloo UG, **Friedland G**. Sexual Transmission Risk Behavior in ART patients in Rural South Africa: The *Sizonq’oba* Study. (WEPE0528) XVI International AIDS Conference Toronto, Canada, August, 2006.

A198. Gandhi NR, Moll A, Pawinski R, Lalloo U, Sturm AW, Zeller K, Andrews J, **Friedland G**. High Prevalence and mortality from Extensively-Drug Resistant (XDR) TB in TB/HIV Coinfected Patients in Rural South Africa (THLB0210) XVI International AIDS Conference Toronto, Canada, August, 2006.

A199. Gandhi NR, Moll A, Pawinski R, Jack C, Lalloo JC, **Friedland G**. Initiating &d Providing Antiretroviral Therapy for HIV/TB coninfected Pts in a Rural TB DOT Pgm in SoAfrica Sizonqoba Study. (ORAL THLB0210) XVI International AIDS Conference Toronto, Canada, August, 2006.

A200. Hoosen K, Mosam A, Aboobaker J, Cassol S, **Friedland G**, Coovadia H. Quality of life (QOL) of patients with HIV/AIDS on Highly Active Antiretroviral Therapy (HAART) in Sub Saharan Africa (SSA) A longitudinal study of 23 patients over 6 months. (THLB04) XVI International AIDS Conference Toronto, Canada, August, 2006.

A201. Burman W, Grund B, roediger MP, Neuhaus J, Wu A, **Friedland G**, Darbyshire J. The Effect of Episodic CD4-guided Antiretroviral Therapy on Quality of Life: a Substudy of the SMART Trial. XVI International AIDS Conference Toronto, Canada, August, 2006.

A202. **Friedland G**,Moll A, Gandhi NR, Pawinski R, Andrews J, Zeller K, Lalloo U, Sturm W. XDR TB among HIV-infected patients in Rural South Africa, (Oral) Symposium on Tuberculosis Infection Control in the Era of HIV-AIDS and MDR-TB. (01071) 37th Union World Conference on Lung Health, Palais des Congrès, Paris, France October-November, 2006.

A203. Gandhi NR, Moll A, Pawinski R, Lalloo U, **Friedland G**. Favorable TB and HIV Outcomes in Integrated TB/HIV Program in Rural KwaZulu Natal, South Africa Blunted by Mortality due to Multidrug Resistant (MDR) TB. 37th Union World Conference on Lung Health, Palais des Congrès, Paris, France October-November, 2006.

A204. Moll A, Gandhi NR, **Friedland G**, van der Merwe TL, Eksteen F, Msomi M, Qali T. Integration of TB and HIV Therapy for Co-infected Patients by Strengthening TB DOTS Infrastructure and Utilizing Community and Family Supports. 37th Union World Conference on Lung Health, Palais des Congrès, Paris, France October-November, 2006.

A205. Gandhi NR, Moll A, Sturm W, Pawinski R, Andrews J, Zeller K, Lalloo U, **Friedland G**. MDR TB Emerges as Principal Cause of death in TB/HIV Patients on Therapy in Rural KwaZulu Natal, South Africa. (PC-61705.02) 37th Union World Conference on Lung Health, Palais des Congrès, Paris, France October-November, 2006.

A206. Gandhi NR, Moll A, Sturm W, Pawinski R, Andrews J, Zeller K, Lalloo U, **Friedland G**. Extensively-Drug Resistant (XDR) TB as Cause of Death in TB/HIV Co-infected Patients in Rural South Africa (Oral) (TS-61718.02) 37th Union World Conference on Lung Health, Palais des Congrès, Paris, France October-November, 2006.

A207. Pawinski R, Gandhi N, Moll A, Zeller K, Lalloo U, **Friedland G**. Low Level of Adverse Events in Patients on Integrated Standard DOT TB Therapy and Once Daily ddI+3TC+EFV in a Rural Resource-constrained Setting in South Africa: Sizonq'oba 1-Year Outcomes. Session: Antiretroviral Therapy-Associated toxicities in Resource-Limited and Developed Countries. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA February 25-28, 2007

A208. Burman W, Grund B, Neuhaus J, Douglas J, **Friedland G**, Rietmeijer C, and the SMART Study Group The Effect of Episodic ART on HIV Transmission Risk: A Substudy of the SMART Study (Abstract #Y-114) The Impact of Episodic Antiretroviral Therapy on HIV Transmission Risk: A Substudy of the SMART Study. *HIV Transmission Risk* 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA February 25-28, 2007.

A209. Moodley P, Moll A, Shah NS, Gandhi NR, **Friedland G**, Andrews J, Sturm AW. Multi- and Extensively Drug-Resistant *Mycobacterium tuberculosis* in KwaZulu Natal. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago. September, 2007.

A210. Telzak E, Huppler Hullsiek, Mannheimer, Peng, Sharma, Gardner, MacArthur, Chesney, **Friedland G**. Impact of Different Levels of Adherence on the Risk of Virologic Failure and Virologic Failure with Resistance [in FIRST] oral presentation IDSA 45th Annual Meeting San Diego, CA, October 4-7, 2007.

A211. Botelho N, Moll A, Eksteen F, van der Merwe T, Shah NS, Gandhi N, Moodley P, Babaria P, Sturm AW, **Friedland G**: Use of Mycobacterial Culture of Blood and Body Fluids for Diagnosis of Drug Resistance in Extrapulmonary TB, KwaZulu-Natal, South Africa. [Poster presentation] 38th Union World Conference on Lung Health, Cape Town, South Africa 2007.

A212. Moll A, Gandhi NR, Andrews J, Sturm AW, Shah NS, Scott M, Lalloo U, Moodley P, **Friedland G**: Extensively Drug-Resistant (XDR) TB More Common than MDR TB in Tugela Ferry, South Africa with Evidence for Resistance Amplification Over Time [Poster presentation] 38th Union World Conference on Lung Health, Cape Town, South Africa 2007.

A213. Andrews JR, Gandhi NR, Moll AP, Shah NS, Sturm AW, Lalloo U, Moodley P, **Friedland G**: High Mortality Among Patients with Multidrug and Extensively Drug-Resistant Tuberculosis in Rural South Africa[Poster presentation] 38th Union World Conference on Lung Health, Cape Town, South Africa 2007.

A214. Andrews JR, Gandhi NR, Moll AP, Shah NS. Sturm AW, Lalloo U, Moodley P, **Friedland G**: Clinical Predictors of Multidrug and Extensively Drug-Resistant Tuberculosis In Tugela Ferry, South Africa [Poster presentation] 38th Union World Conference on Lung Health, Cape Town, South Africa 2007.

A215. Basu S, Andrews J, Poolman E, Galvani A, Moll A, Gandhi N, Shah S, **Friedland G**. Modeling measures to reduce the nosocomial transmission of extensively drug-resistant tuberculosis (XDR TB). 38th Union World Conference on Lung Health. Cape Town, South Africa 2007.

A216. Moodley P, Moll T, Shah NS, Gandhi N, **Friedland G**, Lalloo UG, Andrews J, Sturm AW. Multi- and Extensively Drug-resistant Tuberculosis in KwaZulu-Natal. 38th Union World Conference on Lung Health. Cape Town, South Africa 2007.

A217. Botelho N, Moll AP, Eksteen F, van der Merwe T, Shah NS, Gandhi NR, Sturm AW, Moodley P, **Friedland G**. Mycobacterial blood culture for diagnosis of drug-resistant extrapulmonary TB, KwaZulu-Natal. [poster discussion presented at the 38th Union World Conference on Lung Health, Cape Town 2007]

A218. Andrews J, Gandhi NR, Moll AP, Shah NS, Sturm AW, Lalloo U, Moodley P, **Friedland G**. High mortality among patients with multidrug and extensively drug-resistant tuberculosis in Rural South Africa. [poster discussion presented at the 38th Union World Conference on Lung Health, Cape Town 2007]

A219. Andrews J, Gandhi NR, Moll AP, Shah NS, Sturm AW, Lalloo U, Moodley P, **Friedland G**. Clinical predictors of multidrug and extensively drug-resistant tuberculosis: Tugela Ferry, South Africa. [poster discussion presented at the 38th Union World Conference on Lung Health, Cape Town 2007]

A220. Moll T, Gandhi NR, Sturm AW, Andrews J, Shah NS, Lalloo UG, Moodley P, **Friedland G**. Extensively drug-resistant (XDR) TB now more common than MDR-TB in Tugela Ferry, KwaZulu-Natal, South Africa. [poster discussion presented at the 38th Union World Conference on Lung Health, Cape Town 2007]

A221. Andrews J, Gandhi n, Moodley P, Shah S, Bohlken L, Moll T, Pillay M, **Friedland G**, Sturm W, and the Tugela Ferry Care and Research Collaboration. Exogenous Re-infection with Multidrug-and Extensively Drug Resistant TB among TB/HIV Co-infected Patients in Rural South Africa. (Oral) Paper #143 15th CROI Conference on Retroviruses and Opportunistic Infections Boston, MA, February, 2008.

A223. Gardner E, Peng G, Telzak E, Sharma S, Huppler Hullsiek K, Burman W, Chesney M, **Friedland G**, MacArthur R, Mannheimer S and the Intl Network for Strategic Initiatives in Global HIV Trials (INSIGHT). Analysis of the Relationship between Antiretroviral Medication Adherence and Class-Specific Resistance in a Large Prospective Randomized Clinical Trial poster 727 CROI 2008; (Oral) presentation 3rd IAPAC International Conf HIV Treatment Adherence, March, 2008.

A224. Saukkonen J, VillarinoE, El-Sadr W, Padayatchi N, Weiner M, Murphy AL, **Friedland G**, Menzies D, Seaworth B, Hirsch-Moverman Y, Mnguni N, Price RW, Leshabane N, Gumede Z, Heilig C, MacKenzie B. Abstract: A phase I/II pilot study for evaluation of low dose, once daily, linezolid plus optimized background therapy (OBT) versus placebo plus OBT for the treatment of multi-drug resistant tuberculosis. South African Conference on TB, Durban, South Africa, June, 2008.

A225. Shuper PA, Kiene SM, Mahlase G, MacDonald SP, Christie S, Cornman DH, Kistnasamy B, Pillay S, Shepherd L, Karim QA, **Friedland G**, Lalloo UG, Fisher J D, Fisher WA. Our Abstract #12332, “Correlates of high-risk sexual behaviour among sexually active HIV-positive women and men in clinical care in KwaZulu-Natal, South Africa” Oral presentation, XVII International AIDS Conference Mexico City, 3-8 August, 2008.

A226. Brust JCM, Moll AP, Scott, M, Gandhi NR, Shah NS, Lalloo UG, and **Friedland G** Community-based treatment of multidrug-resistant tuberculosis (MDR TB) and HIV in rural KwaZulu-Natal. XVII International AIDS Conference Mexico City, 3-8 August, 2008.

A227. Babaria P, Shah S, Moll A, Gandhi N, **Friedland G.** “Information, motivation and behavioral skills regarding TB and high rates of pulmonary TB among ARV clinic patients in rural South Africa” 39th Union World Conference on Lung Health of the International Union Against TB and Lung Disease meeting Paris France 18 October, 2008.

A228. Scott M, Brust JCM, Moll AP, Gandhi NR, Shah NS, Lalloo UG, **Friedland G** “Community-Based Treatment of Multidrug-Resistant Tuberculosis (MDR TB) & HIV in Rural South Africa” 39th Union World Conference on Lung Health of the International Union Against TB and Lung Disease meeting Paris France 18 October, 2008.

A229. Bruce RE, Altice FL, Moody DE, Lin SN, Fang WB, Saba JP, Wruck JM, Conner C, Pilliero OPJ, Andrews LA and **Friedland G.** Pharmacokinetic Interactions Between Buprenorphine/Naloxone & Tipranavir/Ritonavir. Abstract #967a, 8th Annual ICAAC & IDSA 46th Annual Meeting, 25-28 October, 2008.

A230. Karim SS, Naidoo K, Grobler A, Padayatchi N, Nair G, Bamber S, Pienaar J, **Friedland G**, El-Sadr W, Karim QA. Initiating Antiretroviral Therapy During Tuberculosis Treatment Significantly Increases Survival in TB-HIV Co-infected Patients Abs 16th Conference on Retroviruses and Opportunistic Infections (CROI) February 8-11, 2009.

A231. Babaria P, Shah NS, Moll A, Gandhi N**, Friedland G**. High Rate of Unrecognized Tuberculosis and Drug-Resistant Tuberculosis among Antiretroviral Clinic Patients in Rural South Africa. Abs 16th Conference on Retroviruses and Opportunistic Infections (CROI) February 8-11, 2009.

A232. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Babaria P, Marra C, Lalloo U and **Friedland G.**  High Early Mortality Among HIV-infected Patients with Multidrug-Resistant (MDR) or Extensively Drug-Resistant Tuberculosis (XDR TB) in Rural South Africa. Abs 16th Conference on Retroviruses and Opportunistic Infections (CROI) February 8-11, 2009.

A233 Catterick K, Shenoi S, Moll AP, Marra C, Gandhi NR, Shah NS, Kanjee Z, **Friedland G.** Infection Control Efforts Can be Feasible and Effective in Limiting Nosocomial Transmission of Multiple and Extensively Drug Resistant (MDR and XDR) TB among HIV Coinfected Patients at District Hospitals in KwaZulu-Natal, South Africa. Oral presentation, South African AIDS Conference, Durban, South Africa, April 2009.

A234 Thomas T, Shenoi S, Heysell S, Eksteen F, Sankari B, Gandhi NR, Shah NS, **Friedland G**. Pediatric XDR TB and HIV coinfection in rural Kwa-Zulu Natal. Oral presentation, South African AIDS Conference, Durban, South Africa April 2009.

A 235 Gandhi NR, Shenoi, S Shah, NS Moodley P, Weissman D, Moll, APSturm AW, **Friedland G**. Low Genetic Diversity among MDR & XDR TB isolates from Tugela Ferry, South Africa, 2005-2006. American Thoracic Society Annual Conference, San Diego, California, May 2009.

A 236 Shenoi S, Gandhi NR, Moll AP, Shah NS, Brooks RP, Van Der Merwe T, **Friedland G,** on behalf of the Tugela Ferry Care and Research (TF CaRes) Collaboration. Clinical Characteristics of Survivors of XDR TB and HIV Co-infection in Rural Kwa-Zulu Natal, South Africa. 5th IAS Conference Capetown, South Africa, July 2009.

A 237 Shah S, Richardson J, Moodley P, Moodley S, Babaria P, Ramtahal M, Heysell S, Moll A, **Friedland G**, Sturm W, Gandhi N, Increasing Second-line Drug Resistance Among Extensively Drug-Resistant Tuberculosis Patients in Rural South Africa Oral Presentation **.** 40th Union World Conference on Lung Health of the International Union Against TB and Lung Disease Meeting, Cancun, Mexico, December 2009.

A 238 Shenoi S, Gandhi NR, Moll A, Master I, Shah NS, Brooks RP, Van Der Merwe T**, Friedland G**, on behalf of the Tugela Ferry Care and Research (TF CARES) Collaboration Comparison of characteristics of XDRTB survivors with those of non-survivors in rural Kwa-Zulu Natal, South Africa, 40th Union World Conference on Lung Health of the International Union Against TB and Lung Disease Meeting, Cancun, Mexico, December 2009.

A 239 Gandhi NR, Weissman D, Andrews J, Moll AP, **Friedland G**, Shah NS. on behalf of the Tugela Ferry Care and Research (TF CARES) Collaboration Nosocomial Spread Of XDR TB In Rural South Africa, 2005-2006, 40th Union World Conference on Lung Health of the International Union Against TB and Lung Disease Meeting Cancun, Mexico, December 2009.

A-240 Rapid Diagnosis of Tuberculosis and MDR TB Using the Microscopic Observation Drug-susceptibility (MODS) Assay in a High HIV Prevalence Setting – South Africa, Shah N, Babaria P, Moodley P, Heysell S, Sturm A W,. Moll A, Mhlongo P, Ramatha M, Xi Li, **Friedland G**, Gandhi N, KwaZulu-Natal Research Institute for TB and HIV (K-RITH) TB Diagnostics Symposium Nelson R Mandela School of Medicine, Durban, South Africa May 2010

A-241 Heysell SK, Thomas T, Gandhi NR, Moll AP, Eksteen F, Roux L, Coovadia Y,Babaria P, Lalloo U, **Friedland G**, Shah S. Blood Cultures for the Diagnosis of Drug-Resistant Tuberculosis in rural South Africa. KwaZulu-Natal Research Institute for TB and HIV (K-RITH) TB Diagnostics Symposium Nelson R Mandela School of Medicine, Durban, South Africa May 2010

A-242 Heysell KS, Moll AP, Gandhi NR, Eksteen F, Babaria P, Roux L, Coovadia Y, Lalloo U, **Friedland G**, Shah NS. Diagnosis of Extensively Drug-Resistant Tuberculosis (XDR-TB) from Lymph Node and Pleural Fluid Aspirates from Rural South Africa. KwaZulu-Natal Research Institute for TB and HIV (K-RITH) TB Diagnostics Symposium Nelson R Mandela School of Medicine, Durban, South Africa May 2010

A-243 Shah NS, Babaria P, Moodley P, Heysell S, Sturm AW, Moll AP, Mhlongo P, Moodley S, Ramathal M, Richardson J, **Friedland G**, Gandhi NR. Rapid Diagnosis of Tuberculosis and MDR TB Using the Microscopic-Observation Drug-Susceptibility (MODS) Assay in a High HIV Prevalence Setting in Kwa Zulu Natal – South Africa. 2nd South African TB Conference 2010, ICC Durban, South Africa, June 2010.

A-244 Brust JCM, Lygizos M, Moll AP, van der Merwe TL, Chaiyachati K, M, Scott M, Shah NS, Li X, Loveday M, Bamber S, Lalloo UG, **Friedland G**, and NR Gandhi Early favorable outcomes for integrated, community-based management of MDR-TB and HIV in Tugela Ferry, 2nd South Africa South African TB Conference Durban, South Africa June 2010

A-245 Myers, B, Shenoi,S, Chonco N, Nombuso M, Moll T, Marra C, Ndlovu Z **Friedland G** Community Intensive Case Finding Program in Rural KwaZulu-Natal, South Africa 2nd South African TB Conference Durban, South Africa June 2010

A-246 Kiene SM, Fisher WA, Shuper P, Cornman D, Christie S, Pillay S, MacDonald S, Shepherd L, Mahlase G, Jojo Z, van Loggerenberg F, Lalloo U, Ngcobo N, Greener R, **Friedland G**, Fisher JD. An Information-Motivation-Behavioral Skills Model (IMB) of HIV-Preventive Behavior Among HIV-Positive Individuals in KwaZulu-Natal, South Africa. XVIII International AIDS Conference, Vienna, Austria, July 2010.

A-247 Shuper PA, Kiene SM, Mahlase G, MacDonald SP, Christie S, Cornman DH, Fisher WA, **Friedland G**, Greener R, Jojo Z, Lalloo UG, Ngcobo N, Pillay S, Shepherd L, van Loggerenberg F, Fisher JD. Predictors of unprotected sexual behavior among HIV-positive South African women and men receiving antiretroviral therapy. Abstract #7827 XVIII International AIDS Conference Vienna, Austria, July 2010.

A-248 Lygizos M, JCM Brust , Moll SP, Brooks RP, **Friedland G**: Natural Ventilation in Traditional Zulu Homes in a Rural Area of South Africa with high rates of Drug-Susceptible, MDR and XDR-TB, Fogarty International Clinical Research Scholars & Fellows & Doris Duke International Fellows Conference. Potomac, MD. Sept 2010.

A-249 Shenoi SV, Gandhi NR, Moll AP, Master I, Shah NS, Barbour, R, Brooks RP, Van Der Merwe T, **Friedland G** on behalf of the Tugela Ferry Care and Research (TF CaRes) Collaboration. Comparison of characteristics of XDRTB survivors with those of non-survivors in rural Kwa-Zulu Natal, South Africa Fogarty International Clinical Research Scholars & Fellows & Doris Duke International Fellows Conference. Potomac, MD. Sept 2010.

A-250 Shenoi SV, Bamber S, Maluleka m, Brooks R, Marra C, Moll AP, **Friedland G**,, on behalf of the Tugela Ferry Care and Research (TF CaRes) Collaboration. Evaluation and outcomes of “TB suspect” pediatric household contacts of adult MDR and XDR TB patients. 41st Union World Conf Berlin, Germany, November 2010.

A-251 Heysell SK, Thomas TA, Moodley P, Montreuil R, Ha X, Mhlongo P, Solwa Z, **Friedland G**, Bamber S, Moll A, Gandhi NR, Sturm AW, Shah NS Improving tuberculosis diagnosis in pediatric patients from rural South Africa by intensifying specimen collection, American Thoracic Society, May 2011, Denver, Colorado.

A-252 Shah S, Rothenberg R, Weissman D, Moodley P, Sturm AW, **Friedland G**, Kreiswirth B, Mathema B, Ramtahal M, Vogenthaler N, Moll A, Gandhi N: Social Network and Molecular Analysis to Evaluate Hospital Transmission of Extensively Drug-resistant Tuberculosis (XDR TB) in South Africa, American Thoracic Society International Conference, May 2011 Denver, Colorado.

A-253 Bruce, RD, Moody, DE, Fang, WB, Chodkowski, D, Andrews, L, Parsons, T, **Friedland, GH**. “Pharmacokinetic Interactions between Buprenorphine/Nalxone and Raltegravir.” 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011). [Poster Presentation] Rome July 17-20, 2011.

A-254 Thomas TA, Heysell SK, Moodley P, Montreuil R, Bamber S, **Friedland G**, Sturm AW, Shah NS, Improving drug-resistant TB diagnosis in South African Children , 42nd Union World TB Conference, November 2011, Lille France.

A-255 Kanjee Z , Amico KR, Li F, Mbolekwa K, AP Moll AP, **Friedland GH**, Tuberculosis Infection Control in Rural South Africa: An Application of the Information-Motivation-Behavioral Skills Model of Behavior Change, 42nd Union World TB Conference, November 2011, Lille France.

A-256 Sani S, Shenoi S, Sani S, Myende H, Ntumba N, Mntambo M, Majola T, Moll AP, **Friedland G**. TB Knowledge Inferior to HIV Knowledge in Rural South Africa. 3rd South Africa Conference on TB, June 2012, Durban, South Africa.

A-257 Shenoi S, Brooks R, Mntambo M, Moll AP, Ntumba N, Khanyile N, Malembe N, **Friedland G,** Conducting Integrated TB and HIV Community Based Intensive Case Finding in Rural KwaZulu Natal, 3rd South Africa Conference on TB, June 2012, Durban, South Africa.

A-258 Lygizos M, Shenoi S, Brooks R, Bhushan A, Brust JCM, Zelterman D, Deng Y, Northrup V, Moll AP, **Friedland G**, Improving Natural Ventilation and Reducing Household TB transmission risk in traditional homes in rural KwaZulu-Natal, South Africa. 3rd South Africa Conference on TB, June 2012, Durban, South Africa.

A-259 **Friedland G**, Moll A, Shenoi S, Brooks R, Brust J, Marra C, Margot B, Declining extensively and multiple drug resistant tuberculosis (XDR/MDR TB) in Tugela Ferry, South Africa, XIX International AIDS Society Meeting in Washington DC July 2012.

A-260 Brust J, Gandhi N, Shah S, van der Merwe T, Bamber S, Yuming, N, Heo M, Moll T, **Friedland G**, Lalloo U, Loveday M, Adverse events in an integrated, home-based treatment program for MDR-TB and HIV in Tugela Ferry, South Africa, XIX International AIDS Society Meeting in Washington DC July 2012.

A-261 Shenoi SV, Brooks R, Mntambo M, Moll AP, Ntumba N, Khanyile N, Malembe N, **Friedland GH**, Conducting Integrated TB and HIV Community-Based Integrated Intensive Case Finding in Rural KwaZulu Natal. 3rd South African TB Conference, Durban June 2012.

A-262 Sani S, Shenoi SV, Myende H, Kyriakides T, Ntumba N, Mntambo M, Moll AP, **Friedland GH**, TB Knowledge Inferior to HIV Knowledge in Rural South Africa. 3rd South African TB Conference, Durban June 2012.

A-263 Lygizos M, Shenoi SV, Brooks R, Bhushan A, Brust JCM, Zelterman D, Deng Y, Northrup V, Moll AP, **Friedland G**, Natural Ventilation and Reducing Household TB Transmission Risk in Traditional Zulu Homes. 3rd South African TB Conference, Durban June 2012.

A-264 Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, Master I, van der Merwe TL, **Friedland GH**, Survival from XDR-TB is Associated with Modifiable Clinical Characteristics in Rural South Africa. 3rd South African TB Conference, Durban June 2012.

A-265 Shuper PA, Kiene SM, Mahlase G, MacDonald S, Christie S, Cornman DH, Fisher WA, **Friedland G**, Greener R, Lalloo U, Ngcobo N, Pillay S, Shepherd L, Smith L, van Loggerenberg F, Fisher JD. Predictors of HIV Transmission Risk Behaviour among HIV-Positive South Africans in Clinical Care, XIX International AIDS Society Meeting in Washington DC, July 2012.

 A-266 **Friedland G**, Moll A, Shenoi S, Brooks R, B rust J, Marra C, Margo B, Declining cases Notifications of XDR and MDR TB in Tugela Ferry, South Africa, XIX International AIDS Society Meeting in Washington DC, July 2012.

 A-267 **Friedland G**, Moll AP, Shenoi SV, Brooks RP, Brust JCM, Marra C, Margot B. Extensively and Multidrug Resistant Tuberculosis (XDR/MDR TB) in Tugela Ferry, South Africa; Five Years Later. Oral Late Breaker. International Union Against TB and Lung Disease, Kuala Lumpur, Malaysia, November 2012

A-268 Shenoi SV, Moll AP, Mntambo AQ, Brooks RP, Upadhya D, Ntumba N, **Friedland G**.High yield from community‐based intensive case finding (CBICF) for TB-HIV I n rural South Africa, International Union Against TB and Lung Disease, Kuala Lumpur, Malaysia, November 2012

A-269 Shenoi SV, Moll AP, Kompala T, Brooks RP, Andrews L, Upadhya D, **Friedland G** The Utility Of a Variety of Congregate Settings In Community-Based VCT In Rural KwaZulu Natal 3rd South African AIDS Conference, Durban, South Africa, June 2013

A-270 Kompala T, Shenoi SV, Mtungwa N, Brooks R, Moll AP, Friedland G HIV Diagnosis is Not Sufficient: A Role for Point-of-Care CD4 Diagnostics IDSA, San Francisco, October 2013

A-271 Shenoi S Moll A, Kompala T, Brooks R, Lalloo U, Andrews L, **Friedland G**, Demography and not HIV predicts active TB in a community sample in rural South Africa, 44th World Conference on Lung Health, Paris, France , November 2013

A-272 Bruce R, Shenoi S, McAlister S, Mbwambo J, Nyandindi,C, Lambdin B, **Friedland G,** Preliminary Report on the First TB-DOT Program Integrated into Methadone Treatment for Heroin Injectors with TB in Sub-Sahara Africa, 44th World Conference on Lung Health, Paris, France, November 2013

A-273 Moll A, Shenoi S, Brooks R, **Friedland G**, Successful Control of Nosocomial Transmission of Drug Resistant TB in Kwa Zulu-Natal, South Africa. Towards safer air: differing approaches to reducing the risk of TB transmission in HIV clinical settings. 44th World Conference on Lung Health, Paris, France, November 2013

A-274 Shenoi SV, Kompala T, AP Moll AP, Brooks RP, Andrews LA, Eksteen F, **Friedland GH,** Perceptions Of Isoniazid Preventive Therapy In Rural South Africa, 4th South African Tuberculosis Conference, Durban, South Africa, June, 2014

A-275 Jacobson KB, Moll AP, **Friedland GH**, Shenoi SV, High Mortality Among HIV Patients Treated For Tuberculosis In Rural South Africa, 4th South African Tuberculosis Conference, Durban, South Africa, June, 2014

A-276 Roundtable Discussion, Padayachi N, Pillay M, Churchyard, G, Masters I, **Friedland GH**. TB in Congregate Settings, 4th South African Tuberculosis Conference, Durban, South Africa, June, 2014

A-277 Shenoi SV, Moll AP, Madi J, Guddera V, Madondo T, Turner D, Brooks RP, Kyriakides T, Andrews L, **Friedland G.** Community-Based Voluntary Counseling and Testing in Rural South Africa**. Oral Presentation.** 21st International AIDS Conference, Durban, July 2016.

A-278 Shenoi SV, Moll AP, Mntungwa N, Kompala T, Andrews L, Brooks RP, **Friedland GH.** Evaluating the proficiency of lay HIV counselors conducting point of care CD4 count tests in a rural community-based voluntary counseling and testing program. 21st International AIDS Conference, Durban, July 2016.

A-279. Beeson A, Shezi L, Moll AP, Madi J, Nkomo N, Guddera V, Andrews L, Brooks R, **Friedland G**, Shenoi SV. Acceptability of Integrated Home-Based Screening for HIV, TB and Non-Communicable Diseases in Rural South Africa 21st International AIDS Conference, Durban, July 2016.

A-280 Beeson A, Moll A, Nkomo K, Guddera V, Andrews L, Brooks R, **Friedland GH**, Shenoi SV, Impilo Iqala Ekhaya (Health Starts at Home); linkage to care and Treatment Initiation Following Home Based HIV Screening in Rural South Africa. 21st International AIDS Conference, Durban, South Africa, July 2016.

A-281Ma M, Moll AP, GudderaV, AndrewsL,**FriedlandG,** Shenoi SV. Perceptions of HIV Pre-Exposure Prophylaxis (PrEP) in KwaZulu-Natal Province, South Africa. 21st International AIDS Conference, Durban, July 2016.

**A-282Friedland G,** Moll A, Brooks R, Margot B, Nogzi J, Radebe Z, Andrews L, Eksteen F, S Shenoi S **Oral Presentation** Significant and sustained decline in extensively and multiple drug resistant tuberculosis (XDR/MDR TB) from 2005-2014 in Tugela Ferry, South Africa, IAS TB 2016, Durban South Africa, July 2016

A-283eeson A, Shenoi SV, Larkan LM, Eksteen F, Moll AP, Loveday M, Mngadi AQ, Andrews LA, **Friedland G**. Unraveling Recent Mortality Trends at a Decentralized MDR-TB Hospital in KwaZulu-Natal, South Africa-47th Union World Conference on Lung Health, Liverpool, England, October 2016.

A-284 Reid D, Shenoi SV, Singh R, Wang M, Patel V, Das R, Hiramen K, Moosa Y, Leng L, Eksteen F, Moll AP, Ndung’u T, Kasprowicz V, **Friedland GH**, Bucala R. Do high expression *MIF* alleles confer protection against active tuberculosis? 47th Union World Conference on Lung Health, Liverpool, England, October 2016.

A-285 Bunda B, Beeson A, Moll AP, Madi J, Andrews LA, Guddera V, **Friedland G**, Shenoi SV. From Community to Clinic: The Success of Community Health Workers in Home Based Screening for TB and Providing Linkage to the Tuberculosis Cascade of Care, 47th Union World Conference on Lung Health, Liverpool, England, October 2016.